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There is no effective vaccine against malaria, a disease currently responsible for 
around 5% of all global mortality. Dire necessity therefore calls for the development 
of effective ways of optimising antigen delivery and presentation, to achieve usable 
vaccines. The objective has been to achieve enhanced levels of irnmunogenicity with 
candidate malaria vaccines based on the parasite-encoded erythrocyte membrane 
proteins. To this end, the C3d-tagging approach, based on coupling antigens to the 
complement protein CM, has been exploited. 
Of the putative surface-expressed parasite-encoded proteins so far discovered, P. 
falciparu,n erythrocyte membrane protein-i (PfEMP-l) has been most thoroughly 
characterised and antibody responses to these antigens correlate with the 
development of age-acquired immunity. This is the rationale underlying the 
development of a malaria vaccine based on this antigenic, but variable protein. Such 
a vaccine could confer the capacity to control parasitaemia and the clinical symptoms 
of the disease by stimulating the production of receptor-blocking antibodies that act 
by preventing adhesion of the parasitised erythrocyte to venous endothelium. 
It was aimed to establish initial 'proof of concept' in the mouse model, using a DNA 
vaccine approach and the BioRad HeIiosTM  Gene Gun. Plasmids were constructed to 
encode C3d/PfEMP-1 fusions and expression of recombinant protein in mammalian 
cells in culture was assayed. Eukaryotic expression of P. falciparuin proteins proved 
to be problematic and a re-codoning approach was adopted to address this. The 
production of polyclonal anti-PfEMP-1 antibodies in mice was assessed in 
immunofluorescence assays and in immunoblot with P. falciparu,n-infected 
erythrocytes. The data question the suitability of a DNA vaccine approach in the 
development of a PfEMP-i-based vaccine using CM. 
In order to raise specific antibodies to PfEMP-1 and to develop a suitable assay to 
assess immunogenicity of this antigen, research efforts became focussed on the 
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production of recombinant PfEMP-1 protein, with a view to immunising mice. A 
recombinant PfEMP-1 domain was expressed in mammalian cells and characterised, 
demonstrating it to be the ligand involved in binding uninfected erythrocytes. Its 
reactivity with immune sera and, therefore, its suitability as a malaria vaccine 
candidate was assessed. Findings highlight the need for further work on the 
development of methods to produce functionally active recombinant protein. They 
also show the necessity of improving methods of detecting surface expression of 
PfEMP-l. 
The suitability of the Sairniri monkey model for CM-based vaccination and P. 
falciparurn challenge experiments was assessed. In other species, the receptor for 
CM is CR2, expressed on B cells. Sairniri B cells were characterised and their 
capacity to bind human CM was demonstrated, indicating that Sairniri is potentially 







AP Alkaline phosphatase 
ATP Adenosine tn phosphate 
BCR B cell receptor 
BMGY Buffered glycerol-complex medium 
B MMY Buffered methanol -complex medium 
BSA Bovine serum albumin 
C Cytosine 
eDNA Complemetary DNA 
CMV Cytomegalovirus 
CR1 Complement receptor 1 
CR2 Complement receptor 2 
CSA Chondroitin sulphate A 
dNTP Deoxynucleoside triphosphate 
dATP Deoxyadenosi ne tn phosphate 
dCTP Deoxycytosine triphosphate 
dGTP Deoxyguanosi ne tn phosphate 
dTTP Deoxythymidi ne tn phosphate 
DAF Decay accelerating factor 
DAPI 4' ,6'-diamidino-2-phenylindole 
DMEM Dulbecco's Modified Eagle's Medium 
DMSO Dimethyl sulfoxide 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
FCS Fetal calf serum 
FDC Follicular dendritic cell 
Gravity 




HRP Horseradish peroxidase 
HPLC High performance liquid chromatography 
HSP Heat shock protein 
ICAM- I Intracellular adhesion molecule-i 
ICAPB Institute of Cell. Animal and Population Biology 
IFA Immunofluorescence assay 
IgG Immunoglobulin G 
1gM Immunoglobulin M 
IP Institute Pasteur 
lx 
iRBC Infected red blood cell 
Kb Kilobases 
LB Luria broth 
LPS Lipopolysaccharide 
mAb Monoclonal antibody 
MCS Multiple cloning site 
MHC Major histocompatibility complex 
MSP-1 Merozoite surface protein 1 
NIMR National Institute for Medical Research 
OD Optical density 
OPD 0-phenylenediamine 
PBS(TM) Phosphate buffered saline (0.05% Tween-20, 5% milk) 
PCR Polymerase chain reaction 
PDG FR Platelet-derived growth factor regulator 
PfEM P- 1 Plasmodium falciparurn erythrocyte membrane protein- I 
PVDF Polyvinylidene difluoride 
RNA Ribonucleic acid 
RPMI-1640 Roswell Park Memorial Institute Medium 1640 
RT Reverse transcription 
SAP Shrimp alkaline phosphatase 
T Thymine 
TAE Tris acetate EDTA 
TLR Toll-like receptor 
U Units of enzyme activity 
UV Ultra violet 
v/v Volume for volume 
w/v Weight for volume 
YPD(S) Yeast extract peptone dextrose (sorbitol) medium 
Chapter 1: Introduction 
The humanitarian imperative for malaria vaccine development is without question. 
An effective vaccine will require that protective antigens are presented to the 
immune system in such a way as to ensure that they are effective and potent 
immunogens. This thesis describes a body of work that addresses this problem using 
a novel strategy for specifically targeting cells of the immune system to elicit a 
strong, specific and effective immune response. Vaccination strategy, production and 
testing are also addressed. By way of introduction, the feasibility of a malaria 
vaccine is discussed and a rational is given for the development of a prototype 
malaria vaccine that targets a specific stage of the malaria parasite life cycle. 
1.1 	Malaria Vaccines 
1.1.1 	Why is a Malaria Vaccine Needed? 
The global malaria burden is huge; the World Health Organisation estimates 1.1 
million deaths each year and —500 million clinical cases, at least 70% of whom are 
women and children. With the emergence of drug-resistant strains, insecticide-
resistant mosquitoes and as a consequence of population increase and environmental 
change, the malaria problem is growing and no sustainable global control program 
currently exists. The majority of the burden is on Sub-Saharan Africa, where malaria 
accounts for —40% of public health expenditure (Narasimhan and Attaran 2003). 
Children who have suffered from malaria often experience cognitive and learning 
difficulties (Holding and Snow 2001). Indeed, illness and learning retardation are so 
common that malaria has been recognised as a serious hurdle to the economic 
development of entire countries (Sachs and Malaney 2002). The need for a malaria 
vaccine is thus clear. 
Malaria is both cause and consequence of the social, economic, environmental and 
political problems that afflict the developing world. A vaccine that is even partially 
effective would be a cost-effective step towards solving these complex problems. 
Malaria vaccines have been sought for many years, with the first report of partially 
successful human immunisation with an irradiated sporozoite vaccine as far back as 
1973 (Clyde et al. 1973). There have been advances, particularly in achieving 
repeatable short-term immunity to sporozoite challenge, yet no vaccine for mass-
immunisation is available. 
1.1.2 	The Current Targets of Candidate Malaria Vaccines 
The malaria parasite life cycle presents several targets for attack and defines the 
parameters for vaccine development (Figure 1. 1). These targets require specialised 
types of vaccine and can be summarised as follows: 
Pre-erythrocytic stage vaccines. Directed against sporozoites and intra-
hepatocytic stages, designed to induce immune responses that prevent sporozoites 
invading the liver or their development in hepatocytes. They thereby prevent the 
establishment of the erythrocytic stage that is responsible for pathology and clinical 
manifestations of the disease. 
Erythrocytic stage vaccines. Designed to confer protection but not necessarily 
sterile clearance, by limiting the erythrocytic replication cycle. The goal is to induce 
immunity against erythrocytic stage parasites and either eliminate all parasite 
invasion of RBCs or modulate the infection to the extent that the parasite burden 
never becomes high enough to cause (severe) disease. 
Anti-mosquito stage vaccines. Aimed at preventing parasite development in the 
mosquito and thereby limiting disease transmission. 
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Figure 1.1 
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Figure 1.1: Life cycle of P. falciparum. Adapted from www.dpd.cdc.gov . The targets of 
candidate malaria vaccines are shown. A: Infection-blocking or pre-erythrocytic-stage 
vaccines. B: Anti-blood-stage vaccines. C: Anti-mosquito-stage or transmission-blocking 
vaccines. During a blood meal, an infected female Anopheles mosquito inoculates 
sporozoites into the human host. Sporozoites infect liver cells and mature into schizonts, 
which rupture and release merozoites. After replication in the liver, parasites undergo 
asexual multiplication in the erythrocytes. Merozoites infect erythrocytes and mature into 
schizonts, which rupture and release more merozoites. Blood-stage parasites are responsible 
for the clinical manifestations of the disease. Some parasites differentiate into sexual stages 
(gametocytes). Mosquitoes ingest gametocytes during a blood meal. Parasite multiplication 
in the mosquito is known as the sporogonic cycle. While in the mosquitos stomach. 
microgametes penetrate the macrogametes generating zygotes. Zygotes in turn become 
motile and elongated (ookinetes) which invade the mid-gut wall of the mosquito where they 
develop into oocysts. Oocysts grow, rupture, and release sporozoites which make their way 
to the mosquito salivary glands. Inoculation of the sporozoites into a new human host 
perpetuates the life cycle. 
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The different parts of the life cycle are susceptible to different host immune 
responses. For all current vaccines in use, relatively little is known about their 
specific mechanisms of action and the types of immune response elicited. Modern 
synthetic vaccines will, ideally, induce appropriate immune responses to specific life 
cycle stages. This requires the identification and characterisation of B and T 
lymphocyte epitopes expressed by the parasite or by parasitised host cells and 
incorporating them into a delivery system that maximizes the interaction between the 
vaccine epitopes and the host immune system. 
Of the four species of Plasmodium that cause malaria in humans (P. ovale, P. vivax 
and P. malariae), P. falciparum causes most death and severe disease including 
cerebral malaria, severe anaemia and malaria in pregnancy. A species-specific 
vaccine for P. falciparum is thus the focus of current malaria vaccine development 
and this thesis. 
All three vaccine strategies are being actively pursued, thanks to recent increases in 
funding (Hoffman 2004). although the main body of malaria vaccine development 
has, to date, been aimed at the pre-erythrocytic stage of the parasite life cycle. 
The characteristic of P. falciparum that makes it a particularly dangerous parasite is 
the ability of parasitised erythrocytes to adhere to the endothelium of the host 
microcirculation. This cytoadherence is unique to P.falciparurn and is likely to be 
the virulence factor that contributes to cerebral malaria (CM), most commonly seen 
in children in endemic areas and often fatal (Berendt et al. 1994). A vaccine that 
induces antibodies to the components of parasitised erythrocytes required for 
endothelial attachment, by preventing or blocking this attachment, could eliminate 
adherence and thereby protect against death from the disease. This is the rational for 
the development of an adhesion-blocking erythrocytic stage vaccine. 
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1.1.3 	The Difficulty of Developing a Malaria Vaccine 
All vaccines, with the exception of Hepatitis B, are based on attenuated or 
inactivated whole pathogens, or material derived directly from the infectious agent. 
Crude preparations of malaria parasites, however, unlike those of some bacteria or 
viruses, have not been shown to be effective as vaccines (Cohen 1985). Since the 
early 1980's and the advent of recombinant protein technology, scientists have tried 
to develop recombinant subunit malaria vaccines. 25 years later, however, there 
remains only one recombinant protein vaccine available for any disease; the synthetic 
Hepatitis B surface antigen, produced in yeast (Hilleman 1987). No licensed human 
vaccine exists based on synthetic peptides, recombinant viruses, recombinant 
bacteria or DNA plasniids. 
There are a number of reasons why a synthetic vaccine has not been developed for 
malaria; not only do malaria parasites have multi-stage life cycles in which they 
express many different proteins at different times, they also have much larger 
genomes, coding for more proteins. Protective immune responses against the 
extracellular sporozoites that enter with the bite of a mosquito may have no effect on 
the asexual erythrocytic stage merozoites. P. falciparuin has enormous variability in 
its proteins (Florens et al. 2002; Gardner et al. 2002). This variability is critical to the 
parasite's survival, enabling it to evade host immune defences, but it also means that 
a vaccine containing a single sequence of a single protein is unlikely to work. 
All existing vaccines are for diseases for which sterile, or near sterile, natural 
immunity is induced after acute exposure to the infectious agent. In the case of P. 
falciparuin, no completely protective immune response, targeting defined antigens or 
epitopes, has been identified and even a lifetime of exposure to repeated and 
continuous infection does not induce sterile immunity. The acquired immunity seen 
in older children and adults is a non-sterilising protection against illness with 
sustained parasitaemias, although these parasitaemias are much lower than those seen 
during disease episodes. 
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That malaria immunity is species-specific was demonstrated by the use of malaria 
infections as a treatment for neurosyphilis. Under controlled conditions, malaria 
therapy patients were inoculated with sequential heterologous infections. Immunity 
was observed when individuals were subject to repeat infections with one species, 
but not when heterologous species were used (Covell and Nicol 1951). That 
immunity is also stage-specific was first proved by Nussenzweig and colleagues in 
1967, who showed that an effective P. berghei irradiated-sporozoite rodent malaria 
vaccine did not protect against challenge with erythrocytic P. berghei challenge 
(Nussenzweig 1967). 
Malaria parasites are capable of immune evasion at the population and individual 
level due to allelic and antigenic variation (Roberts et at. 1992). Active suppression 
of the host immune response may be an additional parasite strategy for survival. This 
is supported by the findings of Urban ci at., who show down-regulation of host 
immune responses via cytoadhesion of P. falciparuin-infected RBCs to dendritic 
cells (DCs). Intact malaria-infected erythrocytes adhere to DCs, inhibit their 
maturation and reduce their capacity to stimulate T cells (Urban et at. 1999). Other 
studies demonstrate that immune responses to P. falciparum infection are genetically 
restricted and that a successful vaccine may need to contain a broad variety of T cell 
epitopes to be effective in a wide variety of HLA backgrounds (Hill etal., 1991). 
Finally, an effective subunit vaccine may need to induce both T cell and antibody 
responses. Both types of response may have to be directed against multiple proteins, 
at different stages of the life cycle, and at the same time. Malaria vaccine developers 
thus face a technical problem that has not been solved for other infectious agents. 
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1.1.4 	Is a Malaria Vaccine Feasible? 
Despite these obstacles, there is reason to believe that a malaria vaccine is 
achievable. There is evidence that protective naturally acquired immunity to malaria 
is achieved with age and experience of multiple infections. What is achieved by 
nature may be achievable by deliberate immunisation. Passive transfer studies using 
purified immunoglobulin from immune individuals have shown that this immunity, 
or at least the humoral component of it, is transferable and can resolve or 
significantly reduce fever in recipients with high parasitaemias (Cohen et al. 1961). 
Several vaccines in development have been shown to protect against malaria in 
animal models and even to a limited extent in humans (Richie and Saul 2002). The 
most success to date has been achieved by immunisation with irradiated sporozoites 
and vaccines based on sporozoite surface components such as the circumsporozoite 
protein, CSP (Stoute et al. 1997). Several such vaccines have been shown to confer 
protection or partial protection against sporozoite challenge in rodents (Nussenzweig 
1967) and in humans (Rieckmann etal. 1974; Clyde 1990; Stoute etal. 1997). 
The pursuit of an attenuated sporozoite vaccine has been largely abandoned due to 
the impracticalities of generating the sheer number of live sporozoites that would be 
needed to immunise large numbers of individuals and the technical and logistical 
impracticalities of carrying out such a vaccination program. Whilst there has been a 
resurgence of interest in this type of vaccine and the founding of a company, Sanaria, 
to develop a radiation-attenuated P. falciparurn sporozoite vaccine (Luke and 
Hoffman 2003; Hoffman 2004), current energies are focussed on the quest for a 
modern subunit malaria vaccine. 
Malaria vaccine development is a controversial field, in which opinion sometimes 
masquerades as established fact. What is clear is that rational development of a 
malaria vaccine requires an understanding of the underlying mechanisms causing the 
pathology of the disease and the immune response to P!asrnodiurn infection. These 
are discussed in the following section. 
1.2 	Pathology, Disease Etiology and Immune 
Response 
	
1.2.1 	Clinical Symptoms 
Malaria is characterised by violent fever, muscle aches and headache. The recurrence 
of these symptoms every 48 hours coincides with the timing of the erythrocytic cycle 
of the P.falciparurn parasite. Fever has three stages; a rapid rise in body temperature 
to 40-41°C, during which the patient feels extremely cold, followed by a feeling of 
unbearable heat lasting 1-2 hours, before intense sweating to restore body 
temperature back to normal. In young children or naïve individuals, severe anaemia, 
respiratory distress, coma and death are common. Older children and adults, 
however, have asymptomatic parasitaemias. Cerebral malaria is typified by impaired 
consciousness (confusion, stupor, unrousable coma), preceded by convulsions, 
immobility and involuntary muscle spasms. The mortality rate in such cases is 
between 15-33% (Marsh and Snow 1999) and is associated with depth of coma 
(Genton et al. 1997; Jaffar et al. 1997). Severe anaemia is seen in 20% of all cases 
(Marsh et al. 1995) and in all infections the severity of red cell destruction is 
associated with high parasitaemia. Other complications including pulmonary oedema 
and respiratory distress, hypoglycaemia, cerebral oedema and renal failure have all 
been documented (reviewed in Patel et al. 2003). Pregnant women are at increased 
risk; malaria infection is linked to low birth-weight and a higher risk of mortality, 
especially for primigravidae (Fried and Duffy 1998). 
1.2.2 	Sequestration 
The ability of mature forms of P. falciparuin parasites to avoid the peripheral 
circulation was first noticed in the initial descriptions of infection over 100 years 
ago. Since then, cytoadherence has been confirmed by demonstration in rat 
mesocecum (Raventos-Suarez et al. 1985) and levels of sequestration in different 
organs (as seen by post-mortem examination) have been correlated with clinical 
presentation and fatality (MacPherson et al. 1985; Pongponratn et al. 1991). Iii fact, 
the earliest recognised and most consistent feature in fatal malaria infections in India 
is the presence of infected red blood cells (iRBCs) in brain capillaries and post-
capillary venules (the work of malariologists in the first decade of the 201h  century, 
reviewed in (Newton et al. 1998). Sequestered parasites are predominantly 
trophozoites and schizonts in the brain, liver, spleen, heart, lungs and gastro-enteric 
tract. Parasitised cells line the endothelia so that blood vessels become swollen and 
sometimes completely blocked. Pathology is believed to be through mechanical 
vascular obstruction and narrowing of the vessel (Berendt et al. 1994), acting in 
combination with high levels of pro-inflammatory cytokines to disrupt normal 
functioning of the brain and other organs. Recently, however, Taylor and colleagues 
looked at the brains of 31 children thought to have died from cerebral malaria and 
found no evidence of parasite sequestration in more than 20% of the patients (Taylor 
et al. 2004). Clearly, the relationship between cerebral malaria and parasite 
sequestration in the brain is not straightforward. 
1.2.3 	Naturally Acquired Immunity 
The naturally acquired immunity developed by older children and adults in endemic 
areas markedly reduces the risk of death from malaria by the age of 5 and fatality is 
rare by the age often (Billewicz and McGregor 1981). The immunity seen in adults 
rarely reaches completion (Marsh 1992), but effectively reduces mortality and 
morbidity. Appreciable parasitaemias are seen in the absence of any particularly 
noticeable ill-effects (Smith etal. 1993). 
Dissecting the immune response to P.falciparuin infection is not easy. Both humoral 
and cellular responses play a part and different immune effector mechanisms are 
elicited by the host to different parasite antigens exposed at different stages of the 
life cycle. Upon inoculation, sporozoites are briefly exposed to the intra-dermal and 
blood-borne immune systems, where they are susceptible to attack by antibodies 
(Mazier et al. 1986; Variderberg and Frevert 2004) and complement (Pied et al. 
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1989; Wenisch et at. 1997). During the pre-erythrocytic stage of the parasite life-
cycle, novel parasite proteins expressed on hepatocytes render parasitised cells 
susceptible to T cell-dependent attack (Romero et at. 1989; Aidoo and Udhayakumar 
2000). Merozoites released from hepatocytes are susceptible to neutralisation by 
invasion-blocking antibody (Holder and Riley 1996). 
1.2.4 	Humoral Erythrocytic-Stage Immunity 
Direct evidence that antibody responses to erythrocytic stage parasites are important 
first came from passive transfer studies using purified immunoglobulin from immune 
individuals. In these studies, purified IgG from adult Gambians was transferred by 
intravenous injection into Gambian children with high parasitaemias (Cohen et al. 
1961). Fever was resolved and parasitaemia was significantly reduced over 4 days in 
these children, whilst non-immune IgG preparations were ineffective. More recent 
work, in which both East Africans and Thais were successfully treated with West 
African sera, suggests that transferred sera contains some of the specificities which 
induce this parasite-clearing type response (Sabchareon et at. 1991). Furthermore, 
Thai children in this study who experienced recrudescence after passive transfusion 
with immune lgG had parasitaemias that remained fully sensitive to the original 
African immune IgG. This observation suggests that the protective antibodies 
recognise conserved rather than variable epitopes. However, this work has not been 
successfully repeated, nor is the mechanism of protection clear. 
Evidence for a variety of protective mechanisms exists and it seems likely that not 
one but several of these mechanisms in combination are responsible for the control of 
disease in immune individuals. Antibodies that block parasite-derived toxin 
(glycosylosphatidylinositol) have been found (Schofield etal. 1996; Schofield et al. 
1999) as well as those proposed to inhibit parasite growth and invasion by activating 
monocytes and macrophages. An antibody-dependent cellular cytotoxicity (A DCC)-
like effect exerted by blood monocytes that inhibits parasite growth has been 
reported, that correlates with protective antibodies (Bouharoun-Tayoun etal. 1990). 
The effect has been named antibody-dependent cellular inhibition (ADCI). Further 
studies have shown a correlation between the ratio of cytophilic to non-cytophilic 
antibodies and the clinical status of protection (Bouharoun-Tayoun and Druilhe 
1992) and more recently, the mechanisms of this protection have been studied 
(Bouharoun-Tayoun et al. 1995). However, these results have proved difficult to 
replicate and the nature of the ADCI response is still poorly understood. 
There is also data supporting the view that reversal of cytoadherence occurs 
(Udeinya et at. 1983; Barnwell et at. 1985; Singh et at. 1988; Udomsangpetch et at. 
1989; Gysin et al. 1996; Duffy and Fried 2003). In one such study, the ability of sera 
from patients with P. falciparum malaria to inhibit the in vitro cytoadherence of 
iRBCs to melanoma cells was tested. Around 50% of the sera both inhibited and 
reversed cytoadherence in one or more of four isolates tested (Singh et al, 1988). 
1.2.5 	Cellular Erythrocytic-Stage Immunity 
Erythrocytes do not have class I or class II MI-IC molecules required for antigen 
presentation. They are therefore unlikely to direct, or be the target of, a direct 
cytotoxic T cell effect. Natural killer (NK) cell activity, however, is not restricted to 
class I MHC recognition and, recently, a novel mechanism of NK cell-mediated 
cytotoxic activity against P. falciparunz-infected RBCs in vitro has been 
demonstrated (Mavoungou et at. 2003). Furthermore, T cells can be stimulated by 
APCs to secrete cytokines which might have indirect effects on parasite killing as 
well as providing help for B cell antibody production. There is evidence for a CD4+ 
T cell role in mice infected with certain rodent malaria species. In P. chabaudi 
infection, complete resolution of parasitaemia is dependent on CD4+T cells. A ThI 
response seems to control initial parasitaemia, followed by a shift to a Th2 response 
and a switch to humoral mechanisms of control of parasitaemia (Langhorne et at. 
2002). However, the behaviour of rodent-derived Plas,nodium species in in-bred 
mouse lines may not reflect the situation in out-bred humans infected with P. 
falciparum. Early observations of T cell mediated responses in HIV-infected 
(CD4+T cell deficient) populations have shown no effect on frequency, level of 
parasitaemia or risk of severe malaria (Butcher 1992). This suggested that T cell 
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mediated responses in human malaria were unimportant. More recent studies, 
however, have indicated that HIV/P. falciparum co-infections lead to more severe 
manifestations of both diseases and that the opposite is true - malaria may in fact be 
playing a major role in the particularly devastating impact of the AIDS epidemic in 
sub-Saharan Africa (Taylor and Hoffman 2000). 
1.2.6 	Summary of the Immune Response to Blood-Stage P. 
falciparurn Infection 
Although an immunodominant protective antigen has not been identified in sufficient 
detail to permit proof by successful immunisation, passive transfer studies suggest 
that antibodies are important in protection against the erythrocyte stage. Cytophilic 
antibodies directed against conserved epitopes are consistent with some evidence, as 
is the alternative theory that immunity consists of an accumulation of multiple 
responses to immunogenic but highly variable epitopes (Hviid et al. 2003) It may be 
that strain-specific immunity requires at least several consecutive infections and is 
therefore gradual, or that critical antigens involved in protection are relatively 
invariant but poorly immunogenic. A role for anti-toxic immunity cannot be 
excluded and antibodies that prevent cytoadherence certainly seem to be important. 
Since the pathology of severe malaria is largely a consequence of the ability of P. 
falciparu,n parasites to cytoadhere and sequester in the peripheral circulation, a 
vaccine that boosts anti -cytoadherent immunity is a rational project. 
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1.3 	The P. falciparurn-Infected Erythrocyte 
The erythrocytic-stage of infection leads to the expression of novel parasite-derived 
antigens on the erythrocyte surface, modifications to the cell membrane to form 
knob-like structures, alterations in metabolite transport, modification of host antigens 
and generalised effects on membrane flexibility. There is now a body of data 
indicating that the development of immunity to malaria involves responses to the 
antigens expressed at the surface of infected erythrocytes (Giha et at. 1999; Giha et 
at. 1999; Bullet at. 2000; Giha etal. 2000). 
1.3.1 	The Immune Response to the P. falciparuin-Infected 
Erythrocyte Surface 
The surface of the infected erythrocyte was identified to be of immunological 
importance as far back as 1938. Eaton and colleagues showed that erythrocytes 
containing mature schizont stage parasites could be agglutinated by immune serum 
(reviewed in (Kyes et at. 2001). Later studies by Barnwell and colleagues, using 
cloned lines of the monkey malaria P. knowlesi, confirmed that that the agglutinating 
antibody response was stage-and isolate-specific and that the parasite had the 
capacity to express successive antigenic variants (Barnwell etal. 1982). Extending 
these simian experiments to the situation in humans, a number of studies have 
reported that the most frequently agglutinated isolates tend to be from those suffering 
from severe disease (Bull et al. 1998; Bull et al. 1999; Bull ci' at. 2000; Giha ci' al. 
2000) suggesting that clinical immunity is acquired through an immune response to 
commonly recognised antigenic variants. This has been supported by recent evidence 
demonstrating serocon version to P. faiciparum-i nfected erythrocyte surface antigens 
(PIESAs) expressed during acute infection (Ofori etal. 2002; Chattopadhyay ci' at. 
2003). Whether these antibodies have specific functional properties other than 
recognising variant surface antigens and the mechanism that links their appearance to 
immunity is still a subject of intense debate. 
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There are a number of candidates in the search for protective PIESAs (reviewed in 
(Sherman et at. 2003). To date, a number of multigene families have been described, 
coding for variant proteins thought to be associated with, or expressed on the iRBC 
surface. These are rifins (Kyes et al. 1999), stevor (Kaviratne et at. 2002) and 
Plasmodium falciparuin Erythrocyte Membrane Protein - ] (PfEM P-i). Of these, 
expression at the iRBC surface has been shown only for the rifins and PfEMP-1, with 
PfEMP-1 as the prime candidate for a role in both the pathology of severe malaria 
and the acquisition of immunity. 
1.3.2 	PfEMP-1 
Data suggests that the way in which parasites differ antigenically is through their 
expression of the antigen PfEMP-1 (reviewed in (Flick and Chen 2004). This protein 
is a high molecular weight protein (200-350 kDa) expressed in late-stage infected 
erythrocytes (Leech et at, 1984). PfEMP-i has been localised to the —100 nm 
diameter 'knob' structures identified at the surface of the infected cell (Berendt et al., 
1994). PfEMP-1 is the only parasite antigen that is proven to be exposed on the 
surface of intact parasitised erythrocytes. 
A protective role for antibodies against PfEMP-I in naturally acquired protective 
immunity has been suggested in a number of longitudinal studies (Giha et at. 1999; 
Giha et al. 1999; Giha et al. 2000). These studies indicate that pre-existing anti-
PfEMP-1 antibodies can reduce the risk of contracting clinical malaria when 
challenged by novel parasite clones expressing homologous, but not heterologous 
variable surface antigens and that antibodies to variant antigens are induced by both 
clinical and sub-clinical infections. 
In Kenyan children with clinical malaria, the antigenic variants of PfEMP 
expressed at the time of the malaria episode were not often recognised by the child's 
pre-infection sera and susceptibility to the disease seems to correlate with 'gaps' in 
the child's developing repertoire of PfEMP-I antibodies (Bull et al. 1998). In this 
study it was concluded that the agglutinating antibody response correlates to some 
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degree with protection against clinical malaria and that pre-existing antibodies only 
provide protection against variants to which they are directed. Biggs and colleagues 
showed that cloned parasites cultured in vitro over several months eventually gave 
rise to antigenically different parasites that express PfEMP- I molecules of different 
size and antigenicity (Biggs et at. 1991). Later studies have demonstrated antigenic 
variation at 2.4% per parasite generation and that antigenic variation in culture is 
linked to different cytoadherence phenotypes (Roberts et at. 1992). That this 
antigenic variation and progression of cytoadherence phenotypes also occurs in 
naturally acquired human infection has been confirmed (Staalsoe et at. 2002). 
1.3.3 	Var Genes 
The multi-gene var family (after variant surface antigen) encoding PfEMP-I has 
been identified and cloned (Baruch et al. 1995; Smith et at. 1995; Su et al. 1995). 
There are —60 var genes, distributed through several chromosomes (Gardner et al. 
2002). Individual iRBCs, however, probably express only a single var gene - many 
var genes are transcribed at the early ring stage, but a single dominant mRNA coding 
for the surface-expressed PfEMP-1 appears to be selected at a later stage (Chen et at. 
1998; Noviyanti et at. 2001). 
There are a number of characteristics of var genes that implicate them as the major 
determinants of antigenic variation and cytoadherence. They have a large repertoire, 
comprising 2%-6% of the haploid genome, and dramatic sequence variation is seen 
both within a single genome and between clones from different geographical 
locations (Kyes et al. 1997). Gene rearrangements are readily detected (Freitas-
Junior et al. 2000) and var genes are variably expressed in different parasite lines. It 
has been shown, for example, that antibodies against several var sero-types are 
induced during an infection (Giha et al. 2000) and expression of variant surface 
antigens associated with severe malaria is accompanied by up-regulation of a 
particular group of var genes (Jensen et al. 2004). 
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Var genes vary in size between 4 and 13kb and consist of two exons separated by an 
intron of —I kb (Figure 1.2). Each var gene has a 5' exon, encoding the large and 
highly variable extra-cellular portion of PfEMP-1 and a 3' exon, encoding a 
conserved intracellular portion. The extra-cellular region consists of a variable 
number of Duffy binding-like (DBL) domains and cysteine-rich inter-domain regions 
(CIDRs). It is the interaction of DBLs and CIDR domains with host ligands that is 
responsible for cytoadherence. 
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Figure 1.2: Var gene schematic. Exon I encodes the extracellular and putative 
transmembrane domains. The NTS (N terminal sequence) is 75-107 amino acids (I 
conserved cysteine) with a predicted globular conformation and conserved central block with 
ci-helical fold. The C2 domain is predicted to have globular features and regions of a-helical 
structure. It is comprised of 140-217 amino acids, with 4 invariant cysteines. The CIDR 
(Cysteine—rich Inter Domain Region) of 300-400 amino acids (13 invariant cysteines) has 
extensive sequence variation, with semi-conserved regions. All var genes encode a variable 
number of DBL (Duffy Binding Like) domains. The TM (transmembrane region) is a 
hydrophobic region encoded at the end of the exon that tits the criteria of a transmembrane 
segment in all var genes. Exon 2 encodes a 45-55kDa conserved C-terminal sequence with 
acid character. The acidic terminal segment (ATS) anchors PfEMP-1 at the knobs and is 
assumed to have a cytoplasmic location. 
1.3.4 	The Duffy Binding-Like Domains of PfEMP-1 
Database searches identify 2 to 4 domains within each var sequence that are 
homologous to cysteine-rich binding domains of certain Plasmodium molecules 
involved in erythrocyte invasion. These erythrocyte-binding antigens (EBAs) contain 
functional binding regions that determine invasion specificity. The homology with 
such EBAs has been used to group these domains into a superfamily, the 'Duffy 
Binding Like' superfamily, after the Duffy binding domain of P. vivax. It is likely 
that PfEMP-1 DBL domains evolved from an ancestral EBA protein. DBLs show 
polymorphism in length and sequence. There is a predicted, related DBL fold, but 
distinct DBL sequence classes, denoted c', 13 , 'y, 8 and E. The position of the DBL 
domain within the full-length protein is denoted by a number (Figure 1.2). DBLIa is 
the most conserved of the domains, with amino acid signatures that distinguish it 
from other domains. Other DBLs have less discriminating signatures. They show 
cross alignment and variation in number, which suggests they undergo shuffling and 
deletion. There are 10 invariant cysteine residues in each DBL, distributed among 10 
semi-conserved homology blocks. All var genes have a terminal DBLIa followed by 
CIDRJ, so the N-terminal region of PfEMP-1 is structurally conserved. 
1.3.5 	The Relationship Between Cytoadherence and PfEMP- 1 
A variety of endothelial receptors have been implicated in cytoadherence (reviewed 
in Kyes et at., 2001) and a number of studies show that differential binding to 
adhesion molecules involved in sequestration correlates with the expression of var 
genes. These adhesion properties have been localised to CIDR and DBL domains 
(Baruch et at. 1995; Smith et at. 1995; Su et al. 1995). CD36-mediated 
cytoadherence has been attributed to CIDRa (Baruch et al. 1997) and the epitopes 
that mediate binding to CSA and ICAM-I have been localised to the DBL'1 and 
DBL(3 domains, respectively (Buffet et al. 1999; Reeder et al. 1999; Smith ci at. 
2000). PfEMP-Is that bind the same receptor may use the same sequence class but 
not all members of a particular DBL class will bind the same molecule. It may be 
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that a single domain type may encode more than one binding attribute, depending on 
the primary sequence. The N-terminal head structure of a single PfEMP-1 from clone 
FCR3SI.2 has been shown to mediate adherence to multiple host receptors including 
CD3I, blood group A antigen, non-immune 1gM, a heparan sulphate—like GAG, and 
CD36 (Chen et at. 2000). The exceptional binding activity of the PfEMP-1 head 
structure and its relatively conserved nature argues that it holds an important role in 
erythrocyte sequestration and therefore in the virulence of the malaria parasite. It is 
hoped to develop prototype malaria vaccines based on antigenic and conserved 
regions of PfEMP-1 and in this respect, the DBL1u/CIDR1 conserved head is of 
particular interest. 
1.3.6 	The Relationship Between Rosetting and PfEMP-1 
One of the few parasite phenotypes proven to be significantly associated with severe 
malaria is an adhesion property known as rosetting (Carlson et al. 1990; Treutiger et 
al. 1992; Rowe et al. 1995). Rosetting can be defined as the spontaneous binding of 
two or more infected erythrocytes to uninfected erythrocytes, forming clumps of red 
cells. It is hypothesised that rosetting plays a direct role in malaria pathogenesis by 
obstructing microvasculature blood-flow (Kaul etal. 1991), or that it may be 
indirectly involved by enhancing parasite growth and survival, leading to higher 
parasitaernias (Rowe et at. 1995). This could be brought about either by increased 
invasion efficiency due to the close proximity of cells to bursting schizonts, or that 
uninfected erythrocytes hide infected cells and aid immune evasion. 
Studies show that the only consistent difference between pairs of rosetting and non-
rosetting clones is in the PfEMP-1 variant expressed. It therefore seems likely that 
PfEMP-1 is the rosetting ligand in all parasites and the DBLIa domain has been 
identified as the parasite-encoded ligand that mediates rosetting in different rosetting 
clones (Rowe et al. 1997; Chen et al. 1998). Recently, Chen and colleagues 
immunised mice with recombinant Semliki forest virus (SFV)-DBLICX particles and 
boosted with an E. co/i-derived DBLIct-GST fusion protein. The antibodies 
generated recognise native PfEMP-1 at the live-iRBC surface, disrupt preformed P. 
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falciparum rosettes in vitro and prevent the sequestration of iRBCs in vivo (Chen et 
al. 2004). This data strongly supports the involvement of DBLIa in rosetting, the 
role of rosette-disruptive antibodies in preventing sequestration and the use of 
DBL1u in a vaccine against severe malaria. 
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1.4 	Testing An Erythrocytic-Stage Malaria Vaccine 
Evaluation of vaccine candidates in clinical trials is fundamental to the selection 
process of product development. Selection of malaria vaccine candidates is based on 
safety and immunogenicity profiles (Phase I), and then by experimental infections in 
humans (Phases ha and b and Phase III). Such experimental infections are a unique 
feature of malaria vaccine trials, ethically possible only because the erythrocytic 
cycle can be broken by drug cure before illness develops. The efficacy of pre-
erythrocytic vaccines in humans can be easily and ethically assessed; they have 
failed if they do not prevent or delay the development of an erythrocytic-stage 
infection. Mild clinical symptoms of malaria are often seen in volunteers during 
Phase II trials (Church et al. 1997) but volunteers are chloroquine-treated at the first 
signs of parasitaemia, as detected by microscopy. Erythrocytic-stage vaccines on the 
other hand, whose primary goal is not to prevent infection but to reduce mortality 
rate, are much harder to assess. It would be difficult for example, to establish 
efficacy of a vaccine designed to prevent the cytoadhesion of iRBCs, if volunteers 
had to be treated at the first sign of parasites in the blood. To establish control of 
infection, by a vaccine that induces a type of immunity that is boosted by the 
infection, requires repeated experimental challenges or field trials. Such 
experimentation is unfeasible and ethically questionable in human populations and, 
whilst new ways of testing these vaccines are being developed (Hermsen et al. 2004), 
there is a strong case for the use of animal models. 
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1.4.1 	An Animal Model for P. falciparurn Challenge 
Experiments 
At present, there is no absolute requirement for disease challenge data in an animal 
model before a candidate vaccine can proceed to human trials. Decisions on whether 
to test a product in humans are made on the assumption that it is made under current 
Good Manufacturing Practices (GMP) and that it has a good toxicology profile. 
However, with some $85 million being invested in malaria vaccine development in 
2004 and the completion of the malaria genome project in 2002 (Gardner el al. 2002) 
which provided sequences of about 5,300 genes and identified many more candidate 
vaccine antigens, there are too many prototype vaccines in development for all to go 
to clinical trials. In the search for the most efficacious immunogens, animal models 
provide an efficient route for comparing candidates made in different expression 
systems and by different folding or purification techniques. They provide efficacy 
data before clinical-grade production and prevent the need for extensive field trials, 
which are very expensive. The mouse model has been used extensively to 
characterise the immunogenicity, antigenicity and presentation of candidate malaria 
vaccines, but mice cannot be challenged with P. falciparum malaria. PflEMP-l-based 
vaccines are in the early stages of development and still very experimental - the 
consequences of an adhesion-blocking vaccine on parasite populations (var gene 
switching, growth rate and adhesive phenotype for example) are uncertain. One 
concern is that a vaccine that blocks the adhesion mediated by a specific ligand, may 
in-fact select for parasites with an alternative (and possibly more virulent) adhesive 
phenotype, using a different ligand. Particularly in the case of a PIEMP-l-based 
vaccine, therefore, P. Jàlciparum challenge experiments (in which protection is 
assayed over the course of challenge with the human malaria parasite) are considered 
by some to be an essential prelude to human clinical trials. 
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1.4.2 	The Sain,iri Monkey Model 
P.Jalciparum does not grow in rodents, nor in any species other than man and a few 
primates. A number of P. falciparum strains are adapted to grow in a subset of New 
World Monkey (NWM), particularly after immuno-compromising the primate by 
removing its spleen. The Palo Alto isolate of P. falciparum is one such strain. Palo 
Alto can infect Saiiniri sciureus monkeys (Gysin et al. 1980; Gysin and Fandeur 
1983), making this species a suitable model for P.falciparum challenge experiments 
and candidate malaria vaccine efficacy modelling. 
Efficacy modelling in the NWM is not without problems. Circumstantial supporting 
evidence for the co-evolution of human MHC epitope specificities and the 
prevalence of Plasmodium allelic polymorphisms (Hill et al. 1991), suggests that 
even a single amino acid substitution can change the specificity and affinity of 
peptide-epitope binding. Differences, therefore, between NWM MHC gene 
sequences and human homologues may make a comparison of the response to 
specific imniunogens in humans and monkeys irrelevant. Furthermore, it is limited 
by the rapid acquisition of blood stage immunity seen in NWMs. 
This said, no ideal animal model exists for P. falciparuin malaria and NWMs have 
several features that make them the best option available. Apart from the uncommon 
ability of NWMs to take a strain of human malaria, there are a number of parallels 
with human infection that can be seen in this model. Like humans, these monkeys 
show within-species karyotype-specific susceptibility to infection. Sequestration has 
been observed, albeit to a lesser extent than in humans (50-60% compared to 95% of 
cerebral microvasculature) and cerebral malaria can also be seen (Gysin etal. 1992). 
Rosettes and anti-rosette formation antibodies formed by squirrel monkeys and 
humans exhibit similar characteristics, making this particular monkey a good 
experimental model to study rosette formation ((Gysin et al. 1992; Tourneur et al. 
1992). Furthermore, when IgG preparations from immune African donors 
(previously shown to control P. falciparurn multiplication in the blood of Thai 
patients) were transferred to Saimiri monkeys acutely infected with P. falciparurn 
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(Gysin et al. 1996), a dose-dependent in vivo inhibition of parasite development was 
observed. These results justify the use of Sairniri monkeys for malaria vaccine trials. 
1.4.3 	The Palo Alto '0' Variant 
The Palo Alto strain of P. falciparurn (FUP) has been adapted for propagation in vivo 
in Sai,niri monkeys (Gysin et al. 1980; Gysin and Fandeur 1983). Since infections 
with Palo Alto in the squirrel monkey were originally established in the early 1980's, 
they have been extensively used as an experimental model for P. falciparuni malaria 
and several in vitro adapted lines have been derived from this isolate. In 1995, two 
isogenic P.falciparum strains were derived from the Palo Alto line - the '0' and 'R' 
variants (Fandeur et al. 1995). The 'R' variant was isolated under immune pressure 
in a splenectomised Saimiri monkey infected with an '0' type inoculum. These '0' 
and 'R' antigenic variants induced strain-specific protection in Sai,niri monkeys. 
Furthermore, they show differences in the morphology of the iRBC membrane, in 
their adhesion properties, surface fluorescence and agglutination specificities. '0' 
parasites have morphologically normal knobs, the trophozoite stages autoagglutinate 
in the absence of immune serum and these parasites form rosettes. Conversely, the 
'R' variant has morphologically abnormal knobs, does not autoagglutinate and does 
not rosette. The var genes expressed by '0' and 'R' parasites were identified by RT-
PCR with UNI-EBP var specific primers (Peterson et al. 1995) reported to amplify 
DBL domains from var genes and other DBL-containing genes (Le Scanf et al. 
1999). '0' and 'R' variants express distinct PfEMP-1 molecules. 
RT-PCR and sequencing of cDNA clones from RNA from '0' type parasites 
cultured in vivo in Sai,niri has identified varO as by far the most dominant var 
transcript in these parasites (Odile Puijalon, personal communication). VarO was 
found in 28 of 49 cDNA clones sequenced. The '0' variant of Palo Alto has been 
cultured in vitro for several years at the Institute Pasteur, Paris, where it has been 
selected for rosetting and the rosetting clone, PA89175, has been isolated by 
micromanipulation. Frequent RT-PCR analysis during routine culturing of PA89F5, 
using redundant var-specific primers shows varO to be the only transcript in late- 
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stage parasites and this has been accepted as indicative evidence that it is the 
expressed var gene in these parasites. 
VarO is thus considered to be a candidate for an erythrocytic-stage malaria vaccine. 
26 
1.5 	The Need for Effective Immunopotentiators in 
Malaria Vaccine Development 
1.5.1 	Adjuvants 
The immunity-promoting activity of any vaccination strategy is determined not only 
by the presence of relevant antigen, but also by the addition of a suitable adjuvant 
capable of activating and promoting an efficient and appropriate immune response 
(Liu 1998). Peptide immunogens lack the non-specific immunostimulation provided 
by multiple proteins present in an attenuated pathogen. Overcoming this is a major 
obstacle in the design of modern vaccines. A variety of substances, known as 
adjuvants, can increase antigen-specific antibody production when added to antigens, 
as first discovered by Ramon in 1925 (reviewed in Schijns 2000). Despite decades of 
research, however, and the recognition of many different types of adjuvant, little is 
known about their mode of action. The well-known immunologist Charles Janeway 
called adjuvants "the immunologists' dirty little secret" (Janeway 1992); 'dirty' 
because adjuvants contaminated the purified vaccine antigen, and 'secret' because 
their mode of action remains a mystery. 
Antigen delivered without adjuvant is quickly taken up by professional APCs or 
removed by neutrophils and macrophages. After initial immune activation, dwindling 
antigen concentration becomes the limiting factor in sustaining T cell stimulation and 
proliferation, so the immune response declines as the antigen disappears. The depot 
theory of antigen action proposes that adjuvants retain antigen at the injection site 
and release it in small quantities over a prolonged period of time, thus maintaining T 
cell activation and extending an otherwise short-lived response (reviewed in Schijns 
2000). Repository adjuvants such as oil-emulsions, antigen-absorbing aluminium 
salts, and polymer or lipid particles, may work in this way. 
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Janeway proposed that the immune system evolved to respond only when necessary, 
that is in situations of stress represented by some 'signature' of a pathogenic 
organism (Janeway 1992). Janeway's theory was that pathogen recognition receptors 
(PRRs) would recognize pathogen-associated microbial patterns (PAMPS) present 
on microorganisms but not on host cells. This recognition event ('Signal 0') is 
necessary for the induction of co-stimulatory 'Signal 2' molecules (the antigen itself 
is 'Signal 1'). 'Signal 2' is essential for the activation of naive T helper cells, the 
coordinators of subsequent T cell-dependent immune responses. Well known 
adjuvants like LPS, pertussis toxoid, mycobacteria and CpG motifs in bacterial DNA 
are thought to work by providing 'Signal 0' through TLR recognition on innate 
immune cells (Hemmi et al. 2000). According to Matzinger's 'danger model' 
(Matzinger 1994: Gallucci et at. 1999), immune activation occurs upon recognition 
of host-derived danger signals from stressed cells in damaged tissues, such as debris 
from necrotic cells, heat shock proteins, nucleotides, reactive oxygen intermediates, 
and cytokines. These endogenous adjuvants activate DCs, again to up-regulate 
'Signal 2' expression. 
The common adjuvants in almost all licensed vaccines (aluminium hydroxide or 
alum-based mineral gel formulations) do not stimulate strong cell-mediated or 
humoral responses and have significant dose limitations. The most effective adjuvant 
- Freund's Complete Adjuvant (FCA) - is a mixture of a non-metabolizable mineral 
oil, a surfactant (Arlacel A), and mycobacteria (M. tuberculosis or M. butvricum). 
Although a potent immunostimulator, it is unsafe for use in humans. At the site of 
injection, FCA causes a chronic inflammatory response, often severe and painful, 
that may result in the formation of chronic granulomas, sterile abscesses and 
ulcerating tissue necrosis. Transient tissue damage at the injection site has been 
observed for many adjuvants and may not be just an undesirable side effect of 
vaccination, but an essential contribution to adjuvanticity, through the release of 
'danger signals' that non-specifically target cells of the immune system. Ideally, 
however, an adjuvant should be a precision drug that activates the desired immune 
reaction, with minimal effect on the health of the injected tissue. There is a genuine 
need for targeted immunopotentiators in order to optimise new vaccine approaches 
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and to raise the titre and increase the affinity of specific antibodies to weak 
immunogens. 
In the case of PfEMP-1, it is worth considering that what might be a potentially 
potent immunogen, may be poorly immunogenic in the context of the erythrocyte 
membrane, where it is surrounded by non-immunogenic host molecules and is 
presented to the immune system without an effective co-stimulatory signal. In a 
recent study, Kinyanjui and colleagues examined the kinetics of antibody responses 
to PIESAs in Kenyan children. They found that resistance to re-parasitization was 
significantly increased in those children that had strong, long-lived antibody 
responses and who showed a switch to the IgG isotype after their initial 1gM 
response (Kinyanjui et al. 2003). These data suggest that in some individuals, or with 
certain PIESA variants, short-lived antibody responses are induced that may be 
associated with poor antibody class switching. To make an effective vaccine based 
on antigenically conserved, protective PIESAs will require significant help in its 
delivery to the immune system to maximize immunogenicity. 
1.5.2 	Complement 
The Complement System is a major defence and clearance system of foreign 
particles and immune complexes in the bloodstream. It forms a vital part of the 
innate immune response to infection. The role of complement in the acquired 
immune response was first demonstrated in the pioneering studies of Pepys in the 
mid 1970s, showing that depleting mice of serum complement C3 by injection of 
cobra venom factor markedly impaired their humoral response to primary antigen 
(Pepys 1974). It later became apparent that activated C3 binds covalently to antigens, 
mediating their uptake by cells bearing C3 receptors (B cells and FDCs), thereby 
enhancing the response to T-dependent antigens and facilitating the generation of 
memory B cells (reviewed in (Fearon and Carroll 2000). 
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During the course of infection, complement is activated via PAMPs on the pathogen 
surface (alternative pathway) or through natural antibody (classical pathway). As a 
consequence of this activation, a cascade pathway is initiated, whereby complement 
protein C3 becomes cleaved to C3b, through the action of the C3 convertase. The 
classical and alternative pathways of the complement cascade are described in Figure 
1.3. C3b is highly reactive, due to the exposure of an internal thioester and either 
remains bound to the C3 convertase, or becomes covalently attached to the pathogen 
surface. Host regulatory molecules (such as membrane bound receptors CR1 and 
DAF and plasma factor H) catalyse the cleavage of bound C3b to inactivated C3b 
(i0b), a potent opsonin, and C3d (Figure 1.4). 
The capacity of C3d to boost the immune response was demonstrated by Dempsey 
and colleagues, in 1996, with experiments using hen egg lysozyme (HEL) as model 
antigen (Dempsey et al. 1996). Recombinant fusion proteins composed of HEL and 2 
or 3 copies of murine C3d were shown to be 1,000 and 10,000 fold more 
immunogenic, respectively, than antigen alone. For HEL fusions to 3 tandemly 
arrayed copies of C3d, the threshold dose required to stimulate an antigen-specific 
response was reduced from 500 to 0.005pmol. Since then, proof of concept has been 
demonstrated in four disease models - measles (Green et al. 2001), HIV (Ross et al. 
2001), influenza (Ross et al. 2000; Watanabe et al. 2003) and malaria (Richard 
Smith, personal communication). Most recently, Barrault and Knight have produced 
C3d 3 coupled to tetanus toxin C fragment (TTCF) using the baculovirus expression 
vector system and shown that this molecule induces responses at doses 100 fold less 
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Figure 1.3: The complement cascade. C3 is the most abundant serum protein in the blood 
and holds a key role in the complement cascade. Both the classical and alternative pathways 
merge at the C3 activation step and continue to form the membrane attack complex. C4b2a is 
the convertase of the classical pathway and C3bBb is the C3 convertase of the alternative 
pathway. The 0 convertase activates 0 by proteolytic cleavage and a conformational 
change in 0 leads to exposure of a highly reactive internal thioester. As such, it is subject to 
nucleophilic attack by water, amino and hydroxyl groups, so it is readily inactivated in the 
absence of pathogen, thereby regulating the system. Alternatively, it becomes bound to the 
pathogen surface, where it can form the C5 convertase (C4b2b3b or C3bBb3b) or be cleaved 






Figure 1.4: C3d is released when C3b, bound to the pathogen surface, is cleaved by 
factor 1. 
C3d is the ligand for complement receptor 2 (CR2/CD21), expressed on mature B 
cells and follicular dendritic cells (FDCs) (Reynes et al. 1985). Evidence for a role 
for CD21 and complement in the induction of B cell responses came from studies on 
CD2 1-deficient mice, that show poor primary and secondary responses to T cell-
dependent antigens (Ahearn etal. 1996; Molina etal. 1996). CD21 associates with 
CD 19. a B cell membrane protein that amplifies B cell activation and is required for 
normal T cell-dependent B cell responses (Rickert et al. 1995). With respect to the 
function of B cells, CD2 1 appears to be involved in the promotion of antigen uptake, 
processing and presentation by B cells to antigen-specific T cells. It can also 
facilitate B cell interactions with FDCs (Fearon and Carroll 2000). 
The mechanism for the enhanced B cell response to complement-tagged antigens is 
not fully understood, although it is becoming clear that the CDI9/CD21 complex 
significantly enhances BCR signalling. Following antigen binding, the BCR 
translocates into plasma membrane lipid rafts that serve as platforms for BCR 
signalling (Cheng et al. 1999). Complement-tagged antigens, however, stimulate the 
translocation of both the BCR and the CDI9/CD2I complex into lipid rafts. This 
results in prolonged residency in and signalling from the rafts, as compared to BCR 
cross-linked with antigen alone. When co-ligated to the BCR. the CD19/CD2I 
complex stabilises and slows the internalization of the BCR. thereby enhancing BCR 
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signalling (Cherukuri et al. 2001). That complement-tagged antigens that co-ligate 
the BCR and the CDI9/CD21 complex promote enhanced antigen presentation has 
also recently been demonstrated (Cherukuri et al. 2001; Barrault and Knight 2004). 
In addition, BCR-independent enhanced antigen processing and presentation has 
been demonstrated for 'C3-tagged' antigens (Thornton et al. 1994; Boackle et al. 
1997). 
The simultaneous presence of antigenic epitopes and CM molecules on the same 
pathogen membrane results in dual recognition by B cells that express both specific 
BCR and CD2I. The activation of B cells under sub-optimal conditions can be 
enhanced or even made achievable via an accessory signal mediated through the 
CD21/CDI9 membrane protein complex. Thus, the necessary 'Signal 2' is provided 
for B cells to overcome the difficulties they face during the initial phase of a primary 
immune response that is to become activated while displaying low-affinity, germ 
line BCR. Coupling CM to candidate antigens remains a promising method for the 
immunopotentiation of malaria vaccines. 
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1.5.3 	Adprotech and Immudaptin TM 
The PhD project is a BBSRC CASE studentship, in which Adprotech Plc is the 
industrial partner. Adprotech is a biopharmaceutical company that applies its 
understanding of the immune system and its unique drug targeting capabilities to 
develop products that address serious illnesses. Adprotech's platform technology, 
developed to enhance the immune response for the production of vaccines, is 
Irnmudaptin TM. ImmudaptinTM harnesses the mechanism for immune stimulation at 
the surface of B cells by using CM to mimic natural immunity. This 
immunopotentiator is 3 copies of CM (C3d3 ) arranged in tandem array and linked to 
antigen. The three copies have been re-engineered at the nucleotide level to prevent 
homologous recombination to C3d 1 in baculovirus expression, or recombination with 
host CM in mammalian expression systems. Immudaptin TM can augment the natural 
immune response and increase antibody production 10,000 fold. Evidence that it 
enhances specific antibody avidity and accelerates isotype switch (Adprotech, 
unpublished) also indicates that germinal centre formation is promoted. It seems 
likely that the 3 copies of C3d coupled to antigen promote multiple interactions 
between B cells and FDCs in germinal centres. Adprotech has used Immudaptin TM in 
the development of a blood-stage malaria vaccine using the merozoite surface protein 
antigen MSP-1 19, with encouraging results. Both protein and DNA immunisation 
approaches have been exemplified using rodent MSP-1 19 fused to C3d 3 . Results 
demonstrate improved survival post challenge, lower parasitaemias and gross 
increases in antibody titre in groups receiving Ag-C3d 3 compared with those 
receiving Ag alone. 
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1.5.4 	The EUROMALVAC Collaboration 
This work has taken place in the context of collaboration with EUROMALVAC, a 
consortium of European university-based malaria vaccine researchers. The 
EUROMALVAC merozoite surface antigens group (under the direction of Dr Tony 
Holder, NIMR) seeks to develop anti-erythrocyte invasion candidate vaccines based 
on antigens expressed on the merozoite surface. Merozoite surface protein-i (MSP -
1) is the leading candidate and Adprotech/NIMR have had some encouraging data 
with work on murine C3d 3 -MSP1 19 fusions (Richard Smith). Another arm of 
EUROMALVAC seeks to develop candidate malaria vaccines based on an anti-
adhesion strategy, with two significant advantages: 
A second class of malaria target antigens for analysis of the efficacy of the 
malaria/immunadaptin strategy 
The possibility of combining the anti-invasion and anti-adhesion targets in a 
multi-antigen vaccine with a common immunopotentiator. 
The EUROMALVAC collaborative groups who have contributed to this project 
were: 
The group of Dr Odile Puijalon at the Institute Pasteur, Paris 
• The group of Dr Mats Wahlgren at the Karolinska Institutet and the 
Swedish Institute for Infectious Disease Control, Stockholm 
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1.6 	DNA Vaccines and Malaria 
Many vaccine systems have been tested for their ability to protect against malaria. 
One reason for the failure to date to develop a practical vaccine has been the 
difficulty of producing candidate vaccines. In 1990, Wolff et al. demonstrated direct 
gene transfer into mice (Wolff et al. 1990) and two years later, the long-term 
persistence of plasmid DNA and foreign gene expression in mouse myocytes was 
confirmed (Wolff et al. 1992). This work paved the way for the development of 
DNA vaccines, a possible short-cut to production of antigenic material by side-
stepping ex-vivo antigen production and driving production by the human cell 
transcription/translation process itself. 
DNA vaccines are eukaryotic expression vectors containing a gene encoding the 
antigen of interest. Upon delivery, DNA enters host cells and directs the expression 
of the plasmid-encoded antigen, thereby inducing an immune response. DNA 
vaccines are currently being developed for a number of infectious diseases (Liu 
1995). The suitability of this route in the case of malaria has been attractive for a 
number of reasons. DNA constructs, unlike recombinant protein, can be easily 
produced using techniques common in molecular biology and at relatively low cost. 
Due to the stability of DNA, they have a long shelf life and the distribution of these 
vaccines would not require a cold chain that could make a protein vaccination 
program logistically unfeasible in the developing countries where a malaria vaccine 
is most needed. DNA vaccine technology is also suited to the development of a 
multi-gene vaccine, which could effectively target multiple stages of the P. 
falciparuin life cycle. This is attractive, not only because of the desirability for 
immune responses against multiple stages of the parasite life cycle, but because 
many antigens are likely to be required to elicit effective immunity against multiple 
wild isolates with variant epitopes. For malaria, DNA vaccines are even more 
seductive, since erythrocytic-stage antigens are likely to be conformationally 
recognised and Plasmodium proteins are difficult to express in current expression 
systems there are often problems with incorrect disulphide bonding and differences 
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in glycosylation between expression systems. That this is a major obstacle is 
exemplified by recent data from Stowers and colleagues, who show that a vaccine 
formulation comprising a glycosylated version of MSP-1 42 conferred no protection to 
P. fa1ciparun challenge in Aotus monkeys, whilst vaccination with an un-
glycosylated version of the same antigen conferred successful protection (Stowers et 
al. 2002). This suggests that differing glycosylation patterns may have a critical role 
in determining vaccine efficacy. 
Animal studies have to some extent alleviated fears about integration into the host 
chromosome and have shown no increase in anti-DNA antibodies or evidence of 
autoimmune disease induction or acceleration after administration of plasmid DNA 
(Tuteja 2002). So far, however, no DNA vaccine has proved sufficiently 
immunogenic to afford protection in humans. Safety and tolerability of a DNA 
vaccine in humans using the circumpsorozoite protein PfCSP has been reported (Le 
et al. 2000), as has some progress with pre-erythrocytic stage vaccines from the 
group of Adrian Hill. The latter group recently reported safety and immunogenicity 
data on a DNA vaccine used in humans, in phase I clinical trials, boosted by a second 
immunisation with modified vaccinia virus Ankara (Moorthy et al. 2003; Moorthy et 
al. 2003). Antigen specific, MHC restricted CD8+ CTL responses seem to have been 
produced in vacinees although, at least by intra-muscular administration, no antigen-
specific antibody responses have been detected. The key to eliciting the desired type 
of response may be in the route of administration and this is being researched, along 
with other improvements in expression and immunogenicity (reviewed in (Gardner et 
al. 1996). 
37 
1.7 	Aims of the Project 
I: To investigate the varO/rosetting relationship and assess the suitability of the 
varODBLla domain as a candidate antigen for a prototype adhesion-blocking 
malaria vaccine. 
To investigate whether C3d 3 fused to a candidate antigen can be used to increase 
the specific antibody response to that antigen, in an erythrocytic-stage malaria 
vaccine. It is hypothesised that an antibody response raised against DBLLu that 
interferes with the rosetting phenotype would afford some level of protection against 
the clinical symptoms of malaria. It was therefore intended to fuse the varO DBLLa 
domain to murine C3d 3 and to immunise mice with this construct, with the aim of 
demonstrating a C3d 3 -induced immunopotention effect. It was aimed to establish 
initial proof of concept using DNA immunisation. 
To investigate whether the squirrel monkey, Sairniri sciureus, is a suitable model 
for C3d 3 -based immunisation and malaria disease challenge experiments using P. 
falciparum. It is aimed to develop the Sai,niri monkey model for P. falciparurn 
challenge experiments to test efficacy and safety of PfEMP-1-based vaccine 
candidates immunopotentiated with human C3d 3 . It was therefore intended to clone 
Saimiri CM to assess the species similarities of this molecule and other animal C3ds. 
It was also aimed to test the hypothesis that a candidate malaria vaccine based on 
human C3d 3 can be tested in the Saimiri model by investigating the capacity of 
human C3d 3 to bind Sairniri B cells. 
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Chapter 2: VarO as an Experimental Antigen for an 
Adhesion-Blocking Malaria Vaccine 
2.1 	Introduction 
2.1.1 	Background 
Previously, a PtEMP-1 sequence was cloned in our Edinburgh Laboratory and 
developed as a malaria DNA vaccine candidate. The sequence (R 2N4 ) is the putative 
CSA-binding DBL'y from 2H3 (Section 8.2.1). I cloned the sequence into one of 
several DNA immunisation vectors developed at Adprotech to fuse antigens to C3d 3 
(described later in Section 3.2.1). Before any such DNA vaccine candidate could be 
tested in mice, it was important to verify that the constructs could be expressed in 
mammalian cells. Towards this end, in vitro expression of the domain by COS-7 
cells transiently transfected with the vaccine constructs was selected as the system of 
choice. COS-7 cells are kidney fibroblasts from the African green monkey 
(Cercopithecus aethiops sabaeus), immortalised by transformation with Simian 
virus-40 (SV40). 
Expression of full-length recombinant R 2N4 -C3d3 (fused either to the N-terminus or 
the C-terminus of C3d 3 ) could not be detected in COS-7 cell supernatants or lysates. 
In the absence of any R 2N4-specific antibodies, detection of recombinant protein was 
dependent upon fusion to a protein tag. In this case, the recombinant protein had a 
predicted MW of 130kDa (lOOkDa C3d 3 plus 30kDa R2N4) and the possibility that 
expression problems were due to the large size of the protein was investigated by 
fusing the sequence to a smaller tag - l4kDa HEL. Again, expression could not be 
detected and it seemed likely that heterologous sequence expression problems were 
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occurring, possibly due to mammalian cell difficulties in transcribing/translating the 
A/T rich P. falciparurn genome. 
2.1.2 	Codon-Usage Bias 
The P. falciparuni genome is the most A/T rich of any genome known (typically 
80% AlT rich and up to 85% in its intragenic regions). The A/T rich P. falciparuin 
genome makes cloning problematic since sequences are often unstable in bacterial 
clones and unpredictable recombination events may occur. It is this A/T richness and 
species-specific differences in codon-usage that are thought to be the major cause of 
the commonly encountered problems that arise when attempting to express 
recombinant P.falciparuin proteins in heterologous expression systems (Sorensen et 
al. 1989; Pizzi and Frontali 2001). Codon bias is observed in all species, and the use 
of selective codons in genes often correlates with gene expression efficiency (Makoff 
et al. 1989). In general, taxonomically-close organisms use similar codons for their 
protein synthesis whereas taxonomically-distant organisms utilise very different 
codons (Ikemura 1982). All heterologous expression systems, apart from 
Dictyostelium (Howard et al. 1988), have a quite different codon-usage to that of P. 
falciparwn. In this project, it was my intention to use the COS-7 cell, mammalian 
expression system to test the expression of P. falciparum proteins prior to DNA 
immunisation in mice. These cells grow well in culture and their codon-usage 
(55.83% G/C) is similar to that of both mice (53.84% G/C) and humans (52.54% 
G/C), making them a good model for expression studies in the mammalian system, 
with a view to testing a vaccine for humans in mice. Unsurprisingly, however, the 
mammalian (Arican green monkey and mouse) genome employs a very different 
codon-usage frequency to that of P. falciparum. In particular, it is much less A/T 
rich. 
Expression in heterologous systems is usually up-regulated and driven by a strong 
promoter and this is likely to rapidly drain the tRNA pool for uncommon codons. 
This problem is further exacerbated in the mammalian system where polyA stretches 
are recognised by RNA polymerases as chain termination sequences, leading to 
premature chain termination. The codon-bias problem in E.coli has been addressed 
by Stratagene in their BL2I-CodonPlus® RIL and RP Competent Cells, in which a 
plasmid encoding extra copies of tRNAs that recognize rare E. coil codons has been 
introduced, allowing over-expression of native Plasmodium genes. This is by no 
means a complete solution to the problem, however, nor is such plasmid-encoded 
assistance available for expression in other systems. There is, therefore, a strong 
rationale for synthesising a codon-optimised version of the sequence of interest, to 
increase expression levels. Nagata and colleagues have shown that the codon 
optimisation level of genes correlates well with translational efficiency in 
mammalian cells (Nagata et al. 1999). Furthermore, codon-optimisation has proven 
successful for the expression of other malaria genes (Nag et at. 1999; Narum et al. 
2001) as well as those from other pathogens, including Listeria tnonocvtogenes 
(Uchijima et al. 1998), tetanus (Stratford et al. 2000) and HIV (DemI et at. 2001). 
2.1.3 	Choice of Antigen 
The development of PfEMP-1-based malaria vaccines is in its early stages and no 
definitive 'protective' antigen exists. The field therefore dictates that the best 
candidates we have be moved forward for comparative testing. The ongoing debate 
that DBL'y was the CSA-binding ligand and that this interaction is the key to the 
pathology of malaria in pregnancy (reviewed (Craig 2004) made DBL'y a 
questionable choice of antigen for this project, especially since the development of 
C3d3 as an adjuvant is also in its experimental stages and one of the aims of this 
project was to investigate the adjuvant effect of C3d 3 in the context of a PfEMP-1-
based vaccine. DBL1a, however, is well established as the rosetting ligand and the 
rosetting phenotype is strongly implicated in the cause of cerebral malaria in African 
children (Carlson et at. 1990; Rowe et at. 1997) and correlates with parasitaemia 
(Rowe et al. 2002). It was arguably the best choice of antigen for this project. 
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I therefore decided to design and synthesise a codon-optimised version of the 
DBLILi domain from varO for use in expression studies to investigate the 
varO/rosetting relationship and for use in immunisation studies to test the ability of 




2.2.1 	A Codon-Optimised Version of VarODBL1a 
To overcome expression problems caused by low frequency mammalian codon-
usage by P. falciparurn, a codon-optimsed version of the varODBLla gene was 
designed and synthesised. It was also intended to use the codon-optimised gene for 
expression in Pichia pastoris and, through on-going collaboration with the Institute 
Pasteur in Paris, for expression in the baculovirus system, which makes use of insect 
cell lines (SJ9) from the moth, Spodoptera friguperda. The design of the gene was 
based on the following parameters: 
To reduce the A/T richness of the sequence by replacing codons, rare in 
mammalian and Spodoptera frugiperda use, for ones more common in the 
mammalian and Spodoptera frugiperda systems. 
The removal of potential N-glycosylation sites, since Pichia pastoris has been 
demonstrated to glycolsylate (and occasionally hyperglycosylate) asparagine (N) 
residues and this can interfere with correct folding and tertiary structure of the 
protein (Bretthauer and Castellino 1999). 
The removal of restriction sites that may have hindered downstream cloning 
techniques. 
To design the gene, the native sequence was first analysed with reference to both 
Homo sapiens and Spodoptera frugiperda codon-usage tables found at 
http://www.kazusa.or.jp/codon  (Figure 2.1). The Homo sapiens codon-usage table 
was taken as representative of the COS-7 and murine systems used in this study. 
Rare codons were taken to be those used in by Homo sapiens or Spodoptera with a 
frequency of less than 15% (0.15) of the fraction for that amino acid. Very rare 
codons were taken to be those used with a frequency of less than 10% of the fraction. 
Codons in the P.falciparum sequence that were identified as rare in the mammalian 
and Spodoptera systems were highlighted (Figure 2.2). The A/T content of the 
sequence was reduced by swapping rare codons for those more common in 
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mammalian and Spodoprera use. The sequence was further analysed for particularly 
A/T rich codons and these were swapped for less A/T rich codons 50-60% of the 
time. The overall AlT content of the sequence was brought down to 58% from an 
original 70%. Table 2.1 shows the AlT rich codons that were identified and their less 
A/T rich replacements. Predicted N-glycosylation sites (N X SIT N) in the amino 
acid sequence were identified using the web-based program 'NetNGlyc' at 
http:/Iwww.cbs.dtu.dklservices/NetNGlycI. To modify these sites, the serine (S) or 
threonine (T) in the motif was replaced with an alanine (A). Alanine is the smallest 
of the amino acids and expected to have the most innocuous effect on secondary 
structure. 
An EcoRl site was identified at the C-terminus (bases 1168-1173). This site is 
common to both the pCR4-TOPO vector and to the Adprotech immunisation vector, 
making it a potential hindrance to cloning and a target for restriction digest analysis. 
This site was also modified by re-coding the glutamic acid (E) and phenylalanine (F) 
residues (coded by GAA and TTC respectively) with the codons GAG and TTT. 
Table 2.1 
Amino Acid Abbreviation AlT Rich Codon Less AlT Rich Codon 
Lysine K AAA AAG 
Phenlyalanine F TTT TIC 
Isoleucine I ATA or ATT ATC 
Tyrosine Y TAT TAC 
Table 2.1: P. falciparuin A/T rich codons. Codons identified in the native varODBLlct 
sequence as being particularly A/T rich are shown, with the less A/T rich codons they were 
replaced with in the codon-optimised version of the sequence. 
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The method for synthesising a codon-optimised version of the gene was based on 
previously established methods (Stemmer et al. 1995: Withers-Martinez etal. 1999). 
A set of 46, non-overlapping, 5' phosphorylated 40mers were designed to cover the 
whole of the 906bp gene fragment (Tables 2.3 and 2.4). Overlaps in complementary 
strands were 20bp and the oligonucleotides were synthesised by MWG Biotech at the 
O.Oltmol synthesis scale, HPLC purified. The Withers-Martinez method involves a 
primary PCR gene assembly' process to build increasingly long DNA fragments 
from a pool of overlapping oligonucleotides and a second PCR to specifically 
amplify the previously assembled synthetic product. After repeated attempts, the 
Withers-Martinez method proved unsuccessful, as were several attempts at step-wise 
ligation and step-wise PCR methods. The sequence was successfully synthesised, 
however, with the help of Dr Mike Steward at Adprotech. The method developed by 
Dr Steward (detailed in Section 8.1. 16) involved an initial gene assembly step using 
Pfu polymerase and Taq ligase, followed by a gene amplification step using 
conventional PCR with Pfu polymerase. This gave a weak product, which was gel-
extracted and re-amplified with Taq polymerase, using using a standard PCR mix 
(described in Section 8.1.2) and primers 218-082F and 218-082R (Table 2.2). The 
result was a band of the right size (Figure 2.3), that was gel-extracted and cloned into 
pCR 4-TOPO. 
Table 2.2 
Primer Name Primer Sequence 5' to 3' Thermal 
Cycling 
Conditions 
218-082F gCggA ': 	TgTFAcggAAggg 
35 cycles of: 
92°C, 30 seconds 
60°C. 30 seconds 
77°C 60 seconds 
218-082R g 
Table 2.2: Oligonucleotides used in cloning codon-optimised varODBLla. BgllI sites 
were introduced in forward primers, shown in and BamHl sites in reverse primers, 
shown in blue. 
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Figure 2.1 
TJTTU P 0.45 (16.9) 
UUC F 0.55 (20.4) 
rJUA L 0.07 (7.2) 
UUG L 0.13 (12.5) 
OUST L 0.13 (12.7) 
CUC L 0.20 (19.4) 
CI1A L 0.07 (6.9) 
COG L 0.41 (40.2) 
AUU I 0.36 (15.7) 
AUC I 0.49 (21.5) 
AUA I 0.16 (7.1) 
AUG M 1.00 (22.3) 
GUU V 0.18 (10.9) 
GUC V 0.24 (14.6) 
GUA V 0.11 (7.0) 
GUG V 0.47 (28.9) 
000 3 0.18 (14.6) 
0CC S 0.22 (17.4) 
'CA S 0.15 (11.7) 
UCG S 0.06 (4.5) 
ccu P 0.28 (17.3) 
CCC P 0.33 (20.0) 
CCA P 0.27 (16.7) 
COG P 0.11 (7.0) 
ACU T 0.24 (12.8) 
ACC T 0.36 (19.2) 
ACA T,0.28 (14.8) 
T 0.12 (6.2) 
GCU A 0.26 (18.6) 
GCC A 0.40 (28.6) 
GCA A 0.23 (16.0) 
COG A 0.11 (7.6) 
TJAU 1 0.43 (12.0) 
UAC 1 0.57 (15.6) 
UAA * 0.28 (0.7) 
UAG * 0.22 (0.6) 
CAU H 0.41 (10.4) 
CAC H 0.59 (14.9) 
CAA Q 0.25 (11.8) 
CAG Q 0.75 (34.6) 
AAU N 0.46 (16.7) 
AAC N 0.54 (19.5) 
AAA K 0.42 (24.0) 
AAG K 0.58 (32.9) 
GAO D 0.46 (22.3) 
GAC D 0.54 (26.0) 
GAA E 0.42 (29.1) 
GAG E 0.58 (40.8) 
UGO 0 0.45 (9.9) 
UGC C 0.55(12.2) 
OGA * 0.50 (1.3) 
UGG W 1.00(12.8) 
CGU R 0.08 (4.7) 
CGC R 0.19(10.9) 
CGA R 0.11 (6.3) 
CGG R 0.21 (11.9) 
AGU S 0.15 (11.9) 
AGC S 0.24 (19.3) 
AGA R 0.20(11.5) 
AGG R 0.20(11.4) 
GGU G 0.16(10.8) 
GGC G 0.34 (22.9) 
GGA G 0.25(16.3) 
GGG G 0.25(16.4) 
Figure 2.1: Homo sapiens codon 	usage table. Adapted from 
http ://w ww.kazusa.or.ip/codon. Fields are: [triplet] [amino acid] [fraction] ([frequency per 
thousand]). An arbitarty cut-off of less than 15% (0.15 of the fraction) was taken to identify 
a rare codon ( 	). Very rare codons (10%; less than 0.10 of the fraction) are highlighted in 




TGT TAT GGA AGG G1A CAA AAC CGT TTT CAT GAA AAT CCC GAA CCC TAT TGT AAT ACT GAT 
C Y S R E Q N P. F D E N A E A Y C N S D 
61/21 	 91/31 
AAA P'TA AGA GGT AAT GAA AAT AAC ACT AAT GGT ACA CCA TGT CCA CCA CCA AGA AGA AGA 
K I 	R C N 	E N N S N G T A C A P 	P P P. R 
121/41 	 151/51 
CAT AT1 TGT CAT CAA AAT TTA GAA TTT TTA SAT AAC AAA AAC ACA AAT ACT ACG CAT GAT 
H I C 0 0 N L E F L D N K N T N T T H 0 
181/61 	 211/71 
TTh TTA GGA AAT GTG Tm GTT ACA GCA AAA TAT GAA GGT AAT TAT ATT GTT AAT GAT CAT 
L L G N V L V T A K Y S G N Y I V N 0 H 
241/81 	 271/91 
CCA CAT AAA AAC AGC AAT GGT AAT AAA TCA GGA ATA TGT ACT TCT CTT GCA CGA ACT TTT 
P 0 K N S N C N K S G I C T S L A P S F 
301/101 	 331/111 
GCA SAT ATA GGA CAT ATT GTA AGA GGA AGA GAT ATG TTT TTA CCT AAT AAG CAT CAT AAA 
A 0 I C 0 I V R C P 0 M F L P N K 0 D K 
361/121 	 391/131 
GTA CAA AAA GSA CTA CAA GTA GTT TTC AAA AAA ATA TAT AAG AGC TTG ACA CCC GAA GCP. 
V Q K G L Q V V F K K I 	I K S L T P 5 A 
421/141 	 451/151 
AGA AAG CAT TAC GCA CAT GCT GAT GGA TCT CGA AAT TAT TCT AAA TTA AGA GAA GAT TGG 
P. K H I A H S D C S 	G N Y 	S K L P E 	0 W 
481/161 	 511/171 
TGG ACT ATA AAT AGA GAA CAA ATh TGG AAA GCC TTA ACA TGT TCT GCT CCA TAT TAT GCT 
N T 	I N P 5 Q I N K A L T C S A P 1 Y A 
541/181 	 571/191 
GAT TAT TTT AGA AAA C,GT T GAT GGT ACT CTA CAT TTT AGC ACT CAC GGA AAG TGC CCC 
0 1 F P K C S 0 5 T L H F S S H C K C C 
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601/201 	 631/211 
CAT AAT GAA GGT GCT CCT CCT ACC TAT PTA GAT TAT GTT CCT CAA TTT PTA CGT TGG TTC 
H N E G A P P T I L D I V P Q F L R W F 
661/221 	 691/231 
GAA GAA TGG AGT GAA GAA TTT TGT AGA ATP. AAA AAA ATA AAA ATC GAT AAA GTT AAA AAA 
K E W S 	E 	E 	F C R 	I 	K K 	I 	K 	I 	D K V K K 
721/241 	 751/251 
GAG TGT CGT GAT GAA CAA AAT AAA AAA TAT TGT AGT GGT GAT GGT CAT GAC TGT ACT CAA 
E C R D E Q N K K I C S G D G H D C T Q 
781/261 	 811/271 
ACC AAT TTA TCC CAT AAT CAA ATT TTT GTA GAT PTA GAT TGC CCA CGC TGT CAG GAT CAA 
T N L S H N Q I F V D L D C P R C Q D Q 
841/281 	 871/291 
TGT ATA AAA TAT AAT GAA TGG ATA GTA AAA AAA TTA GAA GAA TTC TAT AAA CAA AAC CTT 




Figure 2.2: Native nucleotide sequence of varODBLlcz, analysed for low-frequency 
codons, glycosylation sites and problematic restriction sites. Deduced amino acid sequence 
is indicated below. Low frequency codons in mammalian use are shown in 	. Low 
frequency codons in Spodoptera use are shown in . Predicted N-glycosylation sites (N 
X SIT X) are shown in gj.clt and the EcoRJ site in blue. Numbers above are nucleotide / 




Sequence 5' to 3' 






P7 gTJ'A ACgATCATCCAgATAAgAACAgCAATggTAATAAAg 
P8 CTggAAmgTAC11'CTCTggCCCgATCCTI'CgTgATAT 
P9 TggAgATATFgTAAgAggAAgAgATATgTrCTFACCTAAC 











P21 ggCCCATAATCAAAIi 1] 'CgTggATCTCgATrgCCCACgC 
P22 TgTCAggATCAATgTATCAAATATAACgAATggATAgTCA 
P23 AgAAgCTggAAgAg ITIIACAAgCAAAACCTgAAATAT 
Table 2.3: Nucleotide sequences of the sense oligonucleotides involved in gene synthesis 
of the codon-optimised version of varODBLIa. All oligonucleotides are 40mers. with the 
exception of P1 (39mer) and P23 (38mer). A 5' Bg/ll site was introduced into the sequence 





Sequence 5' to 3' 









P1 OR TACCATCgCTACCCTTTCTAAAATAATCAgCgTAgTATgg 
P11 R AgCAgAACATgTCAgggCTTTCCAgATFTgTTCTCTgTTg 
P1 2R ATAgTCCACCAATCTTCTCTCAgTTTggCATAAmCCAg 
P1 3R ATCCATCACCATgAgCgTAATgCTTTCTggCTTCgggTgT 
P1 4R gAggCTCTTgTAgATCTTCTTgAAAACCACTTgCAgTCCC 
P1 SR T1TFgCAC1TFATCATCCTTgTTAggTAAgAACATATCTC 
P1 6R TTCCTCTTACAATATCTCCAATATCAgCgAAggATCgggC 
P1 7R CAgAgAAgTACAAATTCCAgCTTTATTACCATTgCTgTTC 
P1 8R TTATCTggATgATCgTTAACAATATAgTTACCTTCgTACT 
P1 9R TTgCTgTAACCAgCACATTTCCgAgCAgATCATgggCAgT 
P20R gmgTg1TCTTgTTATCgAgAAATTCCAgA1TFTgATCA 
P21 R CAAATATgTCTTCTTCTTggTggTgCACAggCggCACCgT 
P22R TggCgTTgTTTTCATTACCTCTgATCTTATCgCTgTTACA 
P23R ATACgCTTCggCg Fri FCATCgAACCTgTTTTgTTCCCTTCCgTAACA 
Table 2.4: Nucleotide sequences of the anti-sense oligonucleotides involved in gene 
synthesis of the codon-optimised version of ;'arODBLlci. All oligonucleotides are 40mers, 
with the exception of P1R (3Omer) and P23R (48mer). A 3' BamHl site was introduced into 











Figure 2.3: Ethidium bromide-stained 1% agarose gel showing the results of gene 
synthesis of a codon-optimised version of varODBLla. The PCR product of interest at 
approximately 900bp (red arrow) is the result of gene assembly using Taq ligase and Pfil  
polymerase, gene amplification using Pfu polymerase and 2 re-amplification rounds of PCR 
using Taq polymerase. Molecular size markers are shown in bp. 
Table 2.5 
Oligonucleotide Sequence 5' to 3' 
SDMECORV F CgATCCTTCgCTcATA 	ggAgATATTgTAAgAggA 
SDMEoRV R TCCTCTTACAATATCTCC 	TATCAgCgAAggATCg 
SDMBg/l IF CAAgTggTTTTCAAgAA ATCTACAAgAgCCTCAC 
SDMBg/I I R gTgAggCTCTTgTAAT ITCTTgAAAACCACTTg 
SDMKpn2 I F gCTCCTCCTACCTATL ggTTATgTTCCTCAA 
SDMKpn2 I R TTgAggAACATAAILLC gTAggTAggAggAgC 
Table 2.5: Oligonucleotides used for SDM in the synthesis of a codon-optimised version 
of varODBLla. The oligonucleotide sequences were designed to include 16 bases either 
side of the mutant site (shown in ). stopping where possible with a cytosine or guanine 
residue. Restriction sites (underlined) were introduced or removed to facilitate identification 
of corrected clones. 
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The pCR4-TOPO clones were screened by PCR and restriction digest analysis to 
establish those that had inserts of the correct size. Several of these PCR and 
restriction digest positive clones were sequenced, revealing frequent sequence errors 
in all of those analysed. Of four clones sequenced, there were 10, 3, 4 and 9 changes 
to the desired sequence - not surprising since the sequence had been through a 
number of rounds of PCR. The clone with the fewest errors (clone 2, with 3 errors) 
was selected for site-directed mutagenesis (SDM) to restore the original sequence. 
The following changes were identified for mutagenesis, introducing or removing a 
restriction site where possible, to facilitate identification of corrected clones: 
Site 1 (3141315bp): T introduced to correct the deletion at position 314. An EcoRV 
site introduced at position 315 by replacing T with C, maintaining the isoleucine; 
Site 2 (399bp): G to A replacement to remove the BglIt site and maintain the lysine; 
Site 3 (635bp): C to T replacement to maintain the leucine (CCG in the error version 
codes incorrectly for proline) and introduce a Kpn2I1BsprnII site; 
Site 4 (669bp): A silent mutation (GAA to GAG), coding for glutamic acid, was 
dismissed. 
Oligonucleotides were designed for PCR-based SDM of the sequence (Table 2.5) 
and three rounds of SDM were performed as described (Section 8.1.17). After each 
round, bacterial colonies were selected on 100tg/ml ampicillin and PCR-screened 
using primers 218-082F and 218-082R. After thermal cycling, PCR products were 
digested with appropriate restriction endonucleases to confirm that mutagenesis had 
been successful (Figure 2.4). Plasmid DNA was recovered from overnight cultures of 
selected corrected clones and used as a template for the next round of SDM. In round 
1, primers SDMEcoRVF and SDMEcoRVR were used for SDM and EcoRV for 
restriction digest analysis. Products of the expected sizes (314bp and 592bp) were 
generated in clones 1-7 (lanes 2-8 in Figure 2.4) confirming that the EcoRV site had 
been successfully introduced. In round 2. primers SDMBgIIIF and SDMBgIIIR were 
used for SDM and BglII for restriction digest analysis. No fragmentation of the —I kb 
PCR product in clones 1-15 (lanes 1-15 in Figure 2.4) confirmed that the BglII site 
had been successfully mutated. In round 3, using primers SDMKpn2IF and 
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Figure 2.4 




13: Round 2 
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SDMKpn2IVR for SDM and Kpn2I for restriction digest analysis, no fragmentation 
of the PCR product confirmed that the Kpn2I site had been successfully mutated. 
After the third round of SDM, selected clones were sequenced. The final codon-
optimised sequence is shown in Figure 2.5. 
Figure 2.4: Ethidium bromide-stained 1% agarose gels showing results of site-directed 
mutagenesis. Each photograph shows the products of a PCR screen on successfully mutated 
clones, digested with appropriate restriction enzymes. A: Lane 1, marker; lanes 2-8, 3 l4bp 
and 592bp products in clones 1-7; lane 9, positive control (uncorrected clone). B: Lanes 1-
15, clones 1-15; lane 16, positive control (uncorrected clone). C: Lane 1, marker; lanes 2-16, 
clones 2-16; lane 17, positive control (uncorrected clone). 
53 
Figure 2.5 
1/1 	 31/:L1 
TGT TAC GGA AGG GAA CAA AAC AGG TTC GAT GAA AAC GCC GAA GCG TAT TGT AAC AGC GAT 
C Y G R E Q N R F D E N A E A Y C N S D 
61/21 	 91/31 
AAG ATC AGA GGT AAT GAA AAC AAC GCC AAC GGT GCC GCC TGT GCA CCA CCA AGA AGA AGA 
K I R G N E N N A N G A A C A P P R R R 
121/41 	 151/51 
CAT ATT TGT GAT CAA AAT CTG GAA TTT CTC GAT AAC AAG AAC ACA AAC ACT GCC CAT GAT 
H I C D Q N L K F L D N K N T N T A H D 
181/61 	 211/71 
CTG CTC GGA AAT GTG CTG GTT ACA GCA AAG TAC GAA GGT AAC TAT ATT GTT AAC GAT CAT 
L L G N V L V T A K Y E G N Y I V N 0 H 
241/81 	 271/91 
CCA GAT AAG AAC AGC PAT GGT AAT AAA GCT GGA ATT TGT ACT TCT CTG GCC CGA TCC TTC 
P 0 K N S N G N K A G I 	C T S L A R S F 
301/101 	 331/111 
GCT GAT ATT GGA GAT ATT GTA AGA GGA AGA GAT ATG TTC TTA CCT AAC AAG GAT GAT AAA 
A D I 	G D I 	V R G R D N F L P N K D 0 K 
361/121 	 391/131 
GTG CAA AAG GGA CTG CAA GTG GTT TTC AAG AAG ATC TAC AAG AGC CTC ACA CCC GAA GCC 
V Q K G L Q V V F K K I Y K S L T P K A 
421/141 	 451/151 
AGA AAG CAT TAC GCT CAT GGT GAT GGA TCT GGA AAT TAT GCC AAA CTG AGA GAA GAT TGG 
R K H Y A H G D G S G N I A K L R E D N 
481/161 	 511/171 
TGG ACT ATC AAC AGA GAA CAA ATC TGG AAA GCC CTG ACA TGT TCT GCT CCA TAC TAC GCT 
W T I N R K Q I W K A L T C S A P Y I A 
541/181 	 571/191 
GAT TAT TTT AGA AAG GGT AGC GAT GGT ACT CTA CAT TTC AGC AGT CAC GGA AAG TGC GGC 
D I F R K G S 0 G T L H 	F S S H G K C G 
601/201 	 631/211 
CAT AAT GAA GGT GCT CCT CCT ACC TAT CTG GAT TAT GTT CCT CAA TTT CTC CGT TGG TTC 
H N E G A P P T I L 0 Y V P Q F L R W F 
661/221 	 691/231 
GAA GAA TGG TCC GAA GPA TTC TGT AGA ATA AAG AAG ATC AAG ATC GAT AAG GTT AAG AAA 
K K W 	S 	K K 	F C R I 	K K 	I 	K 	I 	0 K V K K 
721/241 	 751/251 
GAG TGT CGT GAT GAA CAA AAC AAG AAA TAC TGT TCT GGT GAT GGT CAT GAC TGT ACT CAA 
E C R D K 0 N K K I C 	S 	G D G H D C T Q 
781/261 	 811/271 
ACC AAT CTG GCC CAT AAT CAA ATT TTC GTG GAT CTC GAT TGC CCA CGC TGT CAG GAT CAA 
T N L A H N Q I F V 0 L 0 C P R C Q D Q 
841/281 	 871/291 
TGT ATC AAA TAT AAC GAA TGG ATA GTC AAG AAG CTG GAA GAG TTT TAC AAG CAA AAC CTG 
C I 	K I N E W I V K K 	L 	E E 	F I K Q N L 
901/301 
AAA TAT 
Figure 2.5: Nucleotide sequence of codon-optimised varODBLla. Deduced amino acid 
sequence is indicated below. Numbers above are nucleotide / amino acid numbers. 
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2.2.2 	DBL1a Mediates Binding to Red Blood Cells 
To confirm that varODBLla mediates binding to RBCs and to verify that the codon-
optimised version retains the function of the native protein, it was aimed to express 
the domain as a surface membrane protein in mammalian cells and test its ability to 
bind RBCs in vitro. 
2.2.2a 	Cloning VarODBL1a in pDisplay 
The vector pDisplay (lnvitrogenT) was used for the expression of codon-optimised 
(do) varODBL I a on the surface of COS-7 cells. The pDisplay vector makes use of a 
CMV promoter for efficient expression, the murine Ig kappa-chain V-J2-C signal 
sequence to direct expressed protein to the cell membrane and a PDGFR 
transmembrane sequence for surface expression. The vector carries myc and HA tags 
upstream and downstream of the multiple cloning site (MCS) respectively, to 
facilitate detection of expressed protein. Analysis of the MCS using DNA Strider 
software showed that directional cloning could be achieved with a BglII-PstI insert. 
Neither of these sites is included in the nucleotide sequence for this domain, so it is 
protected from digestion by restriction endonucleases involved in cloning. The vector 
was prepared for cloning by propagation in recA, endA TOP 10 F cells 
(InvitrogenT 1 ) and selected on 100tg/ml ampicillin. It was linearised by BglII/PstI 
double-digest, dephosphorylated and purified by gel-extraction as described 
(Sections 8. 1.11 to 8.1.13). 
PCR primers were designed to amplify the do varODBLlct domain with the addition 
of a 5' BglII site and a 3' Pst[ site, ensuring that the insert would be in-frame with 
the vector's myc and HA epitopes (Table 2.6). The BglII-varODBLlci-PstI insert 
was PCR-amplified from the do varODBLIu-pCR4-TOPO template, T-cloned into 
pCR4-TOPO, selected on 100tg/ml ampicillin and PCR-screened using insert 
primers. Inserts were released from selected clones by BgIII/Pstl double-digest, to 
give appropriate cohesive ends, and cloned into the linearised pDisplay vector. 
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Transformed ampicillin-resistant bacterial colonies were PCR-screened, as 
previously, and PCR-positive clones were further screened by restriction digest-
analysis using Bg!Il and Pstl (Figure 2.6). An insert of the expected size (-1kb) was 
released from 16 clones, 2 of which (clones 5 and 6; lanes 6 and 7 in Figure 2.6. A 
and B) were sequenced using T7F and BGHR vector primers (lnvitrogenTM, based on 
the T7 promoter and bovine growth hormone receptor sequences respectively), which 
verified them to be correct and in-frame with the HA epitope. 
Table 2.6 
Primer Sequence 5' to 3' Thermal Cycling 
Conditions 
94°C ' minutes 
Bg(Ic/oDBL1F CATAgAATA1IAAgg_T 	gFATAgAAT 
30 cycles of: 
94°C. 15 seconds 
55°C. 30 seconds 
PstIc/oDBLI R gCTgC AgATATFTCAggITITgCTI'gTAAAA 62°C. 60 seconds 
final extension: 
62°C, I minute 
Table 2.6: Primer sequences used to amplify do varODBLlct for BgIII-PstI directional 












B: Restriction digest-screening 
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Figure 2.6: Ethidium bromide-stained agarose gels showing stages of cloning do 
varODBLla in pDisplay. A: Lanes 1 & 18, marker; lanes 2-17, PCR-positive clones, with 
products of the expected size (-1kb). B: Lanes I & 18, marker; lanes 2-17, inserts of —1kb 
released in all clones except in lane 3. C: Lane 1, linearised pDisplay vector (5.3kb); lane 2, 
Bgll I-do varODBL I ct-Psi'! insert (— 1kb). 
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2.2.2b 	Expression of VarODBL1a on the COS-7 Cell Surface 
To express do varODBLla on the surface of COS-7 cells, cells were transfected 
with do varODBLlci-pDisplay DNA as described (section 8.3.6). 'Mock' 
transfected (dH 20 used in place of DNA) and un-transfected cells were set up as 
controls. To test for expression, do varODBLla-pDisplay-transfected COS-7 cells 
and empty vector-transfected negative controls were harvested 48 hours post 
transfection, in SDS sample buffer. Samples of both lysate and supernatant were 
reduced, separated by SDS-PAGE using a 4-12% bis-tris polyacrylamide gel and 
subsequently transferred to PVDF. Anti-HA antibody was used to detect recombinant 
protein in Western blot (Figure 2.7). The surface-expressed DBL1ct recombinant 
protein was calculated to have a MW of approximately 40kDa (-35kDa DBL1ct 
domain plus myc and HA epitopes). An intense band of the expected size was seen in 
the cell lysate of do varODBLla-pDisplay-transfected COS-7 cells (lane 3, Figure 
2.7). This band is not present in the supernatant of these cells (lane 4 of Figure 2.7), 
nor can it be detected in the cell lysate or the supernatant of cells transfected with 
empty pDisplay vector (lanes 1 and 2 respectively of Figure 2.7). Expression was 
further verified by IFA, 48 hours post transfection, using rabbit polyclonal anti-HA 
antibodies, on cells fixed with 2% paraformaldehyde/PBS (Figure 2.8). Successfully 
transfected cells are identified by their strong fluorescence and characteristic pattern 
of surface-specific staining that is more intense at the edges of the cells. Background 
is negligible and un-transfected cells (indicated by white arrows in Figure 2.8) do not 
fluoresce. This is good evidence to support the Western blot data, confirming that 
these cells are surface expressing varODBLla. 
Figure 2.7 




Figure 2.7: Western blot analysis of cell lysates and supernatants from COS-7 cells 
transfected with do varODBLlcz. 1: pDisplay transfected cells (lysate). 2: pDisplay 
transfected cells (supernatant). 3: do varODBLla-pDisplay transfected cells (lysate). 4: do 
varODBLla.-pDisplay transfected cells (supernatant). Western blot was performed using 
rabbit anti-HA antibody (0.8.tg/mI) and HRP-conjugated goat anti-rabbit IgG (2tgIm1). 
Locations of molecular mass markers are shown in kDa. 
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Figure 2.8 
Figure 2.8: COS-7 cells transiently transfected with do varODBLla-pDisplay. Cells are 
stained with rabbit anti-HA primary antibody (Sigma; 1:50 dilution) and goat anti-rabbit lgG 
Alexa Fluor 488 secondary antibody (2 pAg/mI). Cells were viewed under incident light of 
488nm, at a magnification of x 1000. Un-transfected cells are indicated by arrows. 
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2.2.2c 	COS-7 Cells Expressing VarODBL1a Bind RBCs 
To confirm that the codon-optimised version of varODBLla retains the function of 
the native protein and to verify that this domain binds RBCs, COS-7 cells surface-
expressing the domain were tested for their ability to bind RBCs. RBC binding 
assays were carried out (Section 8.3.8) 48 hours post transfection, with COS-7 cells 
transiently transfected with varODBLla-pDisplay. Un-transfected cells, 'mock'-
transfected cells, cells transfected with empty pDisplay and cells transfected with P. 
vivax Erythrocyte Binding Antigen (EBA) in pRE4 (Cohen et al. 1988) were set up 
as controls. Surface expression of the domain was confirmed by fixed IFA on 
duplicate samples of transfected cells, from the same well of each sample culture. 
The anti-HA antibody was used to dtect varODBLla expression in cells transfected 
with pDisplay constructs and anti-pRE4 (1133) antibody was used to detect P. vivax 
EBA in cells transfected with the pRE4 construct. VarODBLIa strongly bound 
RBCs (Figure 2.9 A), as did P. vivax EBA (Figure 2.9 B), whereas no obvious 
binding was observed in un-transfected cells, 'mock'-transfected cells or those 
transfected with empty vector (Figure 2.9 C, D, E). Binding is clear in varODBLlct-
expressing cells; cells are densely covered with closely associated RBCs - binding 
appears to be so tight that RBCs are lined up on their sides at the surface of the 
COS7 cells (indicated by the arrow in A of Figure 2.9). Some RBCs were observed 
to have settled on the cell monolayer, but these can be distinguished from binders as 
they are loosely attached and in the, spaces between cells. To confirm the observed 
binding, plates were shaken and the cells were washed once more by placing in fresh 
PBS for 20 minutes. In the varODBL la-expressing cells, binding was still apparent, 
with obvious densely covered COS-7 cells, with RBCs closely associated. Up to 50% 




... 	c  
B 	
41 

















Figure 2.9: COS-7 ceIIIRBC binding assay. Cells are viewed under phase-contrast 
microscopy at x 40 magnification. A: do varODBLla-pDi splay -transfected cells: B: EBA-
pRE4-transfected cells: C: pDisplay-transfected cells: D: Smock' transfected cells; E: un-
transfected cells. Arrow indicates binding of RBCs to COS-7 cells so tight that RBCs are 
lined up on their sides at the surface of the COS-7 cells. 
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Table 2.7 
Sample % COS-7 Cells IFA Positive % COS-7 Cells with RBCs Bound 
A 45 (30-50) 30(10-50) 
B 25(20-30) 15(5-20) 
C 30(20-50) 2(1-5) 
D 1(1-2) 1(1-2) 
E 1(1-2) 1(1-2) 
Table 2.7: Results of COS-7 cellfRBC binding assay. A: do varODBLla.-pDisplay-
transfected cells: B: EBA-pRE4-transfected cells; C: pDisplay-transfected cells; D: 'mock' 
transfected cells; E: un-transfected cells. Results are the average of 3 experiments, the ranges 
of which are shown in brackets. 
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2.3 	Discussion 
A codon-optimised (do) version of the DBL1z domain of varO has been 
successfully designed and synthesised. The AlT content of the do version of the 
varODBLla domain has been significantly reduced from 70% in the native version 
to 58%. This sequence was expressed at the surface of COS-7 cells fused at the N-
terminus to the myc epitope and at the C-terminus to an HA tag. Expression was 
confirmed in Western blot and by irnmunofluorescence assay using an antibody to 
the HA tag. 
The data reported here confirm that the DBLI(x domain of varO mediates binding to 
RBCs in vitro, strongly implicating it as the rosetting ligand in varO (PA89F5) 
parasites. Whether this is the only rosette-mediating domain in these parasites is still 
uncertain. Experiments are currently underway at the Institute Pasteur, Paris, to clone 
and express the CIDRIa, DBL23, DBL3?, DBL4r and DBL5c domains from 
PA89F5 parasites to test their ability to bind RBCs. Preliminary data seems to 
suggest that the CIDRIct also binds RBCs (Odile Puijalon, personal communication). 
The finding that varODBLlcx expressed on the surface of COS-7 cells is capable of 
binding RBCs suggests that this domain may also be expressed at the surface of 
PA89175 parasites, in such a way that it is accessible to the host receptor(s) involved 
in rosetting. The identity of these receptors and whether the interaction is 
conformation-dependent is not known. Data suggests that complement receptor 1 
(CR1) is an important host receptor for rosetting, since CR1 deficient RBCs show 
greatly reduced rosetting in a number of parasite strains (Rowe et al. 1997; Cockburn 
et al. 2004). This remains to be shown for PA89F5 parasites. 
These findings suggest that varODBLla is a suitable candidate antigen for the 
development of a prototype adhesion-blocking malaria vaccine. 
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Chapter 3: DNA Immunisation Constructs and Pilot 
Immunisation 
3.1 	Introduction 
I aimed to examine whether the C3d component of complement has the ability to 
enhance specific antibody responses to PfEMP-1. The majority of the work 
investigating C3d as an immunopotentiator has employed a DNA vaccine strategy 
(Dempsey etal. 1996; Ross et al. 2000; Green et al. 2001; Mitchell et al. 2003). This 
has largely been driven by the need to address expression problems in producing a 
correctly folded protein of the required size (a single copy of C3d alone is 30-
35kDa), that is not undesirably post-translationally modified and of sufficient quality 
and quantity for immunisation. 
In the previous chapter, I have described the characterisation of the DBLIu domain 
of varO from the Palo Alto (clone PA89175) rosetting strain of P. falciparum. Having 
established both the expression and the candidacy of this PfEMP-1 antigen for use in 
a blood-stage malaria vaccine, I decided to adopt a DNA vaccine approach to 
established initial proof of concept of the use of C3d 3 as an effective 
immunopotentiator for an adhesion-blocking malaria vaccine. It was aimed to 
generate plasmids encoding a secreted form of varODBL I a fused to three tandem 




3.2.1 	Construction of DNA Immunisation Vectors 
Plasmids for DNA immunisation were constructed using Adprotech's previously 
characterised DNA immunisation vector, pVK68-01. The pVK68-0I vector is based 
on pVAX I (Invitrogen TM). It contains the cytomegalovirus (CMV) promoter, the 
tissue plasminogen activator (tPA) leader sequence to ensure secretion of the 
expressed protein and has a 'Kozak' optimized initiation sequence 
(GCCACCATGG). The vector carries kanamycin resistance (KanR) for selection in 
antibiotic media and, in addition to pVAXI, it encodes an mC3d 3 gene cassette. 
Initially, constructs were generated using the native version of the varODBLlct 
sequence. Native varODBLla was PCR-amplified from PA89175 genornic DNA 
(kindly donated by Odile Puijalon) using primers OPBgIIIF and OPBamHIR (Table 
3.1) to introduce a 5' Bg[II site and a 3' BamHI site to the sequence. The sequence 
was T-cloned into pCR ®4-TOPO and released by double digest with BglII and 
BanHl restriction endonucleases to generate 5' BglII and 3' BarnHI cohesive ends. It 
was then cloned into the pVK68-01 vector, to express a secreted form of 
varODBLla, fused to three tandem repeats of mC3d in frame with the tPA leader 
sequence (Figure 3.1). Amino (N)-terminal antigen constructs were made by cloning 
into the unique vector BgIII site (position 771) and carboxyl (C)-terminal antigen 
constructs were made by cloning into the unique vector BamHI site (position 3540), 
using inserts with compatible 5' BglII and 3' BainIll cohesive ends. These plasmid 
constructs were designated pVKnatvarODBLlC3d 3 and pVKC3d 3 natvarODBLl. 
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Table 3. 1 
Primer 
Name 
Primer Sequence 5' to 3' Thermal 
Cycling 
Conditions 
94°C. 2 minutes 
OPBgIIII GgA UACAACgAAggT \ 	( I C'T [gT1 ATggAAgg w cycles of 
94°C. 15 seconds 
59°C. 30 seconds 
OPBamHIR Ag1TI111TggATCC1TgAA11TCCATAgAATATflAAggTflTg 62 °C. 5 minutes 
final extension: 
62 °C, IS minutes 
Table 3.1: Oligonucleotides used in varODBLla cloning. Bglll sites were introduced in 
	
forward primers, shown in 	and BanHl sites in reverse primers, shown in blue. 
Figure 3.1 
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Figure 3.1: Schematic representation of pVK68-01 vector-based constructs used in 
DNA immunisation. Positions of restriction sites are shown, with base numbers in brackets. 
Native and codon-optimised i'arODBLla inserts were cloned into the vector using the Bglll 
and BanHI restriction endonuclease sites. 
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Clones with inserts in the correct orientation were selected by restriction digest 
analysis. Figure 3.2 shows B a,nHI/PstI restriction digest analysis of 
pVKC3d3natvarODBLl clones. With the insert in the correct orientation, 
BamHI/PsrI double digest releases a 1265bp fragment (906bp DBL1a domain plus 
359bp vector sequence), from the 5742bp vector, as in clone 7 (lane 8 of Figure 3.2). 
pVKnatvarODBLlC3d 3 clones with inserts in the correct orientation were identified 
by BgIIIIEcoRl double digest, releasing fragments of 26bp and 880bp. 
Figure 3.2 







Figure 3.2: Restriction digest analysis of pVKC3dnati'arODBL1 clones to establish 
insert orientation. Plasmids were digested with BarnHl and Psrl. Lane 1, marker; lanes 2 to 
11 are clones 1 to 10. Molecular size markers are shown. 1265bp fragment (arrow, lane 8) 
identifies clone 7 as having an insert in the correct orientation. 
To express varODBLIcz alone, the sequence was also cloned into the vector pVAX3 
which is a vector comprising the backbone of pVK68-0 1, without the mC3d 3 cassette 
(Figure 3.3). The pVAX3 vector is based on pVAX1 (lnvitrogen 1 ). It contains the 
cytomegalovirus (CMV) promoter, the tissue plasminogen activator (tPA) leader 
sequence to ensure secretion of the expressed protein and has a Kozak' optimized 
initiation sequence (GCCACCATGG). The vector carries kanamycin resistance 
(KanR) for selection in antibiotic media. VarODBLki inserts were cloned into the 
vector at the unique Bg!Il (position 773) and BamHI (position 785) restriction 
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Figure 3.3: Schematic representation of pVAX3 vector-based constructs. Positions of 
restriction sites are shown, with base numbers in brackets. The positions of vector primers 
(VAXscrn and vaxrev) used in PCR screens to establish insert orientation in pVAX3 clones 
are shown. 
Plasmids were also constructed using the codon-optimised (do) version of 
varODBLlci (do varODBLla). As for the native version, the codon-optimised 
sequence was cloned into the unique BglII and BamHI restriction endonuclease sites 
of pVK68-01 to construct amino-terminal C3d 3 and carboxyl-terminal C3d 3 
immunisation constructs, respectively. These constructs were designated 
pVKvarODBLLC3d 3 and pVKC3d 3 varODBLl. A control immunisation construct 
encoding varODBLlcx was also made, by cloning the sequence into pVAX3 
(designated pVKvarODBLL). Clones were selected on 50ig!ml kanamycin, PCR 
screened using primers 218-082F and 218-082R (Table 2.2), and correct insert 
orientation was established by restriction digest analysis and directional PCR using a 
combination of vector and insert primers. Figure 3.4 shows the —I kb PCR products 
of three pVKC3d 3 varODBLI clones, four pVKvarODBLI clones and 2 
pVKvarODBL1C3d 3 clones, after directional PCR-screening using primers VAXscrn 
and 218-082R, thus establishing correct insert orientation in these clones. Finally, 
clones were sequenced and corrected, in-frame sequences were selected for 
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Figure 3.4: Ethidium bromide-stained 1 % agarose gels showing results from 
directional PCR screens using primers VAXscrn and 218-082R to establish insert 
orientation in do varODBLla immunisation constructs. A: Lane 1, marker; lanes 2-11, 
pVKC3d3 varODBLla constructs showing inserts of the correct orientation in 3 clones (lanes 
3, 9 and 11). B: Lane 1, marker; lanes 2-7, pVKvarODBLI clones showing inserts of the 
correct orientation in 4 clones (lanes 2, 4, 6 and 7); lanes 8-I1, pVKvarODBLlaC3d 3 
constructs showing inserts of the correct orientation in 2 clones (lanes 9 and 10). Molecular 
size markers are shown in Kb. 
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Table 3.2 
Name Description Schematic Expression in  
COS-7 Cells 
pVKnatvarODBLl Native varODBLlu 
cloned in pVAX3 
_____ 
I 	I 
pVKnatvarODBLlC3d 3 Native arODBLlu 
Not detected cloned in pVK68-01. as a JSSO C-terminal CM, construct 
pVKC3dnatvarODBL1 Native varODBILlu 
Not detected cloned in pVK68-01, as an 
N-terminal CM3  construct 
* pVKvarODBL1 C/o varODBLl (1 cloned in 
pVAX3 
_____ 
* pVKvarODBL1C3d C/o u'arODBLla cloned in 
Yes pV K68-0 1. as a C-terminal E:000 C3d construct 
pVKC3d 3 varODBLl C/o varODBLli cloned in 
Yes pVK68-Ol.asan N- 
terminal C3d 3  construct 
Table 3.2: Constructs made for a DNA immunisation study in mice using varODBLla 
as a candidate antigen. In the schematics, the green rectangle represents native 
varODBLlct, the pink rectangle, c/o i'arODBLlcz. The three blue circles represent the three 
different versions of CM in murine C3d. Constructs marked * are those selected for a pilot 
immunisation study. ? indicates that expression could not be tested due to the lack of 
availability of a i'arODBL 1 u-specific antibody. 
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3.2.2 	Expression of VarODBLIa in COS-7 Cells 
To test for successful expression of DNA immunisation constructs in the mammalian 
system, transient transfections were set up in COS-7 cells, as previously, for each 
construct. Empty vector and mock transfections (no DNA) were also set up, along 
with un-transfected COS-7 cells as controls. Transfected cells and supernatants were 
harvested 4 days post transfection and analysed by SDS-PAGE and Western blot, 
using polyclonal rabbit anti-human CM antibodies (Dako). At this stage, it was not 
possible to test for expression of varODBLla uncoupled to C3d 3 due to the lack of 
available antibody to this domain. In Western blot analysis, using anti-CM 
antibodies, expression of the native varODBLla sequence coupled to C3d 3 could not 
be detected. However, C3d 3-fusion proteins of the expected size (-130kDa) were 
detected for the do constructs, corresponding to varODBLlct-C3d 3 or C3d3 -
varODBLlcx (Figure 3.5). C3d3 typically runs at -iOOkDa (lane 2 in Figure 3.5), and 
expressed C3d 3-fusion proteins in supernatants could be detected as bands at 
-130kDa (lanes 3 and 4 in Figure 3.5), with a size shift relative to C3d 3 . These 
protein bands were present in both the supernatants and lysates (lanes 7 and 8 in 
Figure 3.5) of transfected cells, suggesting that, as expected, some recombinant 
protein remains intracellular. A high MW band at -160-170kDa (lanes I to 4 in 
Figure 3.5) was consistently seen in supernatants from transfected and untransfected 
cells and was thought to be non-specific reactivity of the anti-CM polyclonal 
antibody with some component of the cell culture medium. A band at approximately 
30-35kDa was also consistently detected and was thought to correspond to CM in 
culture medium FCS. No proteolytic cleavage of the CM proteins was observed. 
These results indicate that the codon-optimised version of varODBLla, coupled to 
C3d 31  is expressed in mammalian cells and thus the constructs encoding it can be 
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Figure 3.5: SDS-PAGE and Western blot showing results of COS-7 cell transfection 
study to test expression of do varODBLIa, coupled to murine C3d 4 , in the mammalian 
system in vitro. Proteins were separated on a 4-129k bis-tris polyacrylamide gel and 
transferred to nitrocellulose. Western blot was performed using polyclonal rabbit anti-human 
C3d (Dako) and Western Breeze TM  (lnvitrogenTM ) detection kit. Lane I, smock' transfection 
(negative control): 2. pVK68-01 (positive control): 3, pVKvarODBLlC3d 3 ; 4. 
pVKC3drarODBLl. Molecular weight size markers are shown in kDa. C3d 3 typically runs 
at -lOOkDa. Expressed protein (varODBLla-C3d 3  in lane 2 and C3d 3 -varODBLla in lane 
4) runs at the expected size of -130kDa (red arrow). 
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3.2.3 	A Pilot DNA Immunisation Study Using the Codon- 
Optimised Version of VarODBL1a in Mice 
Successfully expressed immunisation constructs were selected for a pilot DNA 
immunisation using the HeliosTM  Gene Gun (BioRad). The aims of this pilot 
immunisation were to test for antigen expression in vivo, with and without C3d 1 and 
to assess the effects of mouse strain variation (in-bred versus out-bred varieties) on 
the immune response to varODBLIa in mice. 
In the initial work on C3d 3 , HEL was fused to the N-terminus of C3d 3 (Dempsey et 
al. 1996). Similarly, Adprotech's previous work with MSP-1 19 (Richard Smith, 
personal communication) suggests that N-terminal antigen fusion to C3d 3 (Ag-C3d 3 ) 
is more effective, since antibody titres are greater than for C-terminal fusion 
constructs (although still greater than controls). This may not be definitive for all 
antigens and it is debatable why this may be the case - it may be related to the ability 
of the C3d units to fold correctly. Addition of antigen at the N-terminus, however, 
can adversely affect expression levels and this may not be such a problem for C-
terminal fusion to C3d 3 . There are arguments, therefore, for comparing responses to 
both constructs in a trial immunisation. However, due to constraints on resources for 
this pilot study, only one of the Ag/C3d 3 constructs (pVKvarODBLLC3d 3 , encoding 
Ag-C3d 3 ) was selected for comparison with un-coupled Ag control 
(pVKvarODBL1). It was intended to compare C3d 3 -Agin a later study. 
DNA-coated gold micro-carrier bullets were prepared for each construct, as 
described (Section 8.6.1) and immunisations were carried out by Dr Sarah Fritchley 
and Dr Rodney Oldroyd (Adprotech). Female Balb/c and CDI mice were included as 
examples of in-bred and out-bred varieties respectively. The immunisation regimen 
for each mouse consisted of 3 doses of the appropriate DNA, administered at 4-week 
intervals and is described in Figure 3.6. 
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Figure 3.6 
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Figure 3.6: Immunisation regimen. Twelve 7-week old female Balblc (1-6) and CD  (7-
12) mice were given 3 doses of DNA, administered at 4-week intervals. Mice 1 to 3 and 7 to 
9 received pVKvarODBLL DNA. Mice 4 to 6 and 10 to 11 received pVKvarODBLIC3d 3 
DNA. Pre-bleeds were taken on day 0 prior to immunisation with ltg DNA per mouse, 
delivered subcutaneously in the abdominal region using the BioRad 11eliosTM  Gene Gun. 
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3.2.4 	Antibody Response to VarODBL1 in DNA Immunisation 
Sera from the immunisation study was tested for reactivity to P. falciparurn infected 
RBCs. IFA was carried out on acetone-fixed iRBCs, infected with four different 
parasite lines; PA89F5, PA17, HB3 and TM284 rosetting-selected parasites. Cells 
were stained with immune sera from each mouse at dilutions of 1:50 - 1:16,000, or 
with the corresponding pre-immune sera as a negative control. A panel of previously 
characterised cross-reactive monoclonal antibodies to the 1RBC surface (courtesy of 
Dr Jana McBride and Dr David Cavanagh, Edinburgh University) was used as a 
positive control. All sera from 5, 9 and 12-week samples were tested. Whilst the 
monoclonal antibody controls were seen to strongly recognise acetone-fixed RBCs 
infected with late-stage parasites (Figure 3.7), none of the sera from the 
immunisation study was shown to recognise any of the parasite strains tested. 
Observation under UV light (A in Figure 3.7) identifies ring-stage (R) and 
trophozoite (T) parasitised cells. The same field viewed under incident light of 
488nm (B in Figure 3.7), shows that one monoclonal antibody (mAb 9.7-1) 
specifically recognises late-stage parasites. Results for immune sera were not 






Figure 3.7: PA89F5 parasites analysed by immunofluorescence assay. IFA was carried 
out on acetone-fixed iRBCs. Cells were stained with monoclonal antibody 9.7-I as a positive 
control for testing reactivity of pVK'arODBLlaC3d 3 immunisation sera. Reactivity was 
detected using Alexa Fluor 488 goat anti-mouse immunoglobulins (used 1:500). Parasite 
nuclei were stained with DAPI (I: 10.000). Cells were observed under oil-immersion, at x 
1.000 magnification. A: Observation under UV light. B: The same field viewed under 
incident light of 488nm. Ring-stage (R) and trophozoite (T) parasitised cells are shown. 
The possibility that the native protein may not be recognised by antibodies to the 
recombinant was investigated by IFA on COS-7 cells surface-expressing the domain. 
COS-7 cells were transfected with do varODBLla-pDisplay DNA. 'Mock' 
transfected (as described in section 2.2.2b) as well as un-transfected cells were 
included as controls. Expressed protein was confirmed 48 hours post-transfection, as 
described (Sections 8.3.7 and 2.2.2b). Having established expression of the 
varODBLlci domain at the surface of transfected cells, duplicate samples of cells 
were removed from the same well of culture and fixed IFA was carried out using 
pooled, week 12, pVKvarODBLlC3d 3 immunisation sera. Transfected COS-7 cells 
were incubated with sera from each mouse, diluted 1:50-1:16,000. The 
corresponding pre-immune sera were used as a negative control. In three separate 
experiments, none of the immunisation sera was found to recognise recombinant 
varODBLla expressed on the surface of COS-7 cells. Taken together, these results 
suggest that varODBLIa, delivered subcutaneously by DNA immunisation, does not 
elicit a significant antibody response, under the conditions tested. 
To further investigate the reactivity of pVKvarODBL1C3d 3 DNA immunisation sera 
against the recombinant protein and to examine the possibility that the antibodies 
generated against the recombinant protein do not recognise conformational epitopes, 
SDS-PAGE followed by Western blot was carried out. Supernatants from COS-7 
cells transfected with pVKvarODBL1-C3d 3 were run on 4-12% bis-tris 
polyacrylamide gels in SDS PAGE. After protein transfer to nitrocellulose, 
membranes were incubated with a range of diluted sera (1:50, 1:100 and 1:500) from 
mice immunised with the pVKvarODBLLC3d 3 construct. Supernatant from 
untransfected COS-7 cells and from COS-7 cells transfected with pVK68-01 
(previously tested as positive for C3d 3-expression) were used as controls. A control 
blot using anti-C3d antibodies was also included. Recombinant COS-7 cell-
expressed varODBLla-C3d 3 could not be detected in any of the sera tested, using 
HRP-conjugated anti-mouse IgG detection antibodies, thus confirming the earlier 
findings. 
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The lack of any well-characterised protein reagent made determining the reactivity of 
the sera very problematic. In the experiments so far described, recombinant 
varODBLIct in the supernatants of transiently transfected COS-7 cells has been 
used. As an alternative source of antigen, I decided to synthesise two varO peptides, 
specific for the DBL1a domain, that could be used in ELISA. Using web-based 
protein structure prediction services (http:/!www.hgmp.mrc.ac.uk, 
http://alphalO.bioch.virginia.edu ) and in consultation with Eurogentec, the 
varODBLla sequence was analysed for predicted immunogenic peptides according 
to the following guidelines: 
Surface probability (accessibility to the immune system making the sequence 
more likely to be antigenic) 
Lack of n-sheets and cc-helices (peptides that do not form these structures are 
easier to make and more likely to be immunogenic) 
• Hydrophobicity (hydrophilic peptides are more likely to be surface-exposed and 
easier to make, whilst hydrophobic sequences tend to curl in on themselves when 
adding to the previous amino acid and the N-terminus often becomes buried) 
• HoppWoods and Kyte-Doolittle charts used to predict antigenic index 
The two predicted most immunogenic sequences were selected for peptide 
production and one of the peptides (DBLlpepl) was used for raising antibodies 
against the domain (Table 3.3). 
Table 3.3 
Name Sequence N-terminal to C-terminal Position in varODBLIa Sequence 
DBLI pepi Biot-GREQNRFDENAEAYCCONH 2 3-17 
DBL1 pep2 Biot-YIVNDHPDKNSNGNKCONH 2 75-89 
Table 3.3: Peptide sequences used in analysing reactivity of DNA immunisation sera to 
varODBLla. The varODBLla sequence was analysed for predicted immunogenic peptides. 
An 8mer is the minimum for an epitope but 15mers were selected to avoid the steric 
hindrance common with a carrier attached. Peptides were synthesised at the 10-20mg 
synthesis scale, N-terminal biotinylated to facilitate binding to streptavidin-coated ELISA 
plates and with a C-terminal amide group to imitate the natural structure and charge of 
internal peptides. In addition, peptide DBLlpepI was coupled at the C-terminus to the 
mitogen keyhole limpet haemocyanin (KLH) for use in raising antibodies in rabbits, using 
Eurogentec's standard immunisation and bleeding protocol. 
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Peptide ELISA was performed as described (Section 8.7.4), using streptavidin 
ELISA plates coated in biotinylated peptide DBLlpepl. 12-week, pooled, 
DBLlpep I-immune rabbit sera was used as a positive control and each set of data 
was corrected by subtracting the pre-immune background for the rabbits, Balb/c mice 
or CD  mice accordingly. Results are shown in Figure 3.8 and indicate that there is 
no antibody response to a varO specific peptide in either Balb/c or CD 1 strains of 
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Figure 3.8: Detection of varODBLla-specific antibodies in sera from DNA 
immunisation using peptide DBLlpepl in ELISA. Pooled 12-week sera from 2 rabbits 
immunised with peptide DBLlpepl and 6 mice per group were tested for reactivity to 
peptide DBLlpepl, using streptavidin ELISA plates coated with 0.5nM per well biotinylated 
DBLlpepl. Each set of results is corrected for background reactivity by subtracting the data 
for the appropriate pre-immune group. 
Taken together, these results strongly suggest that DNA vaccination with 
pVKvarODBLlC3d 3  in the mouse model does not elicit a detectable antibody 
response to this antigen, either as recombinant protein, in live or fixed P. Jalciparum-
infected RBCs or to i'arODBLla peptides. 
3,3 	Discussion 
It was aimed to show some initial proof of concept of the adjuvant effect of C3d 3 in 
the context of a blood-stage malaria vaccine based on PfEMP-1. This was achieved 
by constructing a DNA vaccine that could be tested in mice and involved the 
generation of plasmids that encoded a secreted form of the antigen coupled to mC3d 3 
Using the DBL1a domain from the varO gene of PA89F5 as a candidate antigen 
(and previously, a putative CSA-binding DBL'j, RN), initial attempts to express 
these constructs in mammalian cells indicated that the native version of the P. 
falciparum protein could not be expressed in COS-7 cells in vitro. 
It was hypothesised that the native version of varODBLla was not expressed in 
COS-7 cells due to differences in codon-usage between P. falciparuin and 
mammalian cells, To investigate this possibility, I designed and synthesised a 
synthetic version of varODBLla, codon-optimised for expression in mammalian 
cells. Expression of the codon-optimised version of the sequence in COS-7 cells was 
detected. This supports the findings of a number of other studies that have reported 
increased expression levels and increased immune responses obtained by DNA 
vaccination with a codon-optimised transgene sequence for organisms whose codon 
usage differs substantially from that of mammals (reviewed in (Garmory et al. 2003). 
Recently, Narum and colleagues synthesized gene fragments encoding the receptor-
binding domain of the 175-kDa P.falciparum erythrocyte-binding protein (EBA-175 
region II) and the 42-kDa C-terminal processed fragment of the P. falciparum 
merozoite surface protein 1 (MSP-1 42) using the most frequently occurring codon in 
mammals to code for each amino acid. Plasmids containing codon-optimized 
synthetic gene fragments showed greater than four-fold increased protein expression 
in in vitro transient mammalian-expression assays, compared to those containing 
native gene fragments. Furthermore, the dose of DNA required to induce equivalent 
antibody titres was 10 to 100-fold lower for the codon-optimised than for the native 
sequence. Similar findings have been demonstrated by Nagata and colleagues for P. 
voe lii. 
M. 
It is interesting to note that the codon-optimised version of varODBLIa was 
observed to have increased stability in E. coli during cloning and propagation of 
plasmid constructs. This was demonstrated by the increased ease with which it was 
cloned and a decreased tendency to be excluded by the cell or to mutate, which were 
common problems encountered in handling the native version. Such observations 
would presumably tie in with the increased compatibility of the codon-optimised 
version with host protein-synthesis machinery and the prevention of unpredictable 
recombination events. 
However, whilst the codon-optimised version of varODBLla was found to express 
in vitro, there is little convincing evidence to suggest that it was able to raise an 
antibody response in vivo when delivered subcutaneously as a DNA vaccine using 
the HeliosTM  Gene Gun. This may be related to the dose of DNA delivered, the route 
or method of delivery or, more likely, that the in vivo expression of the P.Jalciparum 
protein was below a threshold level required to elicit antibodies. The possibility also 
remains that the antigen delivered via C3d 3 -immunopotentiated DNA vaccination is 
non-immunogenic 
To investigate the possibility that only antibodies to linear epitopes in the 
varODBLla domain were present in the sera of pVKvarODBLIC3d 3 -immunised 
mice, or that antibody titres were too low to be detected in IFA, an attempt was made 
to analyse the serum by ELISA, using the COS-7 cell-produced recombinant protein. 
After initial optimisation experiments, however, it was found that the concentration 
of varODBLIa protein in COS-7 cell supernatants was too low to successfully coat 
ELISA plates and this experiment was not performed. This problem was addressed in 
part by synthesising varODBLla-specific peptides, DBLlpepl and DBLlpep2, for 
use in ELISA, which also confirmed the previous IFA data and support the finding 
that varODBLla does not elicit a humoral immune response by a DNA vaccine 
approach. 
The possibility that pVKvarODBL1C3d 3 anti-sera did not recognise PA89175 
infected erythrocytes because they were not surface-expressing varO was 
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investigated by imniunofluorescence assay on fixed COS-7 cells surface-expressing 
the recombinant varODBLlct domain. That no recognition could be detected 
confirms the absence of varO-specific antibodies in all sera tested. 
RT-PCR on RNA preps from PA89175 (varO parasite) cultures repeatedly shows 
varO to be the dominant transcript in these parasites. This data, however, does not 
confirm that varO is the PfEMP-1 expressed at the surface of RBCs infected with 
varO parasites. Current opinion favours the hypothesis that the dominant transcript 
determines the protein expressed at the erythrocyte surface, although this is still 
debatable and a highly expressed var gene at the RNA level does not necessarily 
mean it is the one making it to the erythrocyte surface, as demonstrated by the 
findings of Kyes and colleagues (Kyes et al. 2003). Using probes covering a diverse 
var gene repertoire, Kyes and colleagues confirmed by Northern blot that almost all 
var transcript types are detected in ring stages but that the well-conserved var/CSA 
transcript was present constitutively in different laboratory parasites. However, 
although varlCSA has been shown to encode a CSA-binding PfEMP-1, the presence 
of full-length var/CSA transcripts does not correlate with the CSA-binding 
phenotype. 
The fundamental and key requirement of the humoral response induced by any 
candidate vaccine based on PfEMP-1 is antibodies that recognise parasites. To 
investigate this, sera from the trial DNA immunisation using pVKvarODBLI and 
pVKvarODBL1C3d 3 were tested for reactivity to PA89F5-infected RBCs. The 
finding that sera from immunised mice did not recognise parasites is disappointing, 
but is not uncommon in the field. In fact, it is notoriously difficult to raise antibodies 
to the iRBC surface; very few groups have managed (Chen et al. 2004; Gamain et al. 
2004). It is worth noting that the success of Chen and colleagues in raising antibodies 
to the DBLlufrom FCR3S1.2 came almost seven years after publishing the gene 
sequence (Chen et al. 1998). 
The problem of raising iRBC surface-specific antibodies is compounded by the fact 
that interpretation of negative results is not definitive as long as there is uncertainty 
that the antigen is indeed on the surface and that the parasites have not undergone 
antigenic variation. The latter requires monoclonal antibodies to a specific variant, 
for which there are only those raised in the laboratory of Jerg Gysin (Lekana Douki 
et al. 2002). 
That CM can be used to boost the humoral immune response for other antigens in a 
range of different animal models is well documented and in light of the difficulties in 
raising antibodies to PfEMP-1, the failure of a varODBLla-C3d 3 fusion to elicit 
parasite-specific antibodies may not be a failing of CM to boost a response, but a 
problem common to PfEMP-1 domains. 
In conclusion, the need for antibody and antigen target reagents in this field is 
pressing. A good quality, correctly folded protein that is not undesirably modified by 
post-translational activity during expression is extremely desirable for a number of 
reasons. Firstly, the detection of immunising antigen-specific antibodies is made 
extremely problematic due to the lack of availability of parasite-specific reagents. 
Secondly, in light of the lack of antibody response to antigen using a DNA vaccine 
approach, a protein vaccine is desirable. In the next chapter, the results of shifting 
the experimental approach to this goal are described. 
Chapter 4: Production of Recombinant VarODBLlct 
4.1 	Introduction 
A major requirement for a successful recombinant protein-based vaccine is the 
ability to produce biologically active protein that can be economically scaled up for 
large-scale production. Research has shown that the production of a biologically 
active recombinant protein depends upon both the compatibility of codon-usage 
between the native gene sequence and that of the expression host and the 
microenvironment within the host cell used for expression. Historically, E. coil has 
been used for the expression of recombinant proteins. However, due to the lack of an 
appropriate redox environment within the cytoplasmic compartment of E. co/i, it is 
often difficult to produce correctly folded molecules that require the formation of 
disulfide bonds. Recombinant protein expression in E. coil often yields insoluble and 
misfolded or poorly expressed protein. Indeed, my initial attempts to express the 
codon-optirnised version of varODBLlu in E. co/i BL2I cells, as a His-tagged 
recombinant using the vector pET 15x (Adprotech) were unsuccessful. 
The methylotrophic eukaryotic expression host, Pichia pastoris, has been 
successfully developed as an alternative to the E. coli system, for the heterologous 
expression of proteins (Hollenberg and Gellissen 1997; Cereghino and Cregg 2000; 
Gellissen 2000). The hepatitis B surface antigen, currently available as a subunit 
vaccine against hepatitis B virus in South America is expressed in the P. pastoris 
system and a number of other successfully synthesised proteins are being developed 
for use as pharmaceuticals, including insulin-like growth factor-i (IGF-1) and human 
serum albumin (HSA) in clinical trials (Cereghino and Cregg 2000). 
The Pichia expression system is attractive for a number of reasons. Pichia has the 
advantage of being able to perform eukaryotic post-translational modifications, such 
as disulphide bond formation. Thus, it can produce complex molecules that are 
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difficult to express and/or properly fold in bacteria. Furthermore, Pichia can produce 
foreign proteins at high levels; the Pichia system makes use of the alcohol oxidase 
(AOX1) promoter, involved in the first step of methanol metabolism. AOX1 is 
strongly induced by methanol and the protein of interest is highly expressed under 
the control of the AOX 1 promoter when methanol is used as the sole carbon source 
(Cereghino and Cregg 2000). 
The techniques involved in the genetic manipulation of P. pastoris are relatively 
simple and similar to those of the very well characterised Saccharomyces cerevisiae, 
which has been used as an experimental system in biology for many years. Zou and 
colleagues recently described the production of a recombinant form of Pfs25H, the 
cysteine rich 25kDa P. falciparurn surface antigen of zygotes and ookinetes and a 
candidate for a transmission-blocking malaria vaccine. Production problems 
associated with expression in S. cerevisiae were overcome using the P. pastoris 
system. The data demonstrate the superiority of P. pastoris over S. cerevisiae in 
producing high yields of immunologically potent, biologically active recombinant 
protein (Zou et al. 2003). 
The post-translational addition of carbohydrate to proteins is ubiquitous to eukaryotic 
cells (Lis and Sharon 1993). Studies have shown that P. falciparurn has a low N-
glycosylation capability and 0-glycosylation is either absent or present at an 
extremely low level (Gowda and Davidson 1999). One advantage of the Pichia 
system is that it generally does not hypergiycosylate recombinant proteins. Pichia do, 
however, carry out N-linked glycosylation (glycosylation of the amide nitrogen of 
asparagine (N) residues in a protein, when found in the consensus sequence N-X-T-
S, (Bretthauer and Castellino 1999). Carbohydrate moieties can modulate the 
antigenic properties of proteins and to address this problem, the codon-optimised 
version of varODBLlu was designed to remove potential glycosylation sites and 
render it suitable for expression in the Pichia system. 
I thus decided to exploit the Pichia system for the production of recombinant 
varODBLla for use in immunisation studies in order to raise specific antibodies to 
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this antigen and to develop a suitable assay to assess its immunogenicity. This would 
also be a useful investigation into the feasibility of producing functionally active 
varODBLla protein in sufficient quantity for vaccination purposes. 
1-0,261 
4.2 	Results 
4.2.1 	Constructing the Pichia Expression Vector 
The vector pPICZaA (Invitrogen' 5) was selected for expression of a secreted version 
of the varODBLlct domain in Pichia. The vector (outlined in Figure 4.1) makes use 
of the AOX 1 promoter. It has an a-factor signal sequence to ensure secretion of the 
expressed protein and carries Zeocin resistance (ZeoR) for selection in antibiotic 
media. Primers were designed to amplify the varODBLlu sequence with a 5' Kpnl 
site and a 3' XbaI site, for directional cloning into the pPICZctA vector, previously 
linearised by double digest with KpnI and XbaI (Section 8.1.11). The codon-
optimised varODBLlct sequence was PCR-amplified from the pCR4-TOPO 
holding vector (Section 2.2. 1) using a standard PCR mix (Section 8.1.2) and primers 
KpnIF and XbaIR (Table 4.1). The PCR-product was then T-cloned (Section 8. 1.3) 
and released using KpnI and XbaI restriction endonucleases to produce KpnI and 
XbaI cohesive ends. The sequence was then cloned into the dephosphorylated and 




Primer Sequence 5' to 3' Thermal Cycling 
Conditions 
94°C. 2 minutes 
KpnIF g 	TgTTACggAAgggAACAAAACAg 30 cycles of: 
94°C'. IS seconds 
55°C. 30 seconds 
XbaIR gTCTAgATATTTCAggTTTTgCTTgTAAAA 62°C, I minute 
final extension: 
62°C, I minute 
Table 4.1: Oligonucleotides used in pPICZaA cloning. A KpnI site was introduced into 
the t'arODBLlcz sequence using the forward primer (shown in 'd) and an Xhal site was 
introduced using the reverse primer (shown in blue). 
Plasmids were propagated in XL-10 Gold (Stratagene) bacterial cells, PCR-screened 
to confirm the presence of inserts using primers KpnIF and XbaIR, and selected on 
LB plates containing 50.tg/ml Zeocin. A number of PCR-positive and Zeocin 
resistant clones were sequenced to confirm the correct sequence was in-frame with 
the 5' cc-factor signal sequence and the 3' polyhistidine and c-rnyc epitope tag 
sequences. The varODBLla-pPICZaA construct is described in Figure 4.1. 
Figure 4.1 
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Figure 4.1: Schematic representation of varODBLIa-pPICZaA construct used for 
expression of a secreted version of varODBLla. (Adapted from lnvitrogen TM ). The codon-
optimised varODBLlci insert was cloned into the vector using the KpnI and Xbal restriction 
endonuclease sites (shown). The insert was cloned upstream of the c-myc epitope and the 
6xHis tag, to facilitate detection of the expressed recombinant protein. 
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4.2.2 	Pichia Expression Studies and Detection of 
Recombinant Protein 
A selected clone was prepared for transformation by linearising with Sacl and then 
used to transform X-33 wild-type Pichia pastoris cells by electroporation, as 
described (Sections 8.4.1 and 8.4.2). Transformed cells were selected on YPDS 
plates containing 100tg/ml Zeocin. Zeocin resistant clones were selected several 
times using increased concentrations of Zeocin (up to 500tgIml) to ensure that 
satellite colonies (growing in Zeocin resistant zones around positively transformed 
clones) were selected against. Highly Zeocin resistant clones were PCR-screened to 
establish the presence of an insert using primers 5'AOXI and 3'AOXl (EasySelect 
Pichia Expression Kit, Invitrogen TM)  . AOX1 primers amplify from positions 855 
(5'AOX) and 1443 (3'AOX) in the empty pPICZaA vector, yielding a 588bp PCR-
fragment (lanes 2, 3 & 4 in Figure 4.2). In clones successfully transformed with an 
insert of 906bp, the expected PCR-product (including vector sequence) is 1604bp 
(lanes 6 & 7, Figure 4.2). Results confirm the presence of an insert in varODBLla-
pPICZaA transformants 1 and 2. PCR-positive clones were further selected for the 
Mut+ phenotype on MD/MM plates (Section 8.4.4). 
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Figure 4.2 
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Figure 4.2: Establishing the presence of inserts in pPICZaA-transformed P. pastoris 
colonies. Ethidium bromide-stained 1% agarose gel showing the products of PCR-screens on 
Zeocin resistant clones, using primers 5'AOXI and 3'AOXI. Lane 1, marker; lanes 2-5, 
pPICZaA empty vector; lanes 6-9, varODBLla-pPICZuA transformants 1 to 4; lane 9, 
negative control (1-1 20); lane 10, positive control (varODBLlct-pPICZaA plasmid DNA). 
Molecular size markers are indicated in bp. 
Selected clones were then screened for expression on a small scale, as described 
(Section 8.4.5a). Samples of cells and supernatants were collected every 24 hours for 
four days. After 4 days, cells were harvested and supernatants were concentrated 
using a Vivaspin 6 (50,000 MWCO, Vivascience) and analysed by SDS-PAGE and 
Western blot. In small-scale expression studies, when proteins were separated by 
SDS-PAGE and stained with Coomassie blue, a product of the expected MW was 
observed (-4OkDa, including the c-myc and polyhistidine tags) in the supernatants of 
3 of 11 clones analysed. One such clone, RI, is shown in Figure 4.3; the —40kDa 
product was detected in Pichia supernatant 48 hours post-induction and increased in 
intensity up to 96 hours. That the observed —40kDa band is time-course dependent 
after methanol induction is typical of a product accumulating in the supernatant over 
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the course of the induction, as is expected for the secreted product of interest. These 
observations suggest that this band is the recombinant varODBLlu. 
Several attempts were made to detect the —4OkDa band using anti-His and anti-myc 
antibodies in Western blot. For His-tagged proteins an irrelevant His-tagged protein 
Serpin (a —55kDa Brugia malavi serine protease inhibitor, expressed in E. coli and a 
gift from Dr Gavin Nichols) and a His-tagged CIDR 1 from 3137varCHO (a var gene 
from the 3D7 P. ftilciparum strain, selected on Chinese hamster ovary cells) were 
used as positive controls. Despite 6 separate experiments, however, the band of 
interest was not recognised, either with an anti-His antibody (1nvitrogen T1 or 
QiAgen) or with an anti-myc antibody (lnvitrogen or Sigma). 
Figure 4.3 
Hours Post-Induction 
Figure 4.3: Analysis of supernatants from a %'arODBLla-pPICZaA-transformed Pichia 
clone (RI), in a small-scale expression study. Supernatants were concentrated by 
centrifugation using a Vivaspin 6 (50,000 MWCO), reduced and separated by SDS-PAGE 
using 4-12% bis-tris polyacrylamide gels. Proteins were stained using Coomassie blue. MW 
markers are indicated in kDa. Time-dependent expression of a protein of the expected MW 
for varODBLla (-4OkDa) is observed most clearly 96 hours post induction and is indicated 
by the red arrow. 
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These observations were true of both crude and concentrated supernatants from two 
other clones, from several small-scale expression screens. To investigate the 
possibility that expression problems were due to the transformation efficiency, 
several different transformation experiments were carried out in Pichia, each after re-
linearising the original plasmid construct. Several Zeocin resistant and PCR-positive 
clones were selected from each experiment and screened for expression. Attempts 
were made to optimise the expression screens by varying the volume of culture 
media (from 5-20ml), although this had little effect. The observed band was 
consistently faint and to investigate the possibility that expression levels were low 
and detection problems were due to the low concentration of the product of interest, 
different methods of concentrating the supernatant prior to analysis were 
investigated; the speed vac and centrifugation using Vivaspin columns were tried as 
well as tricarboxylic acid (TCA) precipitation and ammonium sulphate precipitation. 
An attempt was also made to purify the His-tagged protein on nickel using a HIS-
SelectTM Spin Column (SIGMA). This again proved unsuccessful. Despite all 
attempts, the —4OkDa band could not be confirmed as the varODBLla recombinant 
in Western blot using either anti-His or anti-myc antibodies. 
To investigate the possibility that expression could be optimised, the fermenter was 
exploited, since it facilitates the careful control of culture conditions (acidity, 
aeration, salt concentration and methanol availability) during induction. A 
fermentation run was carried out with clone RI, as described in Section 8.4.7. Crude 
96-hour supernatants were concentrated using ion exchange chromatography at pH8 
(Sections 8.8.6 and 8.8.7) and analysed by SDS-PAGE and Western blot. Again, the 
—40kDa band was observed and found to be the major detectable protein in 
Coomassie-stained gels (Figure 4.4). As previously, however, the band could not be 
detected in Western blot with anti-His or anti-myc antibodies. 
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Figure 4.4 





Figure 4.4: Analysis of supernatant from fermentation run with clone RI, after 
concentration by ion-exchange chromatography. Proteins were separated by SDS-PAGE 
using a 4-12% bis-tris polyacrylamide gel and stained with Coomassie blue. MW size 
markers are shown in kDa. Lane I, marker; lane 2, crude supernatant; lane 3, pooled 
concentrated RI product. 
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The possibility that recombinant protein was being expressed but not secreted was 
investigated. Cell lysates were prepared from selected clones in expression studies 
(Section 8.4.6) and analysed by SDS-PAGE and Western blot using anti-His 
antibody. No obvious bands of the expected MW were observed in Coomassie 
stained gels and again, recombinant protein could not be detected in Western blot. 
The possibility remained that the —4OkDa band was the product of interest, but that 
the polyhistidine tag had been buried or degraded, thus preventing detection. The 
absence of a good monoclonal or a reliable polyclonal antibody to the varODBLlct 
protein made establishing the integrity of this protein extremely problematic. To 
investigate the possibility that the His or myc tags were not accessible to antibodies, 
Western blots were performed using varO hyper-immune Saiiniri monkey sera and 
Balb/c mouse sera raised against the domain expressed in E. coli (both a gift from 
Odile Puijalon, IP, Paris). Rat sera, raised against the E. coli-expressed domain (Dr 
Qijun Chen, Karolinska Institutet, Stockholm) and affinity purified anti-DBL 1 pep I 
IgG were also used. In each case, the immunising agent was used as a positive 
control and (with the exception of Saiiniri and DBLlpepl) appropriate pre-immune 
sera were used as negative controls. Recombinant Pichia-expressed varODBLlu 
could not be detected using any of these reagents. 
The further investigate the possibility that the His tag was buried and in a final 
attempt to identify the Pichia product, the —4OkDa band observed in Figure 4.4 was 
excised from the gel and analysed using MALDI-TOF mass spectrometry (Section 
8.5.6). Four peptides were found to have identity with the predicted protein (Figure 
4.5, A), giving coverage of 47 out of 337 residues (13.9%). A repeat experiment 
(Figure 4.5, B) gave similar coverage (48 out of 337; 14.2%), although the peptides 
identified were not the same. This degree of coverage was not considered sufficient 
to confidently confirm the identity of the —40kDa band, especially in light of the 
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Figure 4.5: The varODBLla protein sequence, analysed by comparison with the 
MALDU-TOF mass list generated for the putative Pichia expressed varODBLla 
recombinant protein. The varODBLlu sequence was virtually digested with trypsin using 
the program available at http://us.expasy.org/tools . Peptides found to have identity with the 
predicted varO protein are highlighted in . The myc epitope and 6xHis tags of the Pichia 
produced product are shown underlined in ureeii and in blue, respectively. A and B are the 
results from two separate experiments. 
In summary, expression studies using a highly Zeocin resistant, PCR-positive 
varODBLlu-pPICZaA-transformed Pichia clone (RI) in both small-scale (up to 
50m1) and fermenter-scale (up to 5 litres) expression studies yielded a product of 
approximately 40kDa (the expected MW of the Pichia-expressed varODBLIct). 
Expression of this protein was time-course dependent. That it was not apparent in all 
of the clones analysed (only 3 out of 11) suggests that it was not merely a common 
contaminant. However, the protein could not be identified in Western blot using 
antibodies to the myc or polyhistidine tags or using any available antibodies to the 
varODBLla domain. Furthermore, it could not be identified using mass 
spectrometry. On the basis of these findings, it was concluded that the Pichia system 
was not suitable for the production of secreted recombinant varODBLla, detectable 
using any available reagents or methods. Progress was very much dependent upon 
the production of this protein, hence, the decision was made to seek an expression 
system other than Pichia. 
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4.2.3 	Protein Expression in the COS-7 Cell System 
The expression of a secreted version of recombinant varODBLlct, coupled to murine 
C3d 3 , in the COS-7 cell system has already been described in this thesis (Section 
3.2.2). Expression of recombinant protein in COS-7 cells was driven by the CMV 
promoter, encoded by the pVKvarODBL1C3d 3 plasmid. The pVKvarODBLIC3d3 
plasmid had been constructed for the purpose of DNA immunisation and not for the 
expression of enough secreted recombinant protein that could be purified and used 
for protein immunisation. Hence, it contains a promoter that was not intended to 
drive 'large-scale' expression of a secreted product. However, in light of the fact that 
the recombinant could be successfully detected using an antibody directed against the 
CM component of the molecule, it was decided to pursue this system of protein 
production. It was aimed to optimise and scale-up expression of recombinant 
t'arODBLIct and varODBL1ct-C3d 3 in COS-7 cells using the pVKvarODBL1 and 
pVKi'arODBL 1 C3d= constructs. 
The COS7-cell system is well suited for small-scale expression studies and 
diagnostic type experiments, such as those described in Chapters 2 and 3 of this 
thesis. It has not traditionally been exploited for larger scale expression studies or for 
the production of protein that can be purified. The transfection efficiency of COS-7 
cells is generally poor (this is illustrated in Section 2.2.2c where the maximum 
efficiency reached 50%). Furthermore, for cells that are transiently transfected, 
protein expression is limited to the short life (5 to 6 days) of the cell. To prevent the 
need to repeatedly transfect COS-7 cells with the pVKvarODBLI and the 
pVKvarODBLlC3d 3 plasmids, the possibility of making stable transfectants was 
investigated by culturing COS-7 cells in increasing concentrations of the selection 
antibiotic kanamycin - the only selectable marker carried by the pVK68-01 plasmid 
vector and its derivatives (pVKvarODBLI and pVKvarODBL1C3d 3 ). However, 
since kanamycin was used routinely in the culture of COS-7 cells, these cells proved 
to be resistant up to 1 ma/ml kanamycin and the selection of stable transfectants was 
not possible, using these vectors. Without making stable transfectants, it proved 
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difficult to scale-up individual transfections, despite many attempts and instead. 
many small-scale transfections (5m1 in volume) were carried out, to a final volume of 
500m1. Protease inhibitors (0.5mM PMSF and 0.75mM Na,EDTA) were added to the 
supernatants to prevent degradation of recombinant protein, before storage at —80°C. 
As previously described, C3d binds membrane-bound CR2, expressed by B cells and 
FDCs. It was therefore decided to make use of a soluble (CR2)2-196 1 fusion protein 
(Hebell et al. 1991) to purify t'arODBLlct-C3d 1 from pVKvarODBLIC3d 3 -
transfected COS-7 cell supernatant. (CR2) 2-IgG 1 is a recombinant fusion protein 
comprising the first two CR2 short consensus repeat (SCR) domains of human CR2 
fused to murine IgGI variable heavy chains (Figure 4.6). Since the first two CR2 
SCR domains are the C3d-binding domains, it was intended to use this protein to 
affinity purify the varODBLla-C3d recombinant, making use of the C3d 3 tag. 
Figure 4.6 
Figure 4.6: Model of (CR2)-1gG1 adapted from Hebefi et al. 1991. The attachment of the 
SCRs (pink) of CR2 to the heavy chains of the immunoglobulin molecule (black) is shown. 
J558L cells are a myelonia cell line that synthesize a lambda light chain (01 ci al. 
1983). Hebell and colleagues created the J558L IID1 cell line by transfecting J558L 
cells with a plasmid encoding SCRs I and 2 from CR2 fused to the N-terminus of a 
murine y-1 gene specific for the hapten 4-hydroxy-3-nitrophenacetyl (NP). To make 
enough (CR2) 2-IgGl for the construction of an affinity column, J558L IIDI cells (a 
kind gift from Dr Andrew Knight) were cultured as described (Hebell et al. 1991) 
and harvested after 5 days incubation in roller bottles. After filtration and dialysis of 
the supernatant as described (Section 8.8.2), recombinant fusion protein was purified 
using affinity chromatography with Protein G. Eluted fractions were analysed by 
SDS-PAGE and Western blot (Figure 4.7). Protein concentration was determined by 
analysis on Coomassie blue-stained SDS polyacrylamide gels (Figure 4.7 A) and by 
BioRad DC protein assay. Protein containing fractions 10 to 17 (lanes 5 to 12 in 
Figure 4.7 A) were pooled and dialysed against PBS, overnight at 4°C. The dialysed 
product was then analysed by comparison with a sample of purified (CR2) 2-IgG 1 (a 
gift from Dr Andrew Knight) and normal mouse IgGl (mAb 18.1-1-4) in Coomassie-
stained SDS gels (Figure 4.7 B). The band pattern observed for the purified protein is 
as expected for immunoglobulins after reduction and compares with that observed by 
Hebell and colleagues. Dissociated light chains run at —25kDa. The lgGl heavy 
chain plus CR2 domains I and 2 has a predicted MW of 70-75kDa. This band is seen 
in Coomassie-stained gels, however, it seems to be contaminated with normal heavy 
chains (-50kDa, Figure 4.7, A and B). In Western blot, however, a clear size-shift is 
observed when the (CR2) 2-IgGl heavy chains are compared to those of normal 
murine lgG (Figure 4.7, Q. This was taken as evidence that the fusion protein was 
the desired species and suitable for use in the affinity purification of varODBLlct. 
4mg of the purified fusion protein was coupled to activated sepharose 413, to make a 
(CR2)2-IgGl affinity column, as described (Section 8.8.3). 
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Figure 4.7: SDS-PAGE analysis of (CR2)2-lgCl fusion protein, purified by affinity 
chromatography with Protein C. A: Bound protein was eluted using 0.IM glycine (pH3) 
and imI fractions were neutralized with IM tris-base (pHl0.5). Eluted fractions are 
visualised here with Coomassie blue; Lane 1, MW marker; lanes 2 to 12. fractions 7 to 17. 
B: Comparison of purified (CR2) 2-IgGI with normal mouse IgGI. Lane 1, MW marker; lane 
2, purified (CR2)2 -IgG1; lane 3, (CR2)2-lgGl (positive control); lane 4, mouse mAb 18.1-1-
4. C: Duplicate gel B analysed by Western blot using goat anti-mouse lgG (Southern 
Biotech), diluted 1:500. MW markers are shown in kDa. Red arrows indicate the –50kDa 
(lower) and –70kDa (upper) heavy chains of normal lgG and (CR2) 2-lgG1, respectively. 
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COS-7 cells require culture in DMEM supplemented with FCS (cDMEM) containing 
many proteins, including serum complement component 3 and its breakdown 
products. Thus, the abundance of contaminating proteins in culture media, especially 
contamination with single copy C3d, had to be addressed to enable purification using 
the (CR2) 2-IgGl affinity column. This was achieved by adapting the cells to serum 
free medium (VP-SFM, Gibco), over several passages using decreasing ratios of 
cDMEM to VP-SFM. 
The (CR2)2-1gG 1 column was used to purify recombinant varODBLlu-C3d 3 from 
the pooled COS-7 cell supernatants. COS-7 cell supernatants were filtered and 
purified using affinity chromatography, as described (Sections 8.8.4 and 8.8.5), 
taking care to carry out all procedures at 4°C to prevent degradation of the product 
and avoiding contact with plastic wherever possible. Eluted fractions were analysed 
by SDS-PAGE and Western blot using rabbit anti-human CM antibodies. In 
Coomassie stained gels, a band of —lOOkDa was seen (lanes 3 and 4 in Figure 4.8 A), 
of lower MW than the expected —130kDa. This band was detected in duplicate gels 
transferred to PVDF and analysed by Western blot (lanes 3 and 4, Figure 4.8 B), 
confirming it to be a CM-containing molecule. This finding indicates that the column 
can be successfully used for the purification of CM-containing proteins, however, it 
suggests that the full-length varODBLlct protein (expected MW of .—l3OkDa) is 
degraded upon purification, despite the addition of protease inhibitors and despite 


















2 	345 	 12345 
Figure 4.8: Analysis of supernatants from COS-7 cells transiently transfected with 
pVK;'arODBLIC3d3, affinity-purified using (CR2) 2-IgG. Proteins were separated by 
SDS-PAGE using 4-12% bis-tris polyacrylamide gels and stained with Coomassie blue (A) 
or transferred to PVDF membrane and incubated with rabbit anti-human CM (1:500), 
followed by URP-conjugated swine anti-rabbit immunoglobulins (1:1.000) (B). Lane 1, 
cDMEM supernatant from COS-7 cells transiently transfected with pVK68-01; lanes 2 to 4, 
affinity purification fractions 1 to 3; lane 5, MW marker. MW markers are indicated in kDa. 
Red arrow indicates the —lOOkDa bands thought to he degradedv ,,rODBLla-C3d3. 
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The (CR2)2-IgGl affinity column could not be used for the purification of 
rarODBLla not fused to C3d 3 , thus, another method of affinity purification was 
employed. An affinity column was constructed using affinity purified rabbit 
immunoglobulins to peptide DBLlpepl. The peptide was first immobilised using the 
SiilfoLink® Kit (Pierce Biotechnology) and then used for the affinity purification of 
rabbit anti-DBLlpepl IgG, as described in Section 8.8.5. Supernatants were analysed 
using affinity-purified anti-DBLlpepl in Western blot (Figure 4.9). These data 
confirm expression of recombinant varODBLlc, as demonstrated by the bands in 
Western blot at —35kDa, the expected MW of the protein. However, strongly 
recognised bands at —70kDa and just over lOOkDa (around 2 and 3 times the 
expected MW of varODBLla) suggest that the protein is not a single species, but is 
possibly forming dimers and aggregates. Purified anti-DBLlpepl IgG was then 
coupled to activated sepharose 4B (Section 8.8.3) to construct a varODBLla-
specific affinity column. Recombinant varODBLlci was purified from COS-7 cell 
supernatant by affinity chromatography (Section 8.8.5). Eluted fractions were pooled 
and buffer exchanged into PBS using a Vivaspin column (MWCO 20,000). Western 
blot analysis of the purified product using anti-DBLlpepl IgG confirmed it to be the 
protein of interest (Figure 4.10). 
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Figure 4.9: Western blot analysis of supernatants from COS-7 cells transiently 
transfected with pVKvurODBL1 DNA. Proteins were separated by SDS-PAGE using 4-
12% bis-tris polyacrylamide gels and transferred to PVDF membrane. Membranes were 
incubated with affinity purified rabbit anti-DBLlpepl IgG (1:250), followed by HRP-
conjugated swine anti-rabbit immunoglobulins (1:1,000). Lane 1, MW marker; lanes 2 to 15, 
supernatants from individual transfections; lane 16, (negative control) supernatant from 
Smock' transfected cells; lane 17, varODBLIciC3d 3 (positive control). MW markers are 
shown in kDa. 
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Figure 4.10: Western blot analysis of varODBLla produced in COS-7 cells transiently 
transfected with pVKvarODBLI and affinity-purified using cz-DBLlpepl IgG. Proteins 
were separated by SDS-PAGE using 4-12% bis-tris polyacrylamide gels and transferred to 
PVDF membrane. The membrane was incubated with rabbit anti-DBLlpepl IgG (1:250), 
followed by HRP-conjugated swine anti-rabbit immunoglobulins (1:1,000). Lane 1, MW 
marker; lane 2, column flow-through; lanes 3, 4 & 6, column washes; lanes 5 & 7, eluted 
sample from 2 separate experiments. 
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4.3 	Discussion 
I aimed to produce recombinant t.'arODBLla for use as an imniunogen in trial 
vaccination studies. It was intended to express the domain alone and a version 
coupled to murine C3d 3 to investigate the use of C3d as an immunopotentiator for a 
PfEMP- I-based adhesion-blocking malaria vaccine. 
Pichia pastoris seemed a suitable choice of system for the heterologous expression 
of the varODBLla domain, especially given its ability for eukaryotic post-
translational modification. Using this system, a time-dependent product of the 
expected MW (-.-4OkDa) was consistently produced. However, this product could not 
be confirmed as the varODBLla protein in Western blot using antibodies to the myc 
epitope or the polyhistidine tag. Neither was it recognised by anti-sera raised in 
either mice or rats against the domain expressed in E. coil, or affinity purified rabbit 
I mmunoglobulins raised against a varODBL 1 a-specific peptide (DBL I pep I). 
Measures were taken to protect and maintain the integrity of the Pichia-expressed 
protein; protease inhibitors were added to supernatants upon sampling to prevent 
degradation and concentrated supernatants were re-suspended in or dialysed against 
15mM Tris/500mM NaCl, pH7.5, to protect against aggregation. Some evidence of 
aggregation was observed in the case of the Pichia supernatants analysed here, which 
quickly took on a cloudy appearance that was prevented by dialysis against 500mM 
NaCl. Furthermore, in SDS-PAGE, bands at —80kDa and —I20kDa were also seen (2 
and 3 times the MW of the —40kDa product), suggesting the —4OkDa protein was 
forming aggregates (despite the reducing conditions of SDS-PAGE analysis). The 
formation of aggregates has been common in the production of other PfEMP- 1 
domains and has made their handling and analysis problematic (Graham Bentley, 
personal communication). 
The positive controls used in Western blot analysis of the Pichia-derived 
supernatants were an irrelevant His-tagged protein Serpin (a —55kDa Brugia maiavi 
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serine protease inhibitor, expressed in E. co/i) and a His-tagged CIDR I from 
3D7varCHO. The CIDR1 was previously expressed in Pichia, in our Edinburgh 
University laboratory, by Toby Fagan and Saacl Al Kahtani. It is worth noting that, 
whilst the anti-His antibodies used in Western blot strongly recognised Serpin, 
detection of the CIDRI was inconsistent and decreased with time, suggesting that 
some degradation was taking place. This raises the possibility that PfEMP-1 domains 
are not only difficult to express, but that they degrade easily. 
Analysis of the protein in a reduced state by SDS-PAGE and Western blot should 
have rendered conformational epitopes redundant. As such, the possibility that the 
—40kDa band was the product of interest but that it was folded in such as way as to 
be inaccessible to antibodies that recognise conformational epitopes is unlikely. 
These findings are supported by the mass spectrometry data in which percentage 
identity of peptide masses with those from virtual digest of the predicted expressed 
sequence was, on average 14.05%. Coverage of at least —20% is required to indicate 
that this is the protein of interest and to have any confidence, this number should be 
closer to 30-40%. From these data, it seems unlikely that the —4OkDa protein was the 
varODBLla recombinant. 
Why varODBLla was not expressed in Pichia is unclear. More information on this 
might have been gained from an analysis of varODBLict transcripts at the RNA 
level, by Northern blot. However, in the absence of a positive control, these 
experiments were not done and priority was given to protein production, considered 
vital to move the project forward. 
The production of recombinant P.falciparurn proteins in Pichia has been reported by 
several groups; for MSP-1 (Morgan etal. 1999) and for AMA-i (Kocken et at. 
1999), for example. My findings, however, question the use of the Pichia system for 
the production of functional recombinant PfEMP-I domains. in this respect it is 
interesting to note the findings of two recent studies; those of (Milek et al. 2000; 
Letourneur etal. 2001). Milek and colleagues expressed a recombinant P.falciparurn 
transmission-blocking vaccine candidate antigen (Pfs48/45) in Pichia pastoris. 
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Pfs48145 contains conformation-constrained epitopes and its expression in 
Saccharo,nyces cerevisiae led to prematurely terminated transcripts. Premature 
transcription termination was overcome using a synthetic gene (of higher GC content 
than the native version) and by using the Pichia expression system. However, low 
levels of recombinant Pfs48145 were produced in Pichia and, whilst the recombinant 
protein was shown to be disulphide-bridge constrained, it was not recognised by 
transmission-blocking antibodies and did not induce transmission-blocking sera in 
mice. The Letourneur study suggests that the addition of unnatural glycan structures 
by P. pastoris is a potential drawback that should be considered when using this 
expression system. They report heterogeneity in glycosylation of a Pichia-secreted 
recombinant surface antigen (SAGIt) of Toxoplasma gondii. ELISA and Western 
blot analysis show that 0-linked oligosaccharides added by P. pasroris could be 
recognised as antigenic structures, whilst having no major effect on protein 
conformation (Letourneur et al. 2001). 
Despite the problems of expressing varODBLla in Pichia, I have described here the 
successful expression and purification of this domain in the COS-7 cell system. The 
pVK68-01 vector and its derivatives, used here for varODBLla and varODBLla-
C3d3  expression in COS-7 cells were intended for use as plasmids for DNA 
immunisation. They are ideally suited for this purpose, i.e. for the production of 
recombinant protein in vivo and for very small-scale expression testing in vitro. They 
are not well suited to expression of secreted recombinant protein in quantities 
sufficient for purification and vaccination. Using these plasmids, it was not possible 
to make stable transfectants and it proved very difficult to scale up transfections. 
These difficulties were overcome by setting up many small-scale transfections, 
which was both costly and time consuming. Having shown that COS-7 cells are 
capable of varODBLlct expression, which has proved difficult in other systems, it 
would now be interesting to investigate whether expression in this system could be 
optimised by re-engineering the pVK68-01 vector or by making use of a vector 
specifically designed for efficient large-scale protein expression in mammalian cells. 
Such vectors are available - pSecTag2 or pSecTag2/Hygro (Invitrogen), for 
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example, that would allow for the selection of stable transfectants using Zeocin 
pSecTa22 or hygromycin (pSecTag211ygro). 
I have reported here the expression of a secreted version of recombinant 
arODBLla-C3d 3 . However, purification of this protein was not straightforward and 
the product was degraded following affinity purification using the (CR2) 2-mIgGl 
column. It is possible that this was due to the absence of a rich, protein 'buffering' 
environment in the VP-SFM that COS-7 cells were adapted to in order to overcome 
purification problems using CR2. This was investigated by the addition of 1% sterile 
BSA to supernatants prior to storage. I did not, however, find evidence that this 
helped maintain the integrity of the protein. 
Nly previous findings that the vurODBL I u domain expressed as a membrane protein 
in COS-7 cells is functionally active (binds RBCs), suggests that the COS-7 cell 
system is suitable for the expression of recombinant P. falciparurn protein in its 
native conformation. Whether the secreted version of varODBLIcx is functionally 
active, however, remains to be determined. This is discussed in the following 
chapter. 
Chapter 5: Is VarODBL1a a Suitable Antigen for 
Inclusion in a Prototype Adhesion-Blocking Malaria 
Vaccine? 
5.1 	Introduction 
The suitability of varO as a candidate antigen has been previously discussed and this 
thesis has so far described attempts to develop a prototype malaria vaccine based on 
the DBLIa domain from the varO gene. Whilst varO is not proposed to be the ideal 
candidate antigen, it is a useful one for early-stage studies on adhesion-blocking 
prototypes that can be tested for safety and efficacy in a primate malaria model of P. 
/alciparum. The work so far described has highlighted the problems not only of 
testing such vaccines, but also in producing such a vaccine to test. Progress has been 
impeded by the difficulties of expressing recombinant P. falciparum protein in 
heterologous expression systems. Progress has also been hindered by the absence of 
any varO specific sera that can serve as either positive controls for surface IFA or as 
panning reagents to enrich for varO expressing parasites (by necessity, this role is 
served by the rosetting reaction itself). 
Nonetheless, progress has been made and, as described in the previous chapter, 
recombinant DBL1a from varO, expressed in COS-7 cells was produced and 
purified. Furthermore, in collaboration with other groups in the ELJROMALVAC 
consortium, a panel of additional varO reagents have been developed. In view of the 
current data and the pool of varO resources available to our collaborative groups, I 
aimed to re-assess the specific experimental utility of varO to move towards a better 
understanding of this protein, the varO parasites that putatively express it and the 
immune response generated against it. The reagents used in this study are described 
in Table 5.1. 
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Table 5.1 
Reagent Group Comments 
COS-7 cell-produced codon- ICAPB, Edinburgh Section 4.2.3 of this thesis 
optimised varODBLla  
E. co/i-produced native Institute Pasteur, Paris 
varODBL I a  
ftptide DBLlpepl ICAPB, Edinburgh Sequence: GRENRFDENAEAYC 
(Table 3.3, Section 3.2.4 of this thesis) 
Peptide DBLIpep2 ICAPB, Edinburgh Sequence: YIVNDHPDKNSNGNK 
(Table 3.3, Section 3.2.4 of this thesis) 
Affinity purified rabbit anti- ICAPB, Edinburgh Section 4.2.3 of this thesis 
DBLlpepl lgG  
Peptides R23N (R23/4363) Institute Pasteur, Paris N-terminal and C-terminal peptides 
and R23C (R23/4364) from the R23 sequence. R23 is a 
EUROMALVAC I vaccine candidate. 
possibly surface-associated. Used as 
controls for DBLI pep l and DBLlpep2 
Affinity purified rabbit anti- Institute Pasteur, Paris Used as a positive control for detection 
R23N IgG  of surface expression in fixed IFA 
5.1/4365 and 5. 1/4366 rabbit Institute Pasteur, Paris Rabbit antibodies raised to antigen 
anti-Pf60 lgG annotated as PFI0540w expressed in 
late schizonts. Most probably not on 
the surface of P. falciparurn iRBCs. 
IgG used as specificity controls for 
affinity purified rabbit IgG 
Pf60 rabbit sera Institute Pasteur, Paris Sera raised to a common polypeptide 
region of the ATS (cytoplasmic 
PfEMP-1 domain) and possibly other 
merozoite proteins (Carcy el a/. 1994). 
Used as positive control for PfEMP-I 
reactivity on Western blots and 
negative surface reaction by live IFA 
SG 1780* !CAPB, Edinburgh (Lisa Affinity-purified rabbit lgG raised 
Sharling) against a peptide from a conserved 
region of PfEMP-1 exon 2 
AntiZfP2* ICAPB, Edinburgh Affinity-purified rabbit lgG raised 
(Keith Matthews) against a T brucei zinc finger protein 
A ntiPf2P3* ICAPB, Edinburgh Affinity-purified rabbit lgG raised 
(Joanne Thomson) against a polypeptide (18 residues) 
from PfCRMP2 
* Not EUROMALVAC 
Table 5.1: VarO and related reagents of the EUROMALVAC consortium. A brief 
description of the reagent is given and details of the group from which it originated. 
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5.2 	Results 
5.2.1 	Reactivity of VarODBL1a-Specific Antibodies to 
Parasites in IFA 
The purified lgG raised in rabbits against peptide DBLlpepl, used to purify 
recombinant do varODBLIci from COS-7 cells (Sections 3.2.4 and 4.2.3) was tested 
for reactivity to Palo Alto (clone 89F5) parasites by IFA. Anti-R23/4363, anti-
R23/4364, anti-5.1/4365 and anti-5.1/4366 purified rabbit lgGs were used as 
specificity controls for parasite recognition (these antibodies recognise proteins of a 
different cellular localisation to PfEMP-1 and possibly a different stage of 
expression). Secondary antibody alone (Alexa Fluor 488-conjugated anti-rabbit IgG) 
was used as a negative control. Anti-DBLlpepl IgG clearly recognised iRBCs, fixed 
by air-drying, down to 1:400 dilution, with weak recognition down to 1:800 dilution. 
The pattern of fluorescence seen on these cells had a 'dotty' appearance (Figure 5. 1 
B, C) and was very different to that seen with anti-R23 or Pf60 antibodies which 
took on more of a 'block'-type appearance that covered the whole cell (Figure 5.1 
D). The figure shown is representative of three independent experiments. 
114 
Figure 5.1 
Figure 5.1: Affinity purified rabbit anti-DBLlpepl IgG recognises PA89F5 iRBCs in 
fixed IFA. Cells were fixed by air-drying and incubated with affinity-purified anti-
DBLlpepI lgG. diluted 1:50 to 1:800. Secondary antibody (goat anti-rabbit IgG conjugated 
to Alexa Fluor 488) was used 1: 1,000 with 1: 1,000 Hoechst to stain the nuclei of parasitised 
cells. Cells were viewed at x 40 (A, D, E and F) or x 100 magnification (B and C), under 
incident light of 488nm (to view antibody staining, seen here as green fluorescence) and 
under UV for Hoechst (seen here as blue fluorescence). Each panel is the overlay of these 2 
views. A. B. C: Cells stained with anti-DBLl pep l lgG. D: Cells stained with anti-R2314363 
lgG. E: Cells stained with ZfP2. F: Cells stained with affinity-purified pre-immune lgG from 
DBLlpepl immunised rabbits. 
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To further dissect the specificity of the affinity-purified anti -DBLI pep  lgG for varO 
parasites and to investigate its reactivity with other, non-rosetting strains of P. 
falciparum, IFAs were carried out on 3 more rosetting-selected (PA17, R29 and 
TM284) and 3 non-rosetting (HB3, A4 and FCR3/CSA) parasite clones. As controls 
for these experiments, anti-Pf2P3, anti-ZfP2, SG1780 and secondary antibody only 
were used. Pf2P3 is an 18 amino acid polypeptide from P.falciparuin cysteine repeat 
module protein (PfCRMP2). a —400kDa protein expressed in late-stage parasites. 
Anti-ZfP2 is affinity-purified rabbit lgG raised against a T. brucei zinc finger 
protein, used as a negative control and SO 1780 is affinity purified rabbit IgG raised 
against a peptide from a conserved region of PfEMP-1 exon 2. Degree of 
fluorescence was scored on the scale described in Table 5.2. Air-dried iRBCs stained 
with anti-DBLlpepl fluoresced brightly (+ +) for all parasite clones tested, clearly 
demonstrating cross reactivity (Table 5.2). That there is no recognition of any of 
these clones with purified IgG raised against an irrelevant protein (ZfP2) is good 
evidence to suggest that this reactivity is specific to P.falciparurn-infected RBCs. 
No reactivity was observed with the anti-Pf2P3 and SO 1780 antibodies used as 
positive controls, for air-dried cells. However, when paraformaldehyde-fixed cells 
were used, some reactivity was evident, although this recognition was weak and not 






aDBL1PEP1 aPf2P3 SG1780 aZfP2 Secondary 
Only 
PA89F5 + + (+ +) - (+1-) - (-) - (-) - (-) 
FCR3/CSA + + (+) - (-) - (+1-) - (-) - (-) 
R29/R + + (+) - (-) - (+1-) - (-) - (-) 
TM2841R + +  
A4 + +  
11B3 + + (ND) - (ND) ND  
PA17/R + + (ND) - (ND) ND  
Table 5.2: Results of fixed lEA on RBCs infected with different rosetting and non-
rosetting clones of P. falciparum to determine specificity of affinity purified anti-
DBLlpepl IgG. Secondary antibody was Alexa Fluor conjugated goat anti-rabbit IgG 
(1:1,000) and stained cells were observed using x 400 magnification and incident light of 
488nm. Parasitised cells were stained with Hoechst (1:1,000 in secondary antibody dilutions) 
and observed under UV. Results are expressed as degree of fluorescence and are 
representative of 2 separate experiments, for air-dried cells. Scores in brackets are for 
paraformaldehyde-fixed cells. ND = Not done; - = no fluorescence; -1+ = weak fluorescence 
in some iRBCs; + = weak fluorescence in most 1RBCs; + + = bright fluorescence in most or 
all iRBCs; + + + = clear, bright fluorescence in all iRBCs. 
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As a negative control for these experiments, whole prei mill Lille rabbit sera vas not 
considered appropriate, especially given the common tendency of non-immune rabbit 
sera to show background-reactivity to P. falciparum- infected RBCs (Monteiro et al. 
998). Hence, to determine the specificity of the observed reactivity, IFA was 
repeated in the presence of saturating amounts of peptide to block antibody 
recognition sites. IFA was carried out, as previously, with primary antibody 
incubations plus relevant (DBLlpepl) and irrelevant (R23/4363 and R23/4364) 
peptides at molar ratios from 1:50 to 1:15.63. Fluorescence was scored as previously 
and results are described in Table 5.3. Recognition of PA89F5-infected RBCs was 
strongly inhibited in the presence of relevant peptide, at a molar ratio as low as 
I 1 5.6. Such inhibition was not observed, however, when antibody incubations were 
carried out in the presence of two different irrelevant peptides. 
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Table 5.3 
Antibody, to Peptide Molar Ratio 
Antibody/Peptide 
1:125 1:62.5 1:50 1:31.3 1:25 1:15.6 1:12.5 1:6.25 No 
Combination Peptide 
Anti-DBLlpepl ND ND - ND - - 
(1:50)+ DBLlpepl 
Anti-1)BLlpepl - - ND - ND - ND ND + + + 
(1: 100) + 
DBLlpepl 
Anti-l)BLIpepl +++ ±++ ND +++ ND +++ ND ND +++ 
(1:100) + R23/4363 
Anti-DBLlpepl +++ +++ ND +++ ND +++ ND ND +++ 
(1:100)+ R23/4364 
Table 5.3: Results of dry IFA on Palo Alto-infected RBCs to determine specificity of 
affinity purified anti-DBLlpepl IgG. Infected RBCs were air-dried and incubated with 
primary antibody in the presence of relevant peptide (DBLlpep) or irrelevant peptides 
(R2314363 and R23/4364). Different molar ratios of antibody to peptide were used, from x 
125 to x 6.25 saturation. Secondary antibody was Alexa Fluor 488 conjugated goat anti-
rabbit lgG (1:1,000) and stained cells were observed using x 400 magnification under 
incident light of 488nm. Parasitised cells were stained with Hoechst (added 1:1,000 to 
secondary antibody dilutions) and observed under UV. Results are expressed as degree of 
fluorescence and are representative of 2 separate experiments. ND = Not done; - no 
fluorescence; I+ = weak fluorescence in some iRBCs; + = weak fluorescence in most 
iRBCs; + + = bright fluorescence in most or all 1RBCs; + + + = clear, bright fluorescence in 
F1111 11201 
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The possibility remained that the rabbits used to raise antibodies to DBLlpepl had 
pre-immune background reactivity to P. falciparurn iRBCs. To investigate this, the 
pre-immune rabbit serum was affinity purified on the immobilised DBLlpepl 
peptide column used previously to purify the immune serum. The purified pre-
immune lgG was used in serial dilutions from 1:100 to 1:1,600 in IFA with rosetting 
selected PA89F5, R29 and TM284 parasites. Background reactivity that diminished 
with titration was observed for all clones tested with the pre-immune IgG (Figure 
5. 1, F). This reactivity was clearly weaker than that observed with the corresponding 
immune IgG, at the equivalent titration. Nonetheless, it makes interpreting these 
results difficult and questions the validity of the previous findings that demonstrate 
the specific recognition of P.falciparum-infected RBCs by DBLlpep 1-immune lgG. 
This data is further supported by Western blot analysis (Figure 5.2) in which whole 
parasite preparations and membrane fractions of P. falciparum strain A4-infected 
RBCs were probed with the affinity-purified DBLlpepl-immune and pre-immune 
lgG. These results show that, whilst some proteins are more strongly recognised by 
the immune IgG, significant background reactivity is evident with the pre-immune 
IgG, particularly in the high MW region of the blot. Interestingly, a band similar to 
the one observed here just below 250kDa in whole parasite extract (Figure 5.2 A and 
B, lane 3) was previously identified as PfEMP-1 after recognition by SG 1780, exon-
2 specific antibodies (Lisa Sharling, personal communication), suggesting that pre-
immune sera from the rabbits used to raise antibodies to DBLlpepl indeed do 
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Figure 5.2: Western blot analysis of whole parasite preparations and membrane 
fractions of A4-infected RBCs probed with affinity-purified DBLlpepl-immune (A) 
and pre-immune (B) IgG. Samples were prepared and gifted by Lisa Sharling, ICAPB. 
Lane 1, uninfected RBC membrane fraction; lane 2, A4-infected RBC membrane fraction; 
lane 3, whole A4 parasite preparation. The arrow indicates a band previously identified as 
PfEMP-1 using SG 1780, exon-2 specific antibodies. 
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Fixing iRBCs by air-drying permeabilises the cells to some extent and the possibility 
remains that the specific reactivity observed against fixed iRBCs is directed against 
intra-cellular or membrane-associated components of the cell, rather than surface-
exposed proteins. To investigate this possibility, IFA was carried out on live 
PA89F5-infected RBCs using rabbit affinity purified DBLlpepl IgG. Antibodies 
raised in Balb/c mice to E. co/i-produced varODBL 1 a (previously shown by the 
Paris group to recognise PA89F5-infected RBCs in dry IFA), along with anti-R23 
lgG, anti-Pf60 lgG and secondary antibody only controls were used. In live IFA, 
none of the antibodies tested were observed to recognise PA89F5-infected RBCs, 
although no positive control was available for this experiment. Approximately 1-2% 
of' parasitised RBCs incubated with anti-DBLlpepl antibodies did fluoresce, 
although this reactivity was in very late stage parasites and it is not certain that the 
membrane is intact in such cells. 
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5.2.2 	Reactivity of VarODBL1a in ELISA 
The affinity purified COS-7-produced varODBLlu protein was used in ELISA with 
a panel of anti-sera raised against the domain. ELISA plates were coated with protein 
at 0.5p.g/ml and ELISA carried out as described (Section 8.7.3), using affinity 
purified anti-DBLIpepl IgG, sera from out-bred (OF) mice immunised with E. coli-
expressed varODBLlct (Institute Pasteur) and varO hyper-immune Sairniri monkey 
sera. HRP-conjugated secondary antibodies (Promega anti-mouse and anti-rabbit IgG 
and Southern Biotech anti-human IgG, used 1:3,000) were used for detection. Data 
were corrected against appropriate pre-immune mouse or rabbit sera and secondary 
antibody alone controls (pre-immune Sainiiri sera was not available). Of the sera 
tested, as in Western blot, none demonstrated reactivity against the COS-7-cell-
produced protein (Figure 5.3). In fact, over three experiments, the COS-7-cell-
produced protein was the least reactive of all the recombinant proteins tested. 
Purified anti-DBLIpepl IgG showed the greatest reactivity against E. co/i-produced 
DBL1ct, which also reacted with homologous anti-sera in the positive control for this 
experiment. These results suggest that COS-7 cell-expressed varODBLlct has a 
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Figure 5.3: ELISA data showing reactivity of varODBLlct recombinant proteins to a 
panel of anti-sera. Sera from different animal systems were tested for reactivity to COS-7 
cell-expressed and E. co/i-expressed recombinant varODBLlc. Promega AP-conjugated 
appropriate IgG secondary antibodies were used (1:3,000). Data are normalised against 
appropriate pre-immune mouse or rabbit sera and secondary antibody only controls. 
124 
5.2.3 	Reactivity of VarODBLIa-Specific Antibodies to 
Parasites in Western Blot 
The reactivity of affinity purified rabbit anti-DBLl pep l IgG towards linear epitopes 
of iRBCs was investigated by Western blot, using affinity purified rabbit anti-Pf60 
IgG, serum from an out-bred (OF) mouse immunised with anti -E.coli-produced 
varODBLla and serum from Saimiri monkeys, hyper-immune to PA89F5 parasites 
for comparison. Reduced parasite preparations (3x10 7 per well) were separated by 
Sl)S-PAGE using 7.5% bis-tris polyacrylamide gels and transferred to nitrocellulose. 
Membranes were incubated with appropriate primary antibodies at 2-5tg/ml dilution 
and with appropriate AP-conjugated secondary antibodies diluted 1:10,000 (anti-
rabbit, anti-rat and anti-mouse) or 1:5,000 (anti-human, for the detection of monkey 
immunoglobulins). Using this method, there are obvious differences between the 
band patterns observed for infected and uninfected RBCs (Figure 5.4). High MW 
bands, of —200kDa appear (most clearly seen in lane 3 B and D, Figure 5.4), thought 
to be PfEMP-1 molecules. The Western blot data provide little information as to the 
reactivity of different sera to parasite proteins, largely due to the difficulties in 
resolving high molecular weight proteins, of which the PfEMP-1 molecule to which 
these antibodies are directed is one. Using hyper-immune Saimiri serum as a control, 
it is expected to see a clear band at —250kDa (the expected size of the varO PfEMP-
1) that shows size heterogeneity with that observed in this region for FUPICB, 
another Sai,niri adapted Palo Alto line. Using this technique, however, these bands 
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Figure 5.4: Western blot analysis of the reactivity of varODBLla-specific antibodies, 
expressed in different systems, with iRBCs. A: Affinity purified rabbit anti-DBL I pep I 
IgG. B: Affinity purified rabbit anti-Pf60 lgG. C: Sera from OF mouse immunised with anti-
E.co/i-produced varODBL I u. D: Serum from Sairniri monkeys, hyper-immune to PA89F5 




5.3.1 	Closing the Circle on VarO? 
In light of my previous findings and the availability of at-0 reagents of the 
EUROMALVAC collaboration, I aimed to re-assess the suitability of the DBL1c 
domain of varO for inclusion in a prototype adhesion-blocking malaria vaccine. I 
aimed to do this by testing the reactivity of the COS-7 expressed protein to the 
various varODBLla-specific antibodies available, including those generated against 
my DBLlpepI peptide, and to test the reactivity of anti-DBLlpepl antibodies with 
other varODBLl(x recombinants expressed in different systems. It was intended that 
the data generated would provide some information as to the integrity, conformation 
and cross-reactivity of these reagents. This (along with the findings of 
EUROMALVAC colleagues) would then go towards making an assessment as to the 
suitability of this antigen in terms of a) choice of expression system for the 
production of functionally active recombinant protein suitable for vaccination, b) the 
ease with which varODBL la-specific antibodies can be raised, c) the ability of these 
antibodies to block adhesion of iRBCs to RBCs and c) the degree to which these 
antibodies are cross-reactive with different parasite strains. 
I have shown in immunofluorescence assays that affinity-purified antibodies directed 
against a predicted immunogenic peptide from varODBLla (DBLlpepl) recognise 
fixed varO (PA89F5)-infected RBCs. The dotty' pattern of fluorescence observed is 
markedly different to that observed using an antibody directed against R23, a P. 
falciparum-infected RBC membrane-associated protein. Rather, it is similar to that 
seen by other groups who have generated antibodies to DBL domains and confirmed 
specific surface recognition of iRBCs by live IFA (Costa et al. 2003; Chen et al. 
2004). This suggested that anti-DBLlpepl antibodies specifically recognise PA89F5 
infected-RBCs. Specificity was confirmed by IFA in the presence of saturating 
concentrations of peptide DBLlpepI, in which no reactivity was observed. The 
peptide sequences used in these experiments (Table 5.3) had some sequence 
127 
similarities and as such, they suitably demonstrate the degree of specificity of the 
antibodies they block. This is a strong indication of specific binding. 
Further investigations, however, designed to dissect out the exact specificity of these 
antibodies and to confirm that this reagent specifically recognises a varO-encoded 
PfEMP-1, have shown that these same antibodies recognise several different parasite 
clones. Furthermore, the pre-immune sera and the pre-immune sera affinity purified 
on immobilised DBLlpepl show a similar profile of reactivity in IFA (albeit 
abolished at a 2-fold higher dilution). This background reactivity is also evident and 
in Western blot (Figure 5.2). Interpreting the observed reactivity with affinity 
purified pre-immune serum is difficult. It may simply reflect the fact that antibodies 
to this particular peptide (DBLlpepl) react with the surface of PA89F5-infected 
RBCs, and not antibodies to other peptides, indicating that the protein is indeed 
expressed by parasites. A better control might have been the same pre-immune rabbit 
immunoglobulins affinity purified on an irrelevant peptide, although this is not 
usually successful. Taken together, these data cannot be used to confirm the specific 
nature of DBL1 pep 1 anti-peptide antibodies. 
Such background reactivity is common in rabbits (Crandall et al. 1996; Monteiro et 
al. 1998). Non-immune rabbit sera frequently non-specifically recognises iRBCs in 
immunofluorescence assay and it is common to see spectrins (a 220/24OkDa doublet) 
recognised in Western blot with P. falciparum-infected RBCs. The affinity purified 
pre-immune IgGs used here in Western blot indeed recognise the spectrin doublet 
(most clearly seen in lane 2, Figure 5.2 B). For this reason, it is becoming 
increasingly common to screen all pre-immune rabbit sera before using these animals 
in immunisation studies. One suggestion as to why this might be the case is that 
rabbits may have antibodies to conserved proteins from other protozoan species 
(Crvptosporidia and Encephalitozoa, for example) that commonly infect them. These 
antibodies could cross-react with Plasmodium antigens and could well be non-
specifically up-regulated during the primary and secondary immune responses 
elicited by immunisation. 
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\\'hi!st anti-DBLlpepl antibodies recognised fixed iRBCs by lEA, 1 was unable to 
detect reactivity in live IFA, except in very late stage parasites where it is unlikely 
that the RBC membrane is intact so parasite proteins that are usually hidden are 
exposed to the external milieu. This finding is also true of antibodies raised against 
the E. coli-expressed varODBLla domain (Odile Puijalon, personal 
communication). The most likely interpretation for this is the inadequate folding of 
the antigen used to raise antibodies, such that it does not mimic the surface-exposed 
antigenic structures of the protein. The possibility that the protein is surface-
expressed but folded in such a way that the DBL1ct domain is 'hidden' to antibodies 
is unlikely in view of the supposed role of this domain in rosetting. My 
demonstration that expression of the domain on COS-7 cells results in red blood cell 
binding to their surface is consistent with this functional role. 
In ELISA, affinity purified anti-DBLI pep! immunoglobulins reacted strongly with 
the E. coli product, consistent with the notion that the E. coli recombinant protein is 
at least partially unfolded. These immunoglobulins did not, however recognise the 
COS-7 cell-expressed recombinant protein in ELISA, although they did in Western 
blot. Taken together, these data suggest that conformational epitopes are important 
and that the COS-7 cell-expressed protein is folded in such a way that the DBLpepl 
sequence is not accessible to antibodies unless it is in a reduced state, as in SDS gels. 
Western blot data describing the reactivity of anti-DBLlpepl immunoglobulins to 
iRBCs (Figure 5.4) is very difficult to interpret. Reactivity with spectrins is evident 
(most clearly observed as the upper bands in blots A and B, Figure 5.4). Anti-K60 
and Sairniri PA89F5 hyper-immune sera also react with a band of —200kDa, of 
slightly different mobility in PA89F5- and FUP/CB-infected RBCs. This is possibly 
PfEM P- 1. 
Difficulty in raising anti PfEMP-1-antibodies reactive with the infected red blood 
cell surface is not novel. In contrast, this has proved to be problematic in other model 
systems and several expression systems have had to be explored before observing 
production of surface-reactive antibodies. This has been achieved by Costa and 
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colleagues (Costa el at. 2003), by Jensen and colleagues (Jensen et at. 2004) and at 
the Institute Pasteur for a DBL3y (Odile Puijalon, personal communication). 
Interestingly, the success of all of these groups has been by exploiting the 
baculovirus Sf9 insect cell expression system for the production of protein for 
iifliitiiiisatiO1I. 
The findings of Costa and colleagues also demonstrate that the lack of reactivity of 
IFA positive anti-DBL antibodies in Western blot is not uncommon in the field. The 
antibodies generated against a recombinant CSA-binding DBL3y produced by this 
group were reactive with IRBCs in IFA. These antibodies were functionally active 
(they were reported to inhibit binding of RBCs infected with CSA-binding parasites 
to CSA) but did not recognise the antigen in Western blot. These findings illustrate 
the complexity faced in the analysis of conformational epitopes in DBL domains. 
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5.3.2 	Is VarO on the Surface? 
The dominant expression of the varO transcript in late stage parasites by routine RT-
PCR screening of PA89F5 cultures is repeatedly confirmed. This, however, is not 
evidence that varO is expressed as protein and the findings presented here question 
whether varO is actually the expressed PfEMP-1 present at the surface of varO-
infected RBCs. 
It seems that parasites express as mRNA either a single PfEMP-1 molecule or a 
mixture that is dominated by a single PfEMP-1 (Reeder et at. 1999; Noviyanti et al. 
2001). These protein molecules are transported to the surface of the iRBC within 12-
16 hours of invasion (Gardner et at. 1996). Intra-erythrocytic parasites are claimed to 
show predominant transcription of a single var gene in a process of exclusion that is 
controlled at the level of transcription (Scherf et at. 1998). RT-PCR data has 
suggested that many var gene variants are transcribed in early (ring) stages of the 
parasite's life-cycle and that exclusive transcription of the gene encoding the single 
cytoadherent variant occurs in later (pigmented trophozoite) stages (Chen et al. 
1998). However, these PCR data are contradicted by Northern blot data that has 
indicated that full-length transcripts encoding the cytoadherent variant are present 
only in ring stages (Gardner et al. 1996; Smith et al. 1998; Kyes et al. 2000). The 
Northern blot data correlates well with the stage specificity of PfEMP-1-mediated 
binding phenotypes, starting about 16 hours post invasion (Gardner et at. 1996). 
Recently, this discrepancy was investigated by Kyes and colleagues in Northern blot 
experiments with probes covering a diverse var gene repertoire (Kyes et at. 2003). 
The Kyes study confirmed that almost all var transcripts were detected in ring stages 
but one type, the well-conserved varlCSA transcript, was present constitutively in 
several different parasite lines. Interestingly, however, although varICSA has 
previously been proposed to encode a CSA-binding PfEMP-1 (Buffet et at. 1999), 
the presence of full-length varlCSA transcripts does not correlate with the CSA-
binding phenotype. 
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Clearly, there are conflicting data sets and proposals as to the relationship between 
specific var transcripts and the expressed adhesion phenotype. Drawing conclusions 
based on RT-PCR data is risky, as this technique is artefact-prone. Unpublished data 
from Duffy and colleagues show significant variation in the identity and frequency of 
var transcripts amplified on different occasions from the same cDNA of clonal 
populations or single cells. Thus, data generated by the RT-PCR approach should be 
regarded with caution (Duffy et al. 2003). 
Whilst the data I have presented suggests that varO is the expressed PfEMP- 1 variant 
in varO parasites, it remains to be confirmed whether this PfEMP-I is expressed at 
the iRBC surface. 
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Chapter 6: Developing the Saimiri Monkey Model for 
C3d-Based Immunisation and Malaria Challenge 
Experiments 
6.1 	Introduction 
It was aimed to develop the .Sai,niri monkey model lr immunisation and P 
lulciparurn challenge experiments to test efficacy and safety of PfEMP-1-C3d 3 
vaccine candidates. Through on-going collaboration with the Institute Pasteur, Paris, 
we have the possibility of access to Guyanese squirrel monkeys, Saimiri sciureus 
ciureus (de Thoisy and Contamin 1998). Previously, splenectomised Saimiri 
monkeys in the French Guyanese group have been established as an experimental 
host for the PA89F5 strain of P. falciparum (Gysin et al. 1980; Gysin and Fandeur 
1983; Contamin et al. 2000). Ideally, trial of a human vaccine in Sairniri would 
involve a PfEMP-1/C3d 3 construct using human C3d 3 . In this respect, therefore, it is 
important to assess the suitability of human C3d 3 in the Saimiri system. A vital pre-
requisite to the vaccine candidacy of a human PfEMP-1-C3d 3 construct is the 
demonstration that human C3d 3 specifically binds Sairniri B cells. To achieve this, I 
intended to characterise Saimiri B cells by comparison with human B cells, using a 
panel of monoclonal antibodies to known B cell markers and to test the in vitro 
binding of human C3d 3 to Saimiri B cells by fluorescence activated cell sorting. To 
increase the body of knowledge about C3d 3 , I also aimed to clone and sequence 
Sairniri C3d. This would allow its similarity with the human homologue to be 
compared, thus providing information about the relatedness of the two systems with 
respect to C3d. It would also open up the possibility of using Saimiri C3d in a trial 




6.2.1 	Cloning and Sequencing Saimiri C3c1 
Previously, a set of C3d-specific oligonucleotide primers were designed by Dr Mike 
Steward at Adprotech, based on areas of minimal redundancy from a ClustalW 
arrangement of various mammalian C3 sequences (rat, mouse, human, rabbit, guinea 
pig) at the protein level. Primers were designed to flank the coding region for C3d. 
The oligonucleotide sequences and their binding site coordinates on the C3 gene and 
its flanking regions are shown in Table 6.1 and Figure 6. 1. Two sets of primers were 
used to amplify the full-length C3d sequence in two fragments, with two rounds of 
I'CR for each. Fragment I (691bp) was amplified by a first PCR (PCR!) using Farm 
primers I and 4 and PCR2 using Farm primers 3 and 8. Fragment 2 (408bp) was 
amplified by PCR1 using Farm primers 2 and 5 and PCR2 using Farm primers 6 and 
7. 
Table 6.1 

















Table 6.1: Redundant PCR primers used to amplify Sai,niri C3d. Primer pairs were used 
to amplify the full-length Sai,niri C3c1 sequence in 2 fragments, from total RNA isolated 








5' .....................................I 	 1-.......................................3' 
(3084) 
6 	2 	8 	4 
Figure 6.1: Schematic of the CM gene showing the position of primers used for 
amplification of cDNA from total RNA. CM RNA is represented as a solid line, flanked by 
C3 RNA in broken lines. Sense primers are in and anti-sense primers in blue. Primers I -
8  work in pairs (1+4. 2+5, 3+8, 6+7) and form overlapping PCR products that extend several 
hundred bases beyond either end of the CM coding region. Numbers in brackets indicate the 
coordinates of the 1009bpC3d coding region within the C3 gene. 
For each fragment, cDNA was reverse transcribed from uninfected Sai,niri spleen 
total RNA (a gift from Odile Puijalon) using Promega RT System reverse 
transcriptase, as described in Section 8.1.14. Negative controls containing no RNA 
were included in each set of reactions. lOtl of the first reaction mix was used to 
amplify dsDNA from this cDNA template (described in Section 8.1.2). After the first 
round of PCR, lOtl of the amplification product was separated by electrophoresis 
through a 1% TAE agarose gel and visualised by ethidium bromide-staining. After 
one round of PCR. no clear band was obvious, although a smear in the region of the 
expected size was apparent, as seen in Figure 6.2. lane 3. The first PCR product was 
used as a template for a further round of PCR (nested PCR), using the second set of 
primers. 1tl or 3tl of product was added to a 50tl standard PCR reaction mix and a 
second round of PCR carried out under standard conditions. lOtl of each reaction 
was analysed using agarose gel electrophoresis (Figure 6.3). Bands of the expected 
size for fragments 1 and 2 (690bp and 408bp, respectively) were observed (lanes 3 
and 4 in A and lanes 2 and 3 in B, respectively. Figure 6.3). These bands were 
excised under UV light and gel-extracted. The 2 gel-extracted CM fragments were 
T-cloned into the pUC57/T vector. DNA was quantified and restriction digest 
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analysis was carried out using EcoRI and Hindu!. Four clones of each were 
sequenced using both M13F and M13R primers (Invitrogen). The contigs were 









Figure 6.2: Ethidium bromide-stained I% agarose gel of PCR product amplified from 
Sairniri C3d cDNA. Lane 1, marker (molecular sizes indicated); lane 2, negative control 
(without cDNA template); lane 3, Saimiri C3d fragment 1 PCR-product (-690bp). 
Figure 6.3 
B: Fragment 2 
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Figure 6.3: Ethidium bromide-stained 1% agarose gel of nested PCR products 
amplified from Sainjiri C3d DNA. A: Lane 1, marker; lane 2, negative control (no DNA 
template); lanes 3 & 4, -690bp product amplified from 1l and 3t1 template. respectively. 
B: Lane 1. marker; lane 2, negative control (no DNA template); lanes 3 & 4. -400bp product 
amplified from 1tl and 3.tl template, respectively. Molecular size markers are indicated. 
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Figure 6.4 
7CC CCC TCG GGC TGC GGG GAA CAG AAC ATG ATT AGC ATG ACA CCC ACG GTC ATC GCG GTG 
T P S G C G E Q N H I S H T P T V I A V 
• 	 91/31 
TAC CTG GAT CAA ACG GAG CAG TGG GAG AAG TTC GGC CTG GAG AAG CGG CAG GGG GCC 
I L D 0 T E 0 W E K F G L E K R Q G A 
:21/41 	 151/51 
•TG GAG CTC ATC AAG AAG GGG TAC ACA CAG CAG CTG GTC TTC AAA CAA CCC AAC TCT GCC 
E L I K K G Y T Q Q L V F K Q P N S A 
61 	 211/71 
lAT GCG GCC TTC CTG GAC CGG CCT CCC AGC ACC TGG CTG ACC GCC TAC GTG GTC AAG GTC 
I A A F L D R P P S T H L T A Y V V K V 
241/81 	 271/91 
TTC TCT CTG GCC GTC AAC CTC ATT GCC ATC GAC TCC CAA GTC CTC TGC GGG GCT GTT AAA 
I 	S L A V N L 	I A 	I 	D S Q V L C G A V K 
1/101 	 331/111 
TC3I CTG ATC CTG GAG AAG CAG AAG CCT GAC GGG GTC TTC CAG GAG GAT GGG CCC GTG ATA 
W L I 	L E K Q K P 	D G V F Q E 	0 G P V I 
361/121 	 391/131 
CAC CAA GAA ATG ATT GGT GGC TTC CGG AAC ACC CAG GAG AAA GAC ATG GCC CTC ACG GCC 
H 0 E M I G G F P N T Q E K D N A L T A 
421/141 	 451/151 
TTT GTT CTC ATA GCG CTG CAG GAG GCT AAA GAA ATT TGC GAG GAG CTT GTC AAC AGC CTG 
F V L I A L Q E A 	K E I C E E 	L V N S L 
481/161 	 511/171 
CCA CAG AGC ATC ACT GAC GCA GGA AAC TTC CTT GAA GCC AAC TAC ATG AAC CTA CAG AGA 
P Q S 	I T 0 A G N 	F L E A N Y N N L 0 P 
541/181 	 571/191 
TCC TAC ACT GTG GCC ATC GCT GGC TAT GCC CTG GCC CAG TTG GAA AAA CTG AAG GGG CCT 
S Y T V A I A G I 	A 	L A Q L E 	K L K G P 
601/201 	 631/211 
CTT CTC GAG AAA TTT CTG AGC ACA GCC AAA GAT AGG AAC CGC TGG GAG GAG CCT GGT CAG 
L L S K F L S T A 	K 	0 P N P H S S P G 0 
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AG CTC TAC AAT GTG GAG GCC ACA TCC TAT GCC CTC TTG GCC CTC CTG CAG CTA AAA GAC 
L Y N V E A T S 	Y A L L A L L Q L K D 
_1/241 	 751/251 
ITT GPC TCT GTG CTT CCC GTC GTG CGT TGG CTC AAT GAG CAG AGA TAC TAT GGT GGT GGC 
Y D S V L P V V R N L N E 0 R Y Y G G G 
31/261 	 811/271 
rAC GGC TCT ACC CAG GCC ACC TTC ATG GTG TTC CAA GCC TTG GCC CAA TAC CAG AAG GAC 
• 	G S T Q A T F N V F Q A L A 0 Y 0 K D 
41/281 	 871/291 
CTC CCT GAC CAC AAG GAA CTG AAC CTG GAT GTG TCC CTC CAA CTG CCA 
V P D H K K L N L D V S L Q L P 
Figure 6.4: Nucleotide sequence of DNA encoding Saimiri sciureus CM. Numbers above 
are nucleotide / amino acid numbers. Deduced amino acid sequence is indicated below. The 
predicted CR2 binding motif (Lambris et al. 1985) is shown in . Highlighted are the 
conserved residues predicted to be important for interaction with pathogen surfaces (yellow) 
and with CR2 ( (Nagar el al. 1998). 
W. 
Figure 6.5 
sapiens ----sEN4:G:I v:. IAiiLETEEYFLErAEirY 
acaca mulatta ----TPSGCGEQNMITMTPTVIAVHYLIDETEQWEKFGPEKRQGALELIKK 
:alli thrix jacchus HLIVTPSGCGEQNMIGMTPTVIAVHYLDQTEQWEKFGLEKRQGAVELIKK 
rycio1agus cuniculus ----TGSGCGEQNMIAMTHTVIAVHYLDHTEQWDKFSLEKRQEALELIKK 
Canis familiaris HLIVTPSGCGEQNMIGMTPTVIALHYLDQTEQWDKFGLEKRQEALELIKK 
Felis catus ----TPSGCGEQNMIGMTPTVIAVHCLDQTEQWEKFGLEKRQDSLQLIEK 
Equus cabailus HLIVTPSGCGEQNMISNTPTVIP.VHYLDQTEQWEKFGLEKRQESLELIKK 
Boa taurus HLIQTPSGCGEQNMICMTPTVIAVHYLDSTDQWEKFGLEKRQESLELIRK 
Bus scrofa HLIQTPSGCGEQNMTGMTPTVIAVHYLDSTEQWEKFGLEKRQEALELIKK 
.4us inuscul us ----T?AGSGEQNMIGMTPTVIAVHYLDQTEQWEKFGIEKRQEALELIKK 
B.t 	us ncrveaicus HLIVTPSGCGEQNMIGMTPTVIAVHYLDQTEQWEKFGLEKRQEALELIKK 
- 	- - 	TPSGCGEQNMIGMTPTVIAVHYLDQTEQWEKFGLEKRQEALNLINR 
********** 	** 	****** 	** 	******** 	* ********** 
- 	- 	---• -. 	 . LVF<QPNSAYP.AFLDRPPSTWLTAYVVKVFSLAVNLIAIDSQVLC 
TLAFRQPSSAFAAFVKRAPSTWLTAYVVKVFSLAVNLIAI DSQVLC 
Macaca mulatta GYTQQLAFRQPSSAFAAFLNRAPSTWLTAYVVKVFSLAVNLIAIDSQVLC 
Callithrix jacchus GYAQQLAFKQPSSAYAAFLNRPPSTWLTAYVVKVFSLAVNLIAIDSQVLC 
Cryclolagus cuniculus GYTQQLAFKQPNSAYAAFLNRAPSTWLTAYVVKVFSLAVNLIAIDSQVLC 
anis familiaris GYTQQLAFRQPNSAFAAFQNRPSSTWLTPYVVKVFSLATNLIAIEAQVLC 
E'el is ca tus GYSQQLAFRQENSAFAFQNRKASTWLTAYVVKVFSLAANLIAINSQVLC 
Equus cabalius GYTQQLAYRQPSSAYAAFLSRPPSTWLTAYVVKVFALASNLIAIDSQVLC 
Sos taurus GYTQQLAFRQKSSAYAAFQYRPPSTWLTAYVVKVFALAANLIAIDSKDLC 
Sus scrofa GYTQQLAFRQKNSAFAAFQDRLSSTWLTAYVVKVFAMAANLIAIDSQVLC 
Mus musculus GYTQQLAFKQPSSAYAAFNNRPPSTWLTAYVVKVFSLAANLIAIDSHVLC 
Battus norveqicus GYTQQLAFKQPISAYAAFNNRPPSTWLTAMWSP.SFSLAANLIAIDSQVLC 
- 	-. YTQQLAFKQPNWAYFKNRSSTWLTAYVVKVFSLAANLIGIDSEVLC 
-AVKWLILEKQKPDGVFQEDGPVIHQEMIGGFRNTQEKDMALTAFVLIAL 
spi 	ns BAVKWLILEKQKPDGVFQEDAPVIHQEMIGGLRNNNEKDMALTAFVLISL 
Macaca mula tta GAVKWLILEKQKPDGVFQEDAPVIHQEMTGGFRNTNEKDMALTAFVLISL 
Callithrix jacchus GAVKWLILEKQKPDGVFQEDGPVIHQEMIGGFRNTQEKDMALTAFVLISL 
Oryclolagus cuniculus GAVKWLIMEKQKPDGVFQEDAPVIHQEMIGGQRNSVEKERALTAFVLIAL 
Canis familiaris GAVKWLILEKQKPDGIFQEDGPVIHQEMTGGFREAEEKSVSLTAFVLIAL 
Felis ca tus GAVKWLILEKQKPDGVFQEDGPVIHQEMTGGFRENEEKDVALTAFVLIAL 
Equus cabailus GAVKWLILQKQKPDGVFQEDGPVIHQEMIGGFRNAEEKDVSLTAFVLIAL 
Bos taurus ETVKWLILEKQKPDGIFQEDGPVIHQEMIGGFRDTREKDVSLTAFVLIAL 
Sus scrofa GAVKWLILEKQKPDGVFEENGPVIHQEMIGGFKNTEEKDVSLTAFVLIAL 
Mus muscul us GAVKWLILEKQKPDGVFQEDGPVIHQEMIGGFRNAKEADVSLTAFVLIAL 
Rattus norvegicus GAVKWLILEKQKPDGVFQEDGPVIHQEMIGGFRNTKEADVSLThFVLIAL 
Cavia porcellus GAVKWLILEKQKPDGVFQEDGPVIHQEMIGGVRTAQEADVSLTAFVLIAL 
*************************** 	** 	* * 	* 	********** 
Saimiri sciureus QEAKEICEELVNSLPQSITDAGNFLEANYMNLQRSYTVAIAGYALAQLEK 
Homo sapiens QEAKDICEEQVNSLPGSITKAGDFLEANYMNLQRSYTVAIAGYALAQMGR 
Macaca mula tta QEAKEICEEQVNSLPGSITKAGDFLEANYMNLQRSYTVAIAAThLAQMGR 
Caili thrix jacchus QEAKDICEELVNSLPRSIIDAGNFLEANYMNLQRSYTVAIAGYALAQLDK 
Oryclolagus cuniculus QEAREICEEQVNSLAASINKSRDFLAANYMNLQRPYSVAIAAYAWAQQDK 
Canis familiaris KEAEDICIGQVNILPSSIEKAGNYLAAHYQNLRRPYSVAIAGYALAHLDK 
Felis catus QEAKEFCNDQVNSLERSITKAGDYIEFHYRNLRRPYSVAIAGYALAQSGR 
Equus cabailus QEAKDICEGQVNSLARSIIKAGDFLEAHYNNLRRPYSVAIAGYALAQMGK 
Sos taurus HEAKDICEAQVNSLGRSIAKAGDFLENHYRELRRPYTVAIAAYALALLGK 
Sus scrofa QEAKDICEPQVNSLLRSINKARDFLADYYLELKRPYTVAIAGYALALSDK 
Mus musculus QEARDICEGQVNSLPGSINKAGEYIEASYMNLQRPYTVAIAGYALALMNK 
Rattus norvegicus QEARDICEGQVNSLPGSINKAGEYLEASYLNLQRPYTVAIAGYALALMNK 
Cavia porceilus QEAKDICRAQVNNLEANINKAGDYIESRYADVRRPYTLAIAGThLALLER 
******* 	** 	* 	** 	** 	*** 	* 	************** 	* * 
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-ioxno sapiens LKGPLLNKFLTTAKDKNRWEDPGKQLYNVEATSYALLALLQLKDFDFVPP 
1acaca mulatta LKGPLLNKFLTTAKDKNRWEEPGQQLYNVEATSYALLALLQLKDFDFVPP 
a11i thrix jacchus LNGPLUTKFLSTAKDKNRWEEPGQQLYNVEATSYALLALLQMKDFDFVPP 
Qryclolagus cuniculus LRGAFLNKFLSKAKEKNRWEEPGQRLYNVEASSYALLALLLLRDFDSVPP 
anis familiaris LEGDNLRKFLNTARDRNRWVEPGKKLYNVEATSYALLALLLLKDFDNVPP 
Fe1 is ca tus LERDLLEKFLSTAKERTRWEEPGKKLYSVEATSYALLALLVLKDFDFVRP 
Equus cabalius LEDPLLNKFLSAATDRNRWEEPGQKLYNVEATSYALLALLLLRDFDSVPP 
Bos taurus LEGDRLTKFLNTAKERNRWEEPNQKLYNVEATSYALLALLARKDYDTTPP 
Ths scrofa LDEPFLNKLLSTAKERNRWEEPGQKLYNVEATSYALLALLVVKDFDSVPP 
.1us musculus LEEPYLGKFLNTAKDRNRWEEPDQQLYNVEATSYALLALLLLKDFDSVPP 
EE PY LT K FLN TAK DRNR WEE PGQQLYNV EATS YAL LAL LLLKD FDS VPP 
- :GATLQKFLNAATEKNRWEEARQKLYSVEATSYALLALLLLKDFDAVPP 




:aili thrix jacchus VVRWLNEQRYYGGGYGSTQATFMVFQALAQYQKDVPDHKELULDVSLQLP 
Oryclolagus cuniculus VVRWLNEQRYYGGGYGSTQATFMGFQALAQYQTDVPDHKDLNMVVSIQLP 
Canis familiaris VVRWLNEQRYYGGGYGSTQATFMVFQALAQYQKDVPNHKDLNLQVSINLP 
Ccl is ca tus VASWLNEQRYYGGGYGSTQATFMVFQALAQYQKDVPDHKDLNLEVSIELP 
Cquus caballus VVRWLNEQRYYGGGYGSTQATFMVFQALAQYQKDVPNHKDLNLDVSINLP 
SOS taurus VVRWLNEQRYYGGGYGSTQATFMVFQALAQYQKDVPDHKELNLDVSIQLP 
Sus scrofa IVRWLNEQRYYGGGYGSTQATFNVFQALAQYQKDVPDHKDLNLDVSIHLP 
Mus musculus VVRWLNEQRYYGGGYGSTQATFMVFQALAQYQTDVPDHKDLNMDVSFHLP 
.TVRWLNDERYYGYGSTQATFMVFQALAQYRADVPDHKDLNMDVSLHLP 
:TRWLNEQRYYGRGYGSTQATFMVFQALAQYQTDVPDHKDLNMEVALQLP 











Mus rnusculus 	 SSGS 
Rattus norvegicus 	 SR-- 
Cvs rr:e 
Figure 6.5: ClustaIW alignment comparing amino acid sequences from various 
mammalian C3ds. Sai,niri sciureus, Hoino sapiens (human), Macaca inulatta (rhesus 
monkey). Callirhrix jacclzus (marmoset). Orvclolagus cuniculus (rabbit), Canis familiaris 
(dog), Fe/is cams (cat), Equus cabal/us (horse), Bos taurus (cow). Sus scrofa (pig), Mus 
inusculus (mouse). Rartus norvegicus (rat), Ca via parcel/us (guinea pig). 
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Comparison of the full Saimiri C3d sequence with one New World monkey 
(marmoset), one Old World Monkey (rhesus) and human C3d sequences allowed the 
sequence boundaries to be identified. The cDNA sequence consisted of 888 
nucleotides. The deduced amino acid sequence of S. sciureus C3d was compared 
with those from several mammalian species. When compared with the published 
sequence of human C3d (de Bruijn and Fey 1985), Saimiri C3d showed 90% 
identity. The sequence identity between Sain1iri and marmoset (93%), another New 
World monkey, is closer than that observed with Rhesus (91%), an Old World 
monkey. A comparative analysis of identities at the amino acid level is shown in 
Table 6.2. A ClustaIW alignment of these sequences using MacVector® software is 
shown in Figure 6.5 and reveals many areas of strong amino acid conservation 
throughout different mammalian species. In order to illustrate phylogenetic 
relationship among different mammalian C3ds at the protein level, a phylogram was 
constructed, based on C3d amino acid sequences. A phylogenetic tree based on 
distance analysis is presented in Figure 6.6. This analysis shows that the closest 
relationship to the Saimiri C3d sequence is to marmoset, the other New World 























Figure 6.6: Phylogram showing the relatedness of animal C3d sequences. Numbers 
represent distances between nodes, shown in phylogenetic units. A value of 0. 1 corresponds 
to a difference of approximately 10%. 
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6.2.2 	Characterising Saiiniri B Cells 
CR2 is both the C3d receptor and the receptor for Epstein Barr Virus (EBV) 
(Fingeroth et at. 1984). Having an entry-point for EBV thus allows B cells to be 
immortalised for cell culture by transformation with EBV. A Sairniri sciureus B cell 
line, originally transformed with EBV by Scammell and colleagues (Scammell et at. 
1997), was kindly donated by Dr Mariano Rocchi of the University of Ban, Italy. I 
aimed to characterise this B cell line by testing for expression of known B cell 
markers. No Saimiri-specific monoclonal antibodies to B cells exist and in the 
absence of such reagents, it was reasoned that reactivity with a panel of monoclonal 
antibodies directed at various human B cell surface markers would be a means of 
identifying the degree of similarity of the Saimiri B cell surface to that of human B 
cells. 
EBV-transformed Sai,niri B cells were grown in culture and tested for reactivity with 
human B cell markers using monoclonal antibodies to CD19, CD2I, CD23 and 
membrane immunoglobulin (FITC anti-human IgG F(ab') 2). All of the monoclonals 
were raised in mice to human antigens and were of the IgGi isotype. An anti-IL-la 
IgGi monoclonal antibody was used as an isotype control. The human EBV -
transformed B cell line ('Pala', a kind donation from Professor Cohn Watts, 
University of Dundee) and HeLa cells were used as positive and negative controls, 
respectively. FACS analysis was performed on Saimiri and human B cells and on 
HeLa cells, as described (Section 8.9). All primary antibodies (Dako) were used at 2-
5tg/mh (1:100 dilution). Secondary antibodies (Dako FITC-conjugated anti-mouse 
immunoglobulins) were used at 2.3tg/ml (1:1000 dilution). Unlabelled cells and 
cells labelled with secondary antibody alone were included as negative controls. 
Samples were analysed on a Becton Dickinson FACSCAN flow cytometer. The 
viable cell population was gated according to size and granularity and 10,000 events 
were acquired and analysed. Results are shown in Figures 6.7 and 6.8. As expected. 
human B cells were positive for CD 19, CD2I and CD23, although the expression of 
CD2I was very low. Membrane lgG (mIgG) could not be detected on these cells and 
it was therefore assumed that they were expressing membrane 1gM (mIgM), although 
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this has not been proven. The only detectable marker using human-specific reagents 
on Saimiri B cells was membrane IgG (red graph in panel B of Figure 6.7), and 
possibly some very low levels of CD23 (pink graph in panel B of Figure 6.7). Using 
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Figure 6.7: Results of FACS analysis on human and Saimiri B cells. Cells were stained 
with a panel of monoclonal antibodies raised against known human B cell markers. Results 
are numbers of cells, expressed as a percentage of maximum. Unstained cells in 
cells stained with secondary antibody alone (FITC-conjugated mouse anti-human lgG) in 
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Figure 6.8: Summary of the relative staining of human ('Pala') and Saiiniri B cells with 
a panel of monoclonal antibodies raised against known human B cell markers. Results 
are the average of 3 experiments, expressed as mean fluorescence intensity. Error bars 
indicate the data spread around the mean. 
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6.2.3 	Human CM Binds Saimiri B Cells 
Recombinant human C3d3 (hC3d3 ) has been expressed in the baculovirus-Sj9 system 
at Adprotech. To investigate the specific, heterologous binding of hC3d 3 to Saiiniri B 
cells in vitro and to determine functional activity of hC3d 3 in the Saimiri monkey 
system, flow cytometry employing a direct immunofluorescence strategy was carried 
out. CR2 negative HeLa cells (adherent, immortalised human epithelial cells from a 
fatal cervical carcinoma transformed by human papillomavirus 18) were included as 
a control. Cells were incubated with 10g/ml (lOOnM), ltg/ml (lOnM) or 0.ltg/ml 
(lnM) hC3d 3 at room temperature for 30 minutes. Detection antibody was FITC-
conjugated rabbit anti-human C3d, (Dako, clone F0323), used at 1:1,000 dilution 
(2tgIml). Unlabelled cells and cells labelled with secondary antibody alone were 
included as negative controls. Samples were analysed as described in the previous 
section and results are shown in Figure 6.9. Human C3d 3 was found to specifically 
bind to both human and Sairniri B cell populations in vitro. In the case of hC3d 1 
binding to human B cells, a titration effect was observed, with binding still evident 
(although weak) down to mM (red graph in panel A of Figure 6.9). This titration 
effect was not so apparent with Sairniri B cells, which do not demonstrate significant 
binding at concentrations of C3d 3 lower than lOOnM (panel B of Figure 6.9). 
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Figure 6.9 
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Figure 6.9: FACS analysis on human and Saimiri B cells incubated with lOOnM, lOnM 
or mM human C3d3. Results are numbers of cells, expressed as a percentage of maximum. 
Unstained cells in 	, cells stained with secondary antibody (FITC-conjugated rabbit 
anti-human C3d) alone in 	, cells incubated with lOOnM hC3d in 	, cells 
incubated with lOnM hC3d 3  in blue, cells incubated with mM hC3d 3 in 
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6.3 	Discussion 
The Sai,iiiri monkey is uncommon in laboratory research and little of its genome has 
been sequenced. To date, fewer than 11,600 Sairniri sequences are available at the 
NCBI database (www.ncbi.nlm.nih.gov/entrez) . The Sai,niri C3d sequence is first 
described in this thesis. Not surprisingly, it shows closest identity to marmoset C3d 
(93% identity). It shows 90% identity to human and 91% identity to rhesus C3d 
(human and rhesus show 96% identity). Based on these results, it is difficult to make 
hypothetical predictions about its likely affinity for human CR2, given that the C3d 
of different animal species shows diverse and unpredictable affinities for 
heterologous CR2 (Richard Smith, personal communication). Interestingly, human 
CR2 is recognised by rhesus and mouse (only 83% identity with human) but not 
marmoset C3d, even though it shows more identity to human C3d than to mouse. It is 
also interesting to note that an anti-human-C3d monoclonal antibody (Immuno 
Diagnostic Oy) cross-reacts with rhesus and rabbit C3d (which shows 82% identity 
to human) but not mouse or marmoset C3d. A more convincing prediction can be 
made based on the identification of a CR2 binding motif. In studies using a series of 
overlapping synthetic peptides to span the C3d binding region of CR2, Lambris and 
colleagues showed that peptides which bound CR2 shared the sequence LYNVEA 
(Lambris et al. 1985). The Sai,niri sequence indeed contains this motif (highlighted 
in Figure 6.4). More recently, the X-ray crystal structure of human C3d has been 
determined (Nagar et al. 1998). These studies indicate that C3d interacts with 
pathogen surfaces through a covalent link at the conserved glutamine (Q) at the N-
terminal end of the molecule (position 8 in Figure 6.4). A potential site of interaction 
with CR2 is an acidic pocket formed by acidic residues that are highly conserved 
amongst species (asaparagine 24, glutamic acid 148, and tyrosine 189 in Figure 6.4). 
This ties in with data from CR2 structural studies, suggesting that a negatively 
charged pocket in the short consensus repeat (SCR) 2 domain of CR2, containing 
basic residues, is important in C3d binding (Molina et al. 1995; Guthridge et al. 
2001; Szakonyi et al. 2001). 
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Sainiiri B cells were characterised using a panel of monoclonal antibodies to human 
B cell markers. The only detectable marker using these reagents on Saimiri B cells 
was membrane IgG, with some very low levels of CD23. CD19 and, more 
significantly, CD2I could not be detected. The lack of detectable expression or low-
level expression of CD21 is typical for New World monkeys and has been observed 
in both the Owl monkey, Aorus trivirgatus (Scammell et al. 1997), and the Bolivian 
squirrel monkey, Saimiri boliviensis boliviensis (Reynolds et al. 1998), using human-
specific reagents. In the absence of any Saimiri-specific reagents, however, it is 
difficult to tell whether this result is due to the lack of cross-reactivity of human-
specific reagents with the Sairniri cell surface, or to the lack of expression of these 
molecules. There are relatively few monoclonal antibodies that have been 
characterised for their applicability in studies on the immune systems of New World 
monkeys. In one study, Ozwara et at. showed that only 42% of 105 anti-human 
antibodies to T cell antigens and cytokine receptors reacted with Saimiri peripheral 
blood mononuclear cells (Ozwara et al. 1997). The Saiiniri B cells used in this 
experiment were immortalised by transformation with EBV (Scammell et at. 2001). 
These cells, typical of B cells from New World primates, are difficult to transform 
with EBV (Miller et at. 1972; Falk et at. 1974) - this may be due to the low level of 
expression of CD2I which is the EBV receptor (Nemerow et at. 1986) and one of the 
entry points for EBV. An alternative explanation, however, is that these cells indeed 
do not express CD2I (CR2). 
I have reported here the heterologous binding of the human-derived C3d 3 protein 
ligand to Saimiri B cells. This data suggests that Sairniri should be a suitable model 
for human vaccination studies using human C3d-based constructs. The observation 
that binding to Sainiiri B cells is weak at low concentrations suggests that there is a 
threshold concentration for binding to occur, which has important implications for 
vaccine design. The mechanism of this binding event is unknown, although it is 
assumed that C3d is binding its natural receptor, CR2 (Fingeroth et al. 1984; Weis et 
al. 1984). This was investigated in part by including human HeLa (CR2-) cells as a 
negative control for these experiments, which allowed a comparison of the binding of 
C3d to both CR2+ and CR2- cells. A more definitive investigation would be to 
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determine the exact mechanism of binding by blocking the C3d-binding sites on 
CR2-expressing cells using a monoclonal antibody directed against the CR2 binding 
site of C3d. One such inhibitory antibody (mAb 171), directed against the SCRI-2 
ligand-binding fragment of CR2, has been recently described by Guthridge and 
colleagues (Guthridge et al. 2001). The author has been contacted regarding the 
availability of this antibody and seemingly, a commercially available monoclonal 
antibody (mAb 1048, Beckton Dickson) is quite comparable to 171 in blocking C3d 
binding (Michael Holers, personal communication). I have thus planned to 
investigate the specificity of h0d 3!Saimiri CR2 binding using mAb 1048. 
In summary, sequence data for Saimiri sciurcus C3d, previously unpublished, has 
been reported here. Comparison of the Sairniri sequence to other known mammalian 
C3d sequences allowed the relatedness of different C3d sequences to be analysed. 
The sequence contains the predicted CR2 binding motif and other structural 
signatures revealed in CR2/C3d crystal structure data. A prediction has been made as 
to the likely binding properties of the human C3d ligand to its heterologous receptor, 
expressed on Saimiri B cells. Saimiri B cells were cultured and characterised 
according to their expression of known human B cell markers. Using human specific 
reagents, expression of the C3d receptor (CD2I/CR2) could not be detected on the 
surface of Sairniri B cells. An in vitro study of the binding affinity of Sai,niri B cells 
for human C3d3 was carried out and heterologous binding was demonstrated. That 
this binding was CR2-specific remains to be determined and an experiment to 
determine the degree of binding on the presence of a CR2-blocking antibody (mAb 
1048) is planned. These results indicate that Sairniri are a potentially suitable model 
for vaccines immunopotentiated with human C3d. 
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Chapter 7: Discussion 
During the course of this thesis, Chen and colleagues (another EUROMALVAC 
consortium group at the Karolinska Institute in Stockholm) immunised mice with a 
Semliki forest virus (SFV) vaccine construct encoding a mini-PfEMP-1 (DBLIct-
TM-ATS) from an antigenic and rosetting parasite, FCR3SI.2 (Chen et al. 2004). 
The FCR3SI.2 DBLIct was identified as a rosetting ligand, mediating binding to the 
blood group A antigen present on human erythrocytes and heparan sulfate on 
endothelial cells. Chen's study showed that antibodies, generated following a 
regimen of priming with SFV RNA particles and boosting with an E. coli-derived 
recombinant protein, recognise the surface of FCR3S 1.2-infected RBCs and disrupt 
pre-formed rosettes. These antibodies also prevent the adherence of FCR3SI.2-
infected RBCs in the lungs of DBL1ct-immunised rats, in an in vivo model of severe 
malaria, demonstrating the involvement of DBL1a in the adhesion of infected and 
uninfected erythrocytes and the role of rosette-disruptive antibodies in preventing 
these cellular interactions. 
Chen's hypothesis was similar to that investigated in this thesis; that future 
vaccination with one or a few DBL1u domains may prevent the development of 
severe malaria. However, whilst Chen's data go some way to supporting this 
hypothesis, my study did not reach this stage of development. One reason why this is 
the case is that the choice of vaccination strategy, a vital component of any 
successful prototype development, was not optimal. 
The prime-boost strategy for malaria vaccination has been developed by Hill and 
colleagues (Hill et cii. 2000). Different prime-boost approaches give different 
immune responses; DNA priming followed by a recombinant virus boost gives a T 
cell-oriented response (Hoffman and Doolan 2000; Sedegah et al. 2002), whilst 
priming with a recombinant virus and boosting with a recombinant protein usually 
produces a better antibody response (Hoffman and Doolan 2000). To investigate the 
use of C3d 3 as an effective immunopotentiator for an adhesion-blocking malaria 
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vaccine based on DBLIct and to avoid protein production problems, I decided to 
adopt a DNA immunisation approach, reasoning that this would be the most direct 
way to establish proof of concept. Using this strategy, it was expected that gene gun 
immunisation of DNA expressing a secreted antigen would bias the immune 
response toward type 2, as recently demonstrated by Oran and Robinson (Oran and 
Robinson 2003). However, since no response could be detected as a result of the 
immunisation study I have described here, it has not been possible to make this 
analysis. 
It is interesting to note that Chen and colleagues failed to generate functional 
antibodies by immunisation with E. coli-derived proteins alone. Rather, an SFV-
prime and protein boost approach was adopted. Primary immunisation with SFV 
constructs allows antigen to be expressed extra-cellularly but anchored to the cell 
membrane by the TM domain (Andersson et al. 2001). In this way, antigens are 
displayed at the eukaryotic cell surface, as is native PfEMP-1, presumably allowing 
them to fold in a similar way as in the parasite in vivo. In DNA immunisation, using 
ballistic methods, it is presumed that the Langerhan's cells - the chief antigen 
presenting cells of the skin - are the primary targets of DNA vaccine constructs. 
Recombinant SFV virus particles, however, can efficiently infect many cell types, so 
more cells are targeted, presumably increasing the yield of antigenic protein. 
For use in DNA immunisation, it is essential that the gene of interest can be 
expressed in mammalian cells. Difficulties in expressing P. falciparum proteins in 
heterologous expression systems are common; indeed, expression of the native 
version of varODBLIa could not be detected in the COS-7 cell system. To 
overcome expression problems caused by the particularly A/T rich P. falciparurn 
genome, the varODBLIcx sequence was resynthesised to make it more compatible 
with mammalian codon use. The codon-optimised version of the gene was shown to 
be expressed in the COS-7 cell system. Its expression was used to demonstrate that 
varODBLla expressed on the surface of COS-7 cells binds RBCs, confirming that 
i'arODBLla exhibits the predicted cytoadherence profile consistent with a role for 
varO in rosetting in the PA89F5 variant. Subsequently, the codon-optimised 
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varODBLlu sequence was used in a pilot DNA immunisation in mice. DNA 
immunisation, however, failed to induce anti -varO antibodies. Whether this is a 
problem of DNA immunisation failing to induce a strong humoral response or that it 
is due to insufficient vector driven protein production in vi't'o is not known. 
It has been widely accepted that compositional pressure is the major factor shaping 
codon usage in unicellular species displaying extremely biased genomic 
compositions. The recodoned version of the varODBLla gene was thus designed 
based on this principle, that is to reduce the AlT content of the sequence to one more 
like that found in the mammalian genome and to substitute rare codons for those 
more commonly employed in mammalian protein synthesis. This method has indeed 
proved successful in a number of studies, including the synthesis of a recodoned 
version of MSP1 9 by Dr Mike Steward, at Adprotech. However, evidence is coming 
to light that selection, acting at the level of translation, influences codon choices in 
compositionally biased (GC-poor) unicellular eukaryotes Dictyosteliurn discoideum 
and Plasmodium falciparum, (Musto et at. 1999) and the prokaryote, E. histolvtica 
(Romero et al. 2000). Furthermore, it seems that kingdom-specific correlations 
between codon use and protein secondary structure units may reflect kingdom-
specific differences in translational mechanisms, which might be important for 
secondary structure formation and which may have implications for recombinant 
gene design and expression (Oresic and Shalloway 1998). More recent findings are 
also indicating that pausing during mRNA translation occurs when rare triplets are 
encountered in the mRNA, as it takes additional time for the corresponding rare 
species of tRNA to be delivered. It is believed that such pausing plays some role in 
ensuring proper folding of newly synthesized sections of a protein chain and that the 
profiles of rare codons in mRNA can serve in the detection or prediction of 
boundaries between protein domains (Makhoul and Trifonov 2002). The idea of such 
translational modulation is now another consideration in the design of synthetic P. 
falciparum genes. Given these considerations, the varODBLlct sequence could now 
perhaps be more effectively designed for efficient expression in both E. coli and in 
Pichia. 
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Recently, at the Walter Reed Army Institute of Research, Evelina Angov and 
colleagues have developed (and are seeking to patent) an algorithm to 'codon-
harmonize' P. faiciparum sequences with reference to the translational biases of 
heterologous expression systems. This algorithm has been used to analyse the 
'UrODBL1cL sequence for expression in E. coli (thanks to Dr Evelina Angov). 
Unsurprisingly, the codon-harmonized synthetic gene sequence, predicted to yield a 
higher level of soluble expression in E. coil (perhaps due to co-ordinated translation 
rates and proper folding), is significantly different to the recodoned version used in 
this study. This might explain the difficulties experienced in expressing the gene in 
E. (011. 
To investigate the feasibility of scaling-up expression of appropriately folded, 
functionally active varODBLla for vaccination purposes, the Pichia pastoris system 
was exploited. The Pichia expression system has been developed over recent years as 
a promising system for the production of recombinant proteins with eukaryotic post-
translational modifications. Indeed, other groups have reported success in using the 
Pichia system for the expression of secreted, soluble, functionally active 
recombinant P. faiciparuin protein - Yadava and Ockenhouse, for example, 
produced part of the 175-kDa P.falciparum erythrocyte binding antigen (EBA-175) 
superior in solubility to its E. coii-expressed counterpart (Yadava and Ockenhouse 
2003). Why the Pichia system could not be exploited with similar success in this 
thesis is debatable. It seems unlikely that the —40kDa band detected in expression 
studies is the protein of interest. More likely, expression problems were due to the 
inappropriately biased codon composition. 
Recently, Stowers and colleagues evaluated glycosylated and unglycosylated forms 
of P.faiciparuni MSP 142  as an erythrocytic stage malaria vaccine designed to prevent 
invasion of RBCs by merozoites. The glycosylated product was expressed at higher 
levels and was easier to purify, making it a seemingly preferable vaccine candidate to 
the unglycosylated version. However, in the Aotus challenge model, the gycosylated 
form of MSPI 42 gave no protection, whilst the unglycosylated form protected 
monkeys from lethal challenge with P. falciparum (Stowers et al. 2002). These data 
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not only emphasise the importance of glycosylation in determining antigenicity of 
the protein used as a vaccine, they also demonstrate how apparently promising 
vaccine candidates may have disappointing outcomes in primate vaccinees. Trials in 
New World Monkeys, such as Saiiniri, remain a good pre-human test of the safety 
and efficacy of candidate malaria vaccines. 
In this thesis. I have reported evidence to support the use of the S'aiiniri monkey 
model in malaria vaccine trials using candidate vaccines immunopotentiated with 
human C3d3 . If a human malaria vaccine immunopotentiated by human C3d 3 is to be 
tested in Saimiri, it is essential that human C3d 3 binds to its receptor (CR2) in the 
heterologous system. I have demonstrated that human C3d 3 indeed does bind to 
Saimiri B cells in vitro, suggesting that the Saimiri monkey is a suitable model for 
testing such a vaccine. Whether this binding is to CR2, however, is still uncertain 
since CR2 could not be detected on Saimiri B cells. The finding that C3d 3 does not 
bind HeLa cells (a CR2 negative human cell line) suggests that CR2 is important for 
the observed binding, although a better approach would have been to analyse C3d 3 -
binding to B cells in the presence of (or after pre-incubation with) inhibitory 
antibody. The monoclonal antibody 171 has been shown to block the C3d-binding 
sites on human CR2, however, the lack of availability of this antibody during the 
course of this thesis prevented these studies from being performed. 
As previously discussed, Sai,niri have many advantages that make them a suitable 
primate model for malaria challenge experiments in vaccine testing. The lack of 
Saint iri-specific reagents, however, makes working with this system difficult and the 
development of such reagents is necessary if the Saitniri model is to become a more 
compelling alternative to other primate models already in use. 
My findings strongly suggest that the expression system employed for producing 
recombinant protein is critical. The data presented here, along with that from other 
EUROMALVAC studies, indicates that the expression system employed is of key 
importance in determining the immunogenicity of the antigenic protein. Neither E. 
coli nor Pichia have proven to be suitable systems for the expression of recombinant 
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curODBL 1 u that sufficiently mimics the antigenic determinants of the iRBC surface 
exposed, native P. falciparurn-expressed protein. I have shown, however, that 
recombinant varODBLla can be produced in COS-7 cells, both as functionally 
active, surface-expressed protein and as a secreted product. Production and 
purification of the secreted COS-7 cell product, however, was problematic and this 
system (at least using derivatives of the pVK68-01 immunisation vector) is not 
ideally suited to varODBLlci production in quantities sufficient for vaccination. 
Progress will be dependent on finding a more suitable expression system, or by 
finding new ways of purifying and refolding recombinant protein, such as that 
described by Singh and colleagues for PvRII (region II of the P. vivax Duffy binding 
domain) expressed in E. coil (Singh etal. 2001). PvRII, at around 350 amino acids 
and 12 cysteines, is not dissimilar to DBLIa and when expressed in E. coli it is 
incorrectly folded and accumulates in inclusion bodies. The Singh study describes a 
method to enable the E. coli-expressed protein to be refolded into its native 
conformation under denaturing conditions in vitro, resulting in a highly 
immunogenic product that elicits high titre functionally active antibodies. 
I have demonstrated that affinity purified anti-peptide DBLl pep l antibodies react, as 
predicted, with E. coil-derived varODBLlu in ELISA and with varO parasites in 
IFA in a manner that is inhibited by the specific peptide. These findings are very 
similar to those of Dr Odile Puijalon for antisera to E. coil-expressed varODBLla, 
which recognise internal parasite structures but show very little (if any) surface 
reactivity (Odile Puijalon, personal communication). If real, this surface reactivity is 
directed only at RBCs infected with very late stage parasites, which implies that the 
E. coli protein is improperly folded, such that antibodies directed against it do not 
recognise the parasite protein as it is exposed at the iRBC surface. This suggests that 
conformational epitopes are important in the immune response to the iRBC surface. 
If this is the case, it is essential that recombinant PfEMP-1 proteins mimic surface 
folded antigenic determinants if they are to elicit an appropriate immune response. 
This may explain why the secreted COS-7 cell derived varODBLla recombinant 
shows little or no reactivity with varO-derived reagents other than with affinity 
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purified anti-DBLlpepl antibodies, which are not directed at conformation-
dependent epitopes. 
Discussion about the iRBC surface-expressed ligand responsible for CSA binding in 
the special case of malaria in pregnancy underscores the difficulties of studying 
proteins on the erythrocyte surface involved in binding. In pregnancy associated 
malaria, CSA-binding is strongly implicated as the major determinant of 1RBC 
sequestration in the placenta (Fried and Duffy 1996; Beeson et at. 2000; Flick et at. 
2001). There is a body of evidence to suggest that varlCSA is involved in this 
adhesion. Firstly, genetic disruption of varlCSA in FCR3-CSA-infected RBCs leads 
to a phenotypic switch from CSA binding to a CD36 binding phenotype (Andrews et 
at. 2003). Secondly, full-length recombinant DBL3y from FCR3-CSA binds CSA 
and monoclonal antibodies directed against the domain recognise the surface of 
CSA-binding iRBCs and inhibit iRBC binding to CSA (Costa et al. 2003). However, 
these antibodies may be cross-reactive and their binding does not prove that the 
domain expressed on the iRBC surface is identical to the immunising antigen. The 
recent discovery, however, that varlCSA transcription does not correlate as expected 
with the iRBC!CSA binding phenotype (Kyes et at. 2003) has cast doubt on the 
previously supposed role of varlCSA in CSA binding; the constitutive expression of 
varlCSA is obviously not sufficient to predict expression of the corresponding 
PfEMP-1 on the IRBC surface. The debate has been further complicated by the 
finding that another var gene (var2CSA) is transcriptionally upregulated in iRBCs 
selected to bind to CSA (Salanti et al. 2003). Furthermore, Gamain and colleagues 
recently generated rabbit serum against a chemically synthesized 67-residue minimal 
DBLy binding-peptide (Garnain et at. 2004) and showed that, whilst this serum 
specifically recognized CSA-binding iRBCs from different endemic regions, it was 
unable to inhibit the binding of iRBCs to CSA. Interestingly, Gamain and colleagues 
comment that the precise targets of these antibodies could not be identified, given the 
"complete lack of knowledge about what is expressed at the surface of placental 
isolates" (Garnain et at. 2004). 
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Taken together, these findings emphasise the difficulties in defining exactly the 
expressed PfEMP-1 at the iRBC surface and no definitive method exists for the 
detection of these antigens. The uncertainty as to whether or not the varO protein is 
on the surface of varO parasite-infected RBCs will only be addressed when 
appropriate antibodies become available. Attempts to raise antibodies to the surface 
of Palo Alto varO parasites are underway at the Institute Pasteur, using mice 
tolerised to uninfected RBCs, although this is proving difficult, particularly since 
infection with P. falciparum modifies host RBC proteins, to which tolerance has 
been achieved. 
Despite the limited success of the data presented in this thesis to support PfEN1P- I as 
an important target for vaccine development, useful data, indicating better 
approaches towards this end has been generated. Recently, Baruch and colleagues 
immunised Aotus monkeys with a sub-region of a PfEMP-1 from the Malayan Camp 
strain of P.falciparum, MCvarl (Baruch etal. 2002). MCvarl mediates adhesion to 
the host receptor CD36 on the endothelial surface and is another candidate adhesion-
blocking antigen. Immunisation induced a high level of protection against challenge 
with the homologous (but not the heterologous) strain and correlated with the titre of 
agglutinating antibodies. Whilst challenge with a heterologous P. falciparurn strain 
did not bring about protection, it did boost the immune response to MCvarl. 
Furthermore, Yipp and colleagues have recently shown that a recombinant MCvarl 
PfEMP-1 peptide (corresponding to the minimal C1336-binding domain from the 
CIDRL) inhibits and reverses cytoadherence of clinical P.falciparum isolates in vivo 
(Yipp et al. 2003). These data encourage further exploration of the PfEMP-1-based 
adhesion-blocking concept for malaria vaccine development. 
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7.1 	Summary 
To overcome expression problems typically encountered in the expression of P. 
falciparum proteins in heterologous expression systems, I have designed and 
synthesised a codon-optimised version of the varODBLla sequence that is less AlT 
rich than the native version and more compatible with mammalian codon usage. I 
have used the codon-optimised varODBLlcx sequence to investigate the 
i'arO/rosetting relationship and shown that the varODBLla domain, expressed in 
vitro on the surface of COS-7 cells binds red blood cells. On the basis of these 
findings, the varODBLlct domain was considered a suitable candidate antigen for a 
prototype adhesion-blocking malaria vaccine. It was hypothesised that an antibody 
response raised against DBL1cx that interferes with the rosetting phenotype would 
afford some level of protection against the clinical symptoms of malaria. 
To investigate the use of C3d 3 as an effective immunopotentiator for an erythrocytic 
stage malaria vaccine, a DNA immunisation strategy was selected to establish initial 
proof of concept. I constructed a number of DNA immunisation plasmids to encode 
the varODBLlu domain fused to murine C3d 3 . I then showed that in vitro expression 
of the codon-optimised version, but not the native version of the domain, could be 
detected as a secreted product in COS-7 cells. With the aim of demonstrating a C3d 3 -
induced immunopotentiation effect, mice were immunised with plasmids encoding 
varODBL 1 a and varODBL 1 a-C3d 3 . 
Establishing an antibody response was problematic, especially given the limited 
varO-specific reagents available. However, my findings have indicated that DNA 
immunisation is a poor strategy for eliciting an antibody response to varODBLla, 
even when the antigen is fused to C3d 3 . To overcome these problems, I concentrated 
on the production of recombinant varODBLla protein for use in developing a 
suitable assay to assess immunogenicity of this antigen and with a view to 
immunising mice. 
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I have successfully expressed recombinant varODBLlu in COS-7 cells and purified 
this protein by affinity chromatography using varO-specific antibodies raised against 
a DBL1u peptide. The suitability of varODBLIu as a candidate malaria vaccine 
antigen has been re-assessed. The data I have presented has highlighted the 
problematic nature of producing antibodies that recognise the surface of P. 
falciparum-infected erythrocytes and the difficulty in establishing exactly which 
PfEMP-.] variant is expressed at the iRBC surface. 
To investigate whether the squirrel monkey is a suitable model for C3d 3 -based 
immunisation, I have cloned Saimiri sciureus CM and assessed the species 
similarities of this molecule with other animal C3ds. I have shown that Saimiri CM 
has 90% identity to human CM but, as expected, it is most closely related to the C3d 
of marmoset, the New World monkey analysed. Sairniri C3d contains the predicted 
CR2 binding motif and thus, is predicted to bind to this receptor in vivo. I have 
demonstrated that human C3d 3 binds Saimiri B cells in vitro and given evidence to 
suggest that Sai,niri are a potentially suitable model for the testing of vaccines 
i inriiunopotentiated with human C3d. 
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7.2 	Future Work 
The need to resolve the problem of identifying the surface-expressed PfEMP-1 of P. 
falciparum-infected RBCs is pressing. Immunoprecipitation of surface-reactive 
antibodies from immune sera and surface iodination data would be useful, although it 
is difficult to draw conclusions from this data because of cross-reactivity of PfEMP-1 
antibodies with different antigenic variants. A proteomics approach might be a better 
way forward, considering advances in resolving high MW proteins on gels and in 
non-gel based technology to identify proteins in complex mixtures using mass 
spectrometry (Florens et al. 2004; Fried et al. 2004). Defining the surface-expressed 
PfEMP-1 antigen is essential in order to assess the antibody response elicited by any 
PfEMP-1-based candidate vaccine and to validate specific approaches. 
The characterisation of varO is incomplete. In particular, the binding specificities of 
the other domains are not known. It would be interesting to express individual 
domains at the surface of COS-7 cells and test the ability of each to bind red blood 
cells. This would provide more information as to the nature of DBLIa-mediated 
RBC binding - it may be, for example, that the RBC-binding phenotype is not 
exclusively mediated by DBL1a, but that other domains are necessary. This would 
have important implications in the design of a vaccine aimed at blocking such 
adhesion. 
A trial protein immunisation was planned to test the ability of C3d 3 to enhance the 
immune response to varODBLla and indeed to raise varODBLl-specific 
antibodies that are vital in the field. Due to the difficulties encountered in producing 
recombinant varODBLlct coupled to mC3d 3 , protein immunisation could not be 
carried out. Progress on the production of varODBLlct in insect cells is underway at 
the Institute Pasteur (Graham Bentley, personal communication). Furthermore, a 
method for the production of C3d 3 fusion proteins using the baculovirus expression 
system has been recently described (Denise Barrault, submitted and Andrew Knight, 
personal communication). It may now be possible to exploit this system for the 
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production of varODBLla fused to C3d3 and therefore to carry out the planned 
protein immunisation. Subsequently, crystal structure data might also be possible 
through collaboration with the Institute Pasteur and this could provide important 
information as to the sites of the molecule that are most likely to be involved in 
receptor-ligand interactions. 
There are a number of ways in which investigating the use of the Sairniri monkey 
model for malaria vaccine testing could be further developed. It remains uncertain 
whether the observed binding of human C3d 3 to Saimiri B cells is to CR2, or to 
another receptor on the B cell surface. This data could be achieved by blocking the 
C3d binding sites on the CR2 molecule, using monoclonal antibodies 171 and 1048. 
These antibodies are specific for human CR2 and it would be interesting to see if 
they also recognise the Sairniri CR2 molecule, although my finding that Sairniri CR2 
was not recognised by other antibodies raised against human CR2 makes their 
applicability questionable. Should human C3d prove unsuitable for use in the Saimiri 
model, Saimiri C3d could be expressed using the sequence cloned in Section 6.2. 1 of 
this thesis and used to make Saimiri-specific C3d-immunopotentiated vaccines. 
The lack of Saimiri-specific reagents for the detection of B cell markers made 
characterising Saimiri B cells problematic and it would be useful to develop a set of 
reagents, specific for the Sairniri B cell surface, that could be used to more 
completely characterise these cells. Sairniri CR2 and other B cell markers could be 
cloned and expressed for the production of a set of Saiiniri-specific monoclonal 
antibodies. Together, these reagents could be used to provide important evidence to 




PfEMP- 1-based adhesion-blocking vaccines for malaria are in their early stages of 
development. The DBL1a domain of varO has been established as a suitable antigen 
for inclusion in a prototype adhesion-blocking malaria vaccine. Raising antibodies to 
this domain has not proved to be straightforward. Vaccination strategy, the difficult 
nature of expressing functionally active P. falciparum proteins in heterologous 
expression systems and the challenges of establishing the specificity of the antibody 
response are key problems that will need to be overcome if progress is to be made. 
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Chapter 8: Materials and Methods 
8.1 	Amplification and Cloning of DNA Fragments 
8.1.1 	Primer Design 
PCR primers were designed based on known nucleoticle sequences. Melting 
temperature (Tm) was calculated for matching bases, where an A or T residue count 
as 2°C and G or C residues count as 4°C. As far as possible, GC content was 
adjusted to 50% and Tm to above 70°C, by extending the matching region. 
Sequences were analysed for hairpins, self-duplexes and Tm using MacVector 
software. Pairs of oligonucleotides were designed to be of equal (+/-2°C) Tm, rather 
than equal length. A guanine residue was always placed at the 5' end. Where a 
restriction site was incorporated, this was at the 5' end, immediately after the guanine 
residue. Oligonucleotides were synthesised by Oswel or MWG Biotech, at the 
40nmol or 0.1tmol synthesis scale and HPLC purified. Throughout, forward 
primers, specific for the sense DNA strand are denoted 'F' and reverse primers, 
specific for the anti-sense DNA strand are denoted 'R'. 
8.1.2 	PCR 
Unless stated, a 50tl PCR mix was made up as follows, using Promega reagents. 1ig 
template DNA was added to iOtl lOX PCR buffer, 2tl MgCl 2 (25mM), 4.5pJ 
DMSO, 1tl Taq polymerase, ltl dNTP mix (10mM), and 1tl each of forward and 
reverse primers (each at 10tM). The mixture was made up to 50tl with distilled 
water and covered with a drop of mineral oil to prevent evaporation during thermal 
cycling. Thermal cycling conditions were specific for each primer pair and are 




'T' vectors were used as holding vectors for PCR products, for sequencing and for 
subsequent sub-cloning. For pUC57/T and pGEM-T vectors (Promega), a ligation 
mix was set up using 1tl insert DNA, Ilil  lOX T4 DNA ligase buffer, 1il T4 DNA 
ligase, 1tl vector and made up to 10tl with water. This was transferred to a heating 
block and left at 16°C for 12 hours, 37°C for 1 hour, 65°C for 1 hour and 25°C for I 
minute. For PCR04-TOPO and TOPO®XL vectors (Invitrogen), 1tl insert, lp.l 
vector, ltl salt solution and 2tl water were mixed and incubated at room 
temperature for 5 minutes. 
8.1.4 	Bacterial Strains Used 
XL-! Blue (genotype: recAl endAl gyrA96 thi-1 hsdRl7supE44 re/Al IacIF'proAB 
lacP'ZAM15 TnlO (Tet')I) and XL-10 Gold (genotype: T etr t(mcrA)183 A(rncrCB-
hsdSMR-mrr) 173 endA / supE44 thi- / recA / gyrA 96 relA / lac Hte IF' proAB 
lacI"ZAM15 TOO (Tet') Amy C am la) E. coli strains (Stratagene) were used for 
cloning and propagating DNA. The Stratagene E. co/i BL21 strain (genotype: B F 
dcm o,npThsdS(r B m B ) gal) was used for expressing recombinant protein. Cells were 
transformed chemically, based on the manufacturer's recommended protocols. 
Briefly, after thawing on ice, cells were made competent using -mercaptoethanol. 
4tl 3-mercaptoethanol were added to 150!il competent cells, swirled gently and 
incubated on ice for 10 minutes, after which 5pi DNA was added to 50d cells and 
incubated on ice for 45 minutes. Cells were transformed by heat-shock at 42°C for 
exactly 45 seconds, followed by a further incubation on ice for 2 minutes. 150tl pre-
warmed (to 42°C) SOC medium or LB broth was added and the mixture incubated at 
37°C for 90 minutes. The cells were plated out on LB agarose with appropriate 
antibiotic selection and incubated overnight at 37°C to allow colonies to form. 
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8.1.5 	Screening of Bacterial Clones 
Transformed clones were identified by direct colony PCR and by restriction digest of 
plasmid DNA. Cell suspensions were prepared using a sterile pipette tip to transfer a 
bacterial colony to lOO.il PCR grade water. 5-95tl of the cell suspension was used to 
inoculate 5m1 LB with the appropriate selective antibiotic and incubated overnight at 
37°C, with shaking. Plasmid minipreps were carried out on overnight cultures to 
recover plasmid DNA, using the QlAprep Spin Miniprep Kit (QIAGEN), according 
to the manufacturer's instructions. Recovered DNA was incubated with appropriate 
restriction enzymes to release an insert, or to produce a band pattern characteristic of 
a particular insert, which was then analysed by agarose gel electrophoresis. For PCR 
screens, a standard reaction mix was made up (as described in Section 8.1.2) and 1tI 
of cell suspension was added to 9tl of reaction mix and over-lain with mineral oil. 
PCR was carried out under thermal cycling conditions specific for each primer pair, 
as described in relevant results chapters. Amplified DNA was analysed by agarose 
gel electrophoresis. When necessary, PCR conditions were optimised for different 
primer pairs. Clones with inserts in the correct orientation were identified using a 
standard PCR, with primers selected to allow amplification only of an insert in the 
correct orientation. 
8.1.6 	Preparation of Plasmid DNA 
Plasmicl DNA from 5ml overnight cultures was prepared using either the QlAprep 
Spin Miniprep Kit (QIAGEN) or Wizard' Plus SV Minipreps DNA Purification 
System (Promega), according to manufacturers instructions. Unless stated otherwise, 
final elutions were made in 50i.&l buffer EB (QiAprep) or 1OOtl water (Wizard'). For 
transfection quality plasmid recovery, the QlAprep Midiprep Kit (QIAGEN) was 
used with 25m1 overnight cultures and DNA was re-suspended in 200M1  water. 
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8.1.7 	DNA Quantification 
Plasmid DNA concentration was estimated by measuring its absorbance at 260nm. It 
was assumed that an OD260  of 1.0 is equivalent to a concentration of 50tgIml for 
double stranded DNA. The ratio of absorbance at 260 and 280nm (the A260/280 
ratio) was used to assess the purity of DNA preparations. 
8.1.8 	Phenol Chloroform Extraction of DNA 
An equal volume of phenol: chloroform: isoamyl alcohol 25:24: 1 was mixed with the 
sample and spun for one minute at 28,960g in a bench-top microfuge. The resultant 
top layer was transferred to a separate tube and mixed with an equal volume of 
chloroform. After a further spin, as previously, the top layer was taken and mixed 
with 1/10 volumes of 3M sodium acetate (pH 5.2) and 2.5 volumes of 100% ethanol. 
The mixture was left on ice for 30 minutes and spun as before, for 30 minutes. The 
pellet was washed once in 70% ethanol, air-dried and re-suspended in water. 
8.1.9 	Automated DNA Sequencing 
Automated sequencing of plasmid DNA was carried out using dye terminators with 
the PRISMS/S cycle sequencing kit (Applied Biosystems) and the 377 automated 
sequencer (Applied Biosystems). Reactions were set up using 4tl Big Dye 
Terminator (Applied Biosystems), 1.6pmol appropriate sequencing primer and 2tg 
plasmid DNA, made up to 10.il with PCR grade water. Cycle sequencing was 
performed as follows: 25 cycles of 95°C for 30 seconds, 50°C for 20 seconds, 60°C 
for 4 minutes and held at 4°C. PCR products were precipitated by centrifugation in a 
spin column for 2 minutes at top speed in a microfuge and run on an acrylamide gel. 
Chromatograms were viewed and data edited using the SeqEd program (Applied 
Biosystems). Sequences were analysed using Vector NT1 (InforMax), DNA Strider 
(www.cellbiol.com/soft.htm)  or MacVectorTM  software (http://www.accelrys.com ). 
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8.1.10 	Agarose Gel Electrophoresis and Photography 
Agarose gels were used to check the quality of genomic DNA and plasinid 
preparations and to analyse PCR products and restriction digests. 1% agarose was 
dissolved in TAE buffer by boiling. After cooling to around 45°C, ethidium bromide 
as added to a concentration of 0.5ig/ml and the gel poured onto an electrophoresis 
plate and left to set at room temperature. DNA was mixed with 6X DNA loading 
buffer (40% [wlv] sucrose, 50mM EDTA pH8.0, 0.25% bromophenol blue, 0.25% 
xylene cyanol) and loaded into the gel, submerged in TAE. Electrophoresis was 
carried out in TAE at 100-150 volts for an appropriate time, depending on the size of 
the fragments under analysis. Fluorescence from DNA-bound ethidium bromide was 
visualised by short wavelength UV light and photographed. To aid estimation of 
DNA fragment size, 6tl of DNA marker were loaded adjacent to DNA samples on 
gels. The markers used were 'Gene Ruler' 1kb marker (Stratagene) and lkb+ marker 
(Gibco). 
	
8. 1.11 	Restriction Digests 
For digests with a single restriction enzyme, IOU of appropriate restriction enzyme 
were added to 1-10tg DNA with 2p1 appropriate lox buffer and the mixture made 
up to 20p.l with water. The mix was incubated at 37°C in a water-bath for 5-6 hours. 
For double digests, single digests were set up in the same way and 15tl of each 
reaction was transferred to a separate tube and mixed. All three mixtures were 
incubated at 37°C overnight and 5.tl of each was run on an agarose gel to determine 
the efficiency of each reaction. 
8.1.12 	Dephosphorylation of Linearised Vector 
In order to prevent re-circularisation of cut vector during cloning, 5' terminal 
phosphates were removed using SAP. 1tl enzyme (lOU/tl) and 5t1 lOX SAP buffer 
(New England Biolabs) were added to 20il cut vector. The mixture was made up to 
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50tl with water and incubated at 37°C for 2 hours, followed by inactivation of 
phosphatase activity at 75°C and 25°C for one minute. 
	
8.1.13 	Purification of DNA Fragments from Agarose Gels 
DNA fragments from PCR reactions or restriction digests were purified from agarose 
gels prior to cloning using the QiAgen Gel Extraction kit, according to the 
manufacturer's instructions. Clean PCR products (i.e. those containing bands only of 
the predicted size of interest) were purified using QlAquick PCR purification kit, or 
by phenol-chloroform extraction. 
8.1.14 	Reverse Transcription PCR 
Reverse transcription was used for the amplification of eDNA from total RNA. 4tl 
primer I (10tM) was added to 1tl RNA, 4tl magnesium chloride (25mM), 2tl 
dNTPs (10mM), 1tl DMSO, 2!.tl  lox reverse transcriptase buffer, 0.5tl Rnasin and 
0.5tl reverse transcriptase (Promega), made up to 20tI with water. Thermal cycling 
was carried out at 42°C for 30 minutes, followed by 95°C for 5 minutes and the 
reaction mix cooled at 27°C for 1 minute before use in subsequent PCR. To amplify 
dsDNA from this cDNA template, IOtl of the first reaction mix was added to a 
second reaction mix consisting of 2t! primer 2 (10mM), 41.11 iox PCR buffer, 2tl 
magnesium chloride (25mM), 4.5pi DMSO, 1tl Taq polymerase (Promega). This 
was made up to 50tl with PCR grade water and PCR carried out (94°C, 10 minutes, 
I cycle followed by 35 cycles of 94°C for 30 seconds, 55°C for 30 seconds and 72°C 
for 90 seconds. Final extension at 72°C for 1 minute, 1 cycle). 
8.1.15 	Ligation 
Linearised vector and insert DNA were purified by gel-extraction as described and 
bOng vector DNA was incubated with 1:1, 1:3 and 1:5 molar ratios of vector:insert 
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DNA. Controls were included using linearised vector alone. !O&l reaction mixtures 
were set up, with 1-3U T4 DNA ligase (Promega) and T4 DNA ligase buffer (30mM 
Tris-HCI, pH7.8, 10mM MgCl 2, 10mM DT-F, 1mM ATP) and incubated at 16°C for 
12 hours, followed by 37°C for one hour and 65°C for one hour to denature the 
ligase and prevent further activity. 
8.1.16 	Synthetic Gene Synthesis 
The method of synthesising a codon-optimised synthetic gene was developed by Dr 
Mike Steward at Adprotech. lpmol of each oligonucleotide was mixed with 0.2mM 
dNTPs, 2.5tl Taq ligase buffer, 2.5d Pfu buffer, li1 Taq ligase and 11 Pfu 
polymerase, in a 50d reaction mix. This was cycled 20 times at 52°C for 5 minutes, 
72°C for 5 minutes and 92°C for 30 seconds. 5tl of the first product was used as a 
template for a gene amplification step using conventional PCR with Pfu polymerase 
and the two outer-most oligonucleotides (P1 and PIR, Tables 2.2 and 2.3 
respectively). 0.2tM of each primer was added to 5t1 PJii buffer, 1 tl Pfu and 0.2mM 
dNTPs in a 50d reaction mix. Thermal cycling was carried out 35 times at 50°C for 
30 seconds, 72°C for 60 seconds and 92°C for 30 seconds. 
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8.1.17 	Site-Directed Mutagenesis 
Site-directed mutagenesis was used to correct errors in the DNA sequence that arose 
as a result of repeated rounds of PCR in the gene-synthesis stage of codon-
optimisation. Plasmid DNA was denatured to produce single strands and a synthetic 
mutant' oligonucleotide with the desired mutation (point mutation, deletion, or 
insertion), annealed to the target region. The 'mutant' oligonucleotide was extended 
using a plasmid DNA strand as the template and the synthetic heteroduplex selected 
against parental DNA using the restriction endonuclease DpnI. DpnI recognises the 
Dam-methylated dsDNA (5-Gm6ATC-3), typical of that propagated in E. coli. A 
501i1 PCR mix was made up containing 25ng template plasmid DNA with Cloned 
Pfu buffer (Stratagene; 20mM Tris-HCI, pH 8.8, 10mM KCI, 10mM (NH 4) 2SO4 , 
2mM MgSO4 , 0.1% Triton® X-100 and 0.1mg/mi nuclease-free BSA), 125ng each of 
appropriate forward and reverse primers, 2.5mM each of dATP, dCTP, dGTP and 
dTTP and 2.5U Pfu 'Turbo' DNA Polymerase® (Stratagene). Thermal cycling was 
performed at 95°C for 5 minutes, followed by 16 rounds of 95°C for 1 minute, 52°C 
for 1 minute and 68°C for 9 minutes, with a final minute at 25°C to cool. After 
thermal cycling, I tl DpnI was added to the reaction mix and incubated for 2 hours at 
37°C to digest methylated parental DNA. 5tl of this mix was then used to transform 
XL-10 Gold super-competent cells, as described. 
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8.2 	Culturing of Asexual Parasites 
Cultures of P. falciparum parasites were maintained using standard methods (Trager 
and Jensen 1976). 
	
8.2.1 	Parasites 
Parasite cultures used in this work are: 
PA89F5: a rosetting clone from the Ugandan Palo Alto strain, isolated at the 
Institute Pasteur, Paris 
R29: a rosetting clone derived from the ITOR strain, originally from Brazil (Roberts 
et al. 1992) 
TM284: a rosetting isolate derived from a Thai patient with severe malaria (Carlson 
et al. 1992) 
PA17: a rosetting isolate derived from the Ugandan Palo Alto strain (Helmby et al. 
1998) 
2113: an isolate derived from the peripheral blood of a multi-gravid Sudanese female, 
suffering from malaria in pregnancy. The parasite is differentially recognised by 
pooled male and female sera, collected from an area of hyper-endemicity in Ghana. 
8.2.2 	Culture Media 
Parasites were maintained in continuous culture in group O type human red blood 
cells, in complete RPMI-1640 medium (cRPMI) supplemented with 10% human 
serum, 37.5mM 1-IEPES, 100tM hypoxanthine, 20mM glucose, 2mM glutamine, 
2mg/mI NaHCO 3 , 25g/ml gentamycin sulphate and sodium hydroxide to pH 7.2. 
Incomplete RPMI (iRPMI), i.e. without supplements was used for all washes, unless 
stated. Pooled human sera was used for all parasite strains except Palo Alto clone 
89F5, for which human AB serum was used. Unless stated, all washes involved 
pelleting cells by spinning at 1000g for 2 minutes and re-suspending the pellet in an 
excess of incomplete iRPMI. All culture media was supplied as sterile or sterilised 
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using O.22tm filters and stored at 4°C. Washed human RBCs were added to a 
hematocrit of 5%. RBCs and serum (previously collected into citrate phosphate 
dextrose blood packs, to prevent coagulation) were obtained from the Scottish Blood 
Transfusion Service. Edinburgh, UK. 
	
8.2.3 	Preparation of RBCs 
Iresh. human RBCs were washed to remove leucocvtes and serum. The differential 
density of red and white blood cells provided the basis for the purification method, 
which leaves a thin, visible layer of white blood cells and platelets (buffy coat) on 
top of the red cell layer after centrifugation. I 5ml aliquots of blood were spun at 
1 000g for 2 minutes. Serum and buffy coat were drawn off and cells were washed 
three times. Cells were finally re-suspended in iRPMI at 50% haematocrit and stored 
at 4°C for up to one month. 
8.2.4 	Maintenance of Parasites 
Infected RBC cultures were maintained in sterile flasks at 37°C in a modified gas 
mixture of 96% N 2, 3% CO2 and 1% 02. Medium was replaced daily and 
parasitaemia was maintained at 1-10%. For washes, cells were centrifuged in a 
microfuge at l,000g for 5 minutes to sediment without damaging the parasitised 
cells. All media and experimental materials were pre-warmed to 37°C before use. 
Liquid waste was disinfected in 1% virkon before disposal. Contaminated 
consumables were disposed of by incineration. 
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8.2.5 	Assessment of Parasitaemia 
Parasitaemia was determined daily by thin film blood smear. A small sample of 
iRBCs at approximately 40% haematocrit was smeared on a clean glass slide. The 
sample was air-dried and fixed by soaking in 100% methanol for 10-20 seconds. 
Once dried, fixed blood smears were stained with Giemsa's solution (10% Giemsa in 
Sorensen's buffer, pH7.2) for 15-30 minutes. Excess stain was removed by washing 
with water and, once dry, slides were examined by light microscopy, at x 1,000 
magnification, under oil immersion. The parasitaemia was counted as a percentage of 
infected to uninfected cells and the rate of ring-stage to trophozoite/schizont stage 
parasites was assessed. 
8.2.6 	Synchronisation of Asexual Parasite Cultures 
The 48 hour natural life cycle of P. falciparuin is not tightly maintained in vitro and 
parasites slowly become asynchronous. Infected RBCs, older than 18-20 hours post 
invasion, undergo changes that render them permeable to sorbitol. A method has 
been developed for the preferential lysis of older parasites, based on osmotic stress 
using sorbitol (Lambros and Vanderberg 1979). To maintain parasites within a 
narrow age range for experiments, parasites were enriched for ring stages by 
treatment with sorbitol. Parasite cultures were pelleted by centrifugation at room 
temperature and the medium removed by aspiration. The culture was washed by 
adding 10 volumes incomplete RPMI-1640, followed by centrifugation. Cells were 
re-suspended in 5% (v/v) sterile sorbitol/PBS and incubated at 37°C for 10 minutes. 
The suspension was centrifuged at 1,500g and washed twice in incomplete RPN11-
1640. The parasites were transferred back to culture and examined by blood smear 
after 24 hours, at which point they are trophozoites. 
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8.2.7 	Enrichment for Rosetting 
Mature, knob-positive non-rosetting parasites can be separated from ring stages and 
RBCs by flotation in a gelatine solution (Pasvol et al., 1978). This method is based 
on the fact that iRBCs between 18 and 48 hours have a lower density than uninfected 
RBCs and early ring stages. 5ml parasite suspension was gently layered over 5m1 
60% Percoll/RPMI-1640 and spun at 1,800g for 10 minutes. The supernatant was 
removed and the pellet (containing mature parasites) was washed once in 10 volumes 
iRPMI. The washed cells were sub-cultured using fresh RBCs, at 5% hematocrit. The 
efficiency of the procedure was assessed by thin smear examination. 
8.2.8 	Assessment of Rosetting 
Parasites were stained with ethidium bromide (500tI culture + 2tl of 5 igIml 
ethidium bromide) for 5 minutes, after which 15il culture was mounted on a clean 
glass microscope slide using a 22mm x 22mm coverslip previously prepared with 
vaseline around the edges to act as a sealant. Rosettes were observed using a 
combination of bright field and fluorescence microscopy - adjusted so that stained 
iRBCs and unstained RBCs could be viewed simultaneously. Rosettes were counted 
as the binding of 2 or more infected cells to an uninfected red blood cell. 
8.2.9 	Storage of Parasitised Cells 
Samples of iRBCs were frozen in cryoprotectant, for long-term storage and 
preservation. Such individual samples were referred to as stabilates. Mature stage 
parasites undergo modifications that render the iRBC membrane relatively inflexible. 
This means that only young, ring stages can be successfully frozen. Cells from 5m1 
cultures were pelleted by centrifugation and the supernatant drawn off. The pellet 
was slowly re-suspended in an equal volume of deep-freeze solution (28% glycerol, 
3% sorbitol, 0.65% sodium chloride) at room temperature and transferred in 0.5m1 
aliquots to freezing vials, which were then plunged in to liquid nitrogen (-196°C). 
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8.2.10 	Thawing of Frozen Stabilates 
Thawing was performed carefully using a series of salt solutions to minimise lysis 
and return the cells to normal osmolarity. Samples were thawed at 37°C and 
transferred to 50ml centrifuge tubes. For every Imi thawed blood, 0.2 volumes of 
12% (wlv) sodium chloride was added drop-wise over 5 minutes, with continuous 
mixing. After incubation at room temperature for 3 minutes, 10 volumes of 1.6% 
(w/v) sodium chloride was added drop-wise over 5 minutes. Following centrifugation 
at 500g for 5 minutes, supernatant was removed and 10 volumes of 0.2% 
dextrose/0.9% (wlv) sodium chloride was added drop-wise over 5 minutes. After a 
final centrifugation at 500g for 5 minutes, supernatant was removed and cells were 
re-suspended in cRPMI to 5% haematocrit and the culture maintained under normal 
conditions. 
8.2.11 	Preparation of Parasites for Fixed lEA 
Cells at 5-10% parasitaemia were pelleted by centrifugation at l000g for 2 minutes, 
washed twice in iRPMI and re-suspended to 5% haematocrit. 25tl of this suspension 
was spotted onto each spot of clean, multi-spot microbiological glass slides (C.A. 
Hendley-Essex) and left to dry at room temperature. Slides were wrapped in 
parafilm, sealed in plastic bags with dry silica gel as desiccant and stored at -20°C. 
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8.2.12 	Preparation of Parasite DNA 
5m1 of asexual culture at 5-10% parasitaemia was centrifuged at l000gtor 2 minutes 
to pellet iRBCs. The pellet was re-suspended in imI of 0.15% saponin in iRPNII and 
mixed until lysis was observed. An equal volume of iRPMI was added and the 
mixture spun at 500g for 10 minutes. The supernatant was removed by aspiration and 
the parasite pellet washed once more in iRPMI. A greyish layer of broken red cell 
membranes was removed by gentle pipetting, when required. DNA was extracted 
from the parasite pellet using QlAamp ® DNA Minikit, according to the 
ivaiiufacturer's instructions. 
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8.3 	Cell Culture 
8.3.1 	Culture Media 
Adherent cells (COS-7 cells and HeLa cells) were routinely cultured in DMEM, 
supplemented with 10% fetal calf serum, 2mM glutamine, 50tgIml kanamycin, non-
essential amino acids (Gibco) and 5tl/ml 3mercaptoethanol (from stock made by 
diluting 9tI of 98% I3mercaptoethanol in 12ml iDMEM). B cells were routinely 
cultured in RPMI-1640, supplemented with 10% FCS, 2mM glutamine, 4.5mg/mI 
glucose, 10mM Hepes, 1.0mM sodium pyruvate, non-essential amino acids and - 
mercaptoethanol as above. Cultures were routinely incubated at 37°C, 5% CO2 . 
8.3.2 	Resuscitation of Frozen Cell Lines 
Cells were transferred from storage in liquid nitrogen on dry ice and thawed in a 
water-bath at 37°C until a small amount of ice remained. The vial was transferred to 
a class II safety cabinet and swabbed with 70% ethanol. lOmI complete medium was 
added drop-wise to replace DMSO. After centrifugation at 300g for 5 minutes, 
supernatant was removed and cells were re-suspended in 5-10mi fresh medium and 
transferred to culture in a T25 flask at 37°C, 5% CO2. 
8.3.3 	Subculture of Adherent Cell Lines 
Cells that had reached 80-90% confluence were diluted to 10-20% confluence, to 
prevent cell death. Cells were brought into suspension using trypsin!EDTA. Fetal 
calf serum contains trypsin inhibitors so cells were washed twice in Sml iDMEM to 
remove traces of fetal calf serum prior to trypsinisation. lml trypsin per 25cm 2 
surface area of cell monolayer was added to the washed cell monolayer and the cells 
incubated at 37°C for 2-10 minutes. After examination using an inverted microscope 
to ensure all the cells were detached, 5m1 cDMEM was added to inactivate trypsin. A 
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1Ot1 sample was removed for counting (Section 8.3.4) and the cells spun at 3 00g for 
5-10 minutes at room temperature. Cells were re-suspended in an appropriate volume 
of eDMEM and culturing continued at 37°C. 5% CO2. 
	
8.3.4 	Cell Quantification 
A 10il sample was removed from a cell suspension and mixed with lO!tl Trypan 
Blue. A clean haemocytometer was prepared by moistening the coverslip with 
exhaled breath and sliding over the chamber with slight pressure until Newton's 
refraction rings appear. Both sides of the chamber were filled with cell suspension 
(5-10tl) and cells were viewed at x 200 magnification. The average number of cells 
in the 25 large squares of the grid was calculated and this number multiplied by iO 
to calculate the number of cells in imI original suspension. The Trypan Blue dilution 
factor was taken into account by multiplying by 2. The number of viable (bright, 
colourless cells) and number of dead cells (stained blue) was counted and percentage 
viability calculated. 
8.3.5 	Cryopreservation of Cell Lines 
Cell viability in excess of 90% is desired for cryopreservation. A cell count was 
made (Section 8.3.4), after which the culture was pelleted at 300g for 5 minutes and 
re-suspended at a concentration of 2-4 x 106  cells per ml in cryoprotectant (10% 
DMSO in FCS). Ampoules were frozen slowly overnight at -80°C and then 
transferred to storage in liquid nitrogen at -196°C. 
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8.3.6 	Transfection of COS-7 Cells 
COS-7 cells were transfected with Effectene Transfection Reagent (QIAGEN). 
The day before transfection, 2.5 x 105 cells were seeded in each well of a tissue 
culture grade 6-well plate. Cells were incubated overnight, to reach 50-80% 
confluence on the day of transfection. DNA was diluted with sterile water to 
100tg/ml. Ratios of 1:10, 1:25 and 1:50 DNA:Effectene Tm were used during 
optimisation experiments. Appropriate amounts of DNA were pipetted into 
eppendorfs and made up to 100l by adding buffer EC. Relevant volumes of 
enhancer were added to each and the mixtures mixed and vortexed for 1 second. 
After a 3-minute incubation at room temperature, relevant volumes of Effectene TM 
were added and mixed by pipetting up and down. The mixture was incubated at room 
temperature for 10 minutes. During incubation, culture medium was removed from 
the cells by aspiration and 1.6m1 fresh medium was added. To each tube containing 
the transfection complexes, 600iil medium was added and mixed by gentle pipetting. 
The transfection mixture was transferred immediately to the cells, drop-wise. After 
swirling gently to ensure uniform distribution, cultures were incubated at 37°C, 5% 
CO2 , for up to 6 days. 
8.3.7 	Fixed Immunofluorescence Assay on COS-7 Cells 
To confirm that transfected cells in COS-7/RBC binding assays were expressing 
recombinant protein, fixed IFA was carried out on cells adherent to 2 out of the 4 
coverslips in each well of a six well plate. 48 hours post transfection, cells were 
washed twice in PBS and fixed by immersing in 2% formaldehyde/PBS for 20 
minutes. Antibodies were made up in PBS/O. 1% BSA at 2-5tg/ml. To detect the 1-IA 
epitope on cells transfected with pDisplay constructs, rabbit anti-HA antibody was 
used (at 1:40 dilution) with goat anti-rabbit IgG FITC conjugated secondary antibody 
(1:100) were used. The mouse monoclonal antibody 1D3 (specific for cells 
transfected with the pRE4 vector) was used (1:500) with goat anti-mouse lgG Alexa 
Fluor 488 (1:200) secondary antibody to detect products of pRE4 construct 
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transfection. After fixation, cells were washed three times, 10 minutes each, in PBS 
and then incubated with 40il primary antibody for 1 hour. Cells were washed three 
times in PBS and incubated with 40tl of secondary antibody for 30 minutes. Finally, 
cells were washed three times in PBS, mounted on a clean glass slide (cell side 
down) in Fluoromount-G (Electron Microscopy Sciences) and visualised with 
incident light of 450-490nm, at a magnification of x 400 or 1000. 
8.3.8 	Red Blood Cell // COS-7 Cell Binding Assay 
(Adapted from ( Rowe ci al. I 997 
COS-7 cells were cultured in 6 well plates containing 12mm diameter glass 
coverslips (4 per well). Cells were transfected as described (Section 8.3.6) with 
1.5tg per well DNA. Medium was replaced with fresh cDMEM 24 hours post 
transfection and the binding assay was carried out 48 hours post transfection on 
duplicate samples from each well. RBCs were made up at 5% haematocrit in 
cDMEM with 10% human serum (heat-inactivated at 56°C for 1 hour). 60p.l of RBC 
suspension was added to each coverslip and incubated for 2 hours at 37°C, 5% CO2 . 
Washing was performed by inverting the coverslip in lOmI PBS at room temperature 
for 45 minutes, to allow non-adherent RBC to float off under gravity. After washing, 
coverslips were turned the right way up and viewed using an inverted microscope. 
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8.4 	Expression of Recombinant Protein in Pichia 
8.4. 1 	Preparation of Vectors for Transformation 
pP!CZct vectors were propagated in Stratagene JM 109 cells (genotype: e 14 (McrA) 
recAl endAl gyrA96 thi-] hsdRI7 (rKrnK) supE44 relAl (1ac-proAB) IF traD36 
proAB IacPZAM151. Plasmid DNA was isolated using a QlAprep Midiprep kit, 
according to the manufacturer's instructions. Plasmids were linearised within the 5' 
AOXI region, to promote integration into the host genome, by digest with Sac!. 5- 
10ig of plasmid DNA was incubated with Ip.l Sac! and 2[d Sac! lOX buffer in a 
20.il reaction at 37°C overnight. Linearised DNA was phenol chloroform extracted 
(Section 8.1.8). 
8.4.2 	Transformation of Pichia Pastoris 
Wild-type (X33) Pichia pastoris cells were made competent and transformed 
according to the Easy Select T" Pichia Expression Kit manual (Invitrogen TM). 
Briefly, I OOml YPD was inoculated with 1 colony of P. pastoris and incubated 
overnight at 30°C with shaking at 250rpm in an orbital shaker, to an 0D 600 of 1.3-
1.5. Cells were centrifuged at 1500g for 5 minutes at 4°C and re-suspended 
successively with lOOmI, then 50m1, followed by 4m1 ice-cold sterile water, then 
O. 5m1 ice-cold 1M sorbitol. Competent cells were kept on ice and used the same day. 
80tl cells per transformation were mixed with 5-10tg of linearised DNA (in 5-10l.tl 
sterile water), transferred to an ice-cold 0.2cm electroporation cuvette and incubated 
on ice for 5 minutes. Electroporation was carried out using a BioRad GenePulser, at 
1,500V, 25vF and 200Q. lml of ice-cold IM sorbitol was added immediately to the 
cuvette and the contents transferred to a sterile lSml tube. The cells were then 
incubated at 30°C without shaking for 1-2 hours, after which time 10, 25, 50 and 
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100&l were plated on separate YPDS Zeocin 	(100tg/rn1) plates. Plates were 
incubated at 30°C for 2-3 days until colonies formed. 
8.4.3 	Direct Screening of Pic/iia Clones 
In order to establish the presence of an insert in transformed east cells, a PCR 
screen was carried out. Yeast cells were lysed by lyticase, followed by 
freezing/heating treatment to release gDNA which was then used as a PCR template, 
according to the Easy Select TM  Pichia Expression Kit manual (Invitrogen TM). PCR 
positive colonies were re-streaked on YPD plates containing 100tg/mI, 200tgIml 
and 500tg/111I Zeoci 11 TM 
8.4.4 	Selection for the Methanol Utilization (Mut+) Phenotype 
Transformed colonies were picked using a sterile pipette tip and spotted onto MD 
and MM plates (Appendix 2) and incubated at 28°C for 3 days. After incubation for 
3 days, the Mut+ phenotype was confirmed by slow growth (small colony size) on 
MM compared to MD. The original colony was identified on the base of the plate 
and re-streaked onto fresh YPDS 100tg!rnl Z eoc i n TM . 
8.4.5 	Screening Recombinant Pichia Strains for Expression 
8.4.5a 	Small-Scale Expression Screening 
Selected colonies were picked into lOmI (in a 50ml centrifuge tube) or 50ml (in 
250m1 a baffled flask) BMGY and incubated overnight at 28-30°C in a shaking 
incubator at 250-300rpm. When the cultures had reached an OD 6. of 2-6 (indicating 
log-phase growth), the cells were harvested by centrifugation at 1 ,500-3,000g and 
washed in sterile PBS to remove traces of glycerol that may adversely affect 
methanol induction. Cells were then re-suspended to an OD 6. 1.0 in 100-200ml of 
BMMY, in a I litre baffled flask, to induce expression. Incubation was continued and 
100% methanol was added to a final concentration of 0.5% every 24 hours for 4 days 
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to maintain induction. 500.il samples were removed at appropriate time points, 
centrifuged for 2 minutes at maximum speed in a bench-top microfuge and 
supernatants transferred to fresh tubes. Both supernatants and cell pellets were frozen 
quickly in a dry ice/ethanol bath and stored at -80°C. 
8.4.51b 	Scale-Up of Expression 
The same procedure as for small-scale cultures was followed with initial inoculums 
of 100-200ml in a litre baffled flask. To induce expression, cells were re-suspended 
in 1 litre of BMMY in a 4 litre baffled flask and incubated at 28-30°C with vigorous 
shaking to ensure adequate aeration. 
8.4.6 	Preparation of Cell Lysates for Analysis 
Cells were washed once in Breaking Buffer (BB, Appendix 2) by re-suspending them 
and centrifuging for 5-10 minutes at 3,000g. 4°C. Cells were re-suspended in BB 
(l00d BB for each imI sample of cells). An equal volume of acid-washed glass 
beads (0.5mm) was added and the mixture vortexed for 30 seconds, then incubated 
on ice for 30 seconds. This was repeated seven more times after which the mixture 
was centrifuged at 4°C for 5-10 minutes at 12,000g. 
8.4.7 	Fermentation 
The fermentation run consisted of the following stages: 
Glycerol Batch Phase - 20 hours 
Glycerol Feed Batch phase —20 hours 
Starvation phase - 1 hour 
Methanol Feed Batch - 70 hours 
Harvest 
Six litres of Basal Salts Medium (Appendix 2) were added to the fermenter. After 
sterilization and cooling, the temperature was set to 30°C, agitation and aeration were 
set to routine operating conditions (maximum rpm and 1:10 volume of gas:volume of 
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liquid) and the p1-I was set to 5 with 28% ammonium hydroxide. Maintaining 
sterility, 4.35ml11 of PTM (Appendix 2) was added and the inoculum seed flask 
preparation (500m1) was added to the fermentor culture. The culture was incubated 
until complete glycerol consumption (approximately 20 hours), after which initiation 
of glycerol-feed was started using 50% glycerol containing I 2ml of PTM. The feed 
rate was adjusted to 18.1 5 mi/hour per litre of initial fermentation volume. Glycerol 
feeding was terminated and 30 minutes of carbon source starvation was carried out 
before the production phase of the culture was started. The production phase started 
with 12m1/l PTM in methanol, and the feed rate was set to 3.5rnl/h/l for 3 hours. 
After adaptation to methanol utilization, the feed rate was set at 7.3 ml/i/h for 2 
hours. The methanol feed rate was changed to 11 mI/i/h to the end of the run (65 
hours), at which point the culture was collected into 500m1 or 1000ml centrifuge 
bottles and centrifuged at l,lOOg to separate cells from supernatant. 
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8.5 	Analysis of Proteins 
8.5.1 	SDS-PAGE 
Samples were added to 4X sample buffer (40% glycerol, 8% sodium dodecyl sulfate, 
125mM Tris HC1, 10mM EDTA, 0.1% Bromophenol Blue, 1.5mM 
imercaptoethano1) and heated at 90°C for 5-10 minutes. 4-12% bis-tris 
polyacrylamide NuPAGEFM  Novex high-performance pre-cast gels (Invitrogen TM ) 
were removed from packaging and washed three times with water, before transfer to 
500m1 per tank of either MOPS (for high MW) or MES (for low MW proteins) 
running buffer (Invitrogen TM)  . 6iI SeeBlue® Plus 2 Pre-stained Protein Standard 
(Invitrogen TM) and 20-30t1 of each sample were loaded in each well and 
electrophoresis was carried out at 200V, constant voltage for approximately 50 
minutes, or until the loading dye front had reached the bottom of the gel. 
8.5.2 	Coornassie Staining of SDS Gels 
In-gel staining with Coomassie Blue is sensitive for up to ltg of protein and was 
used accordingly. Gels were incubated for at least one hour with gentle agitation in 
45% methanol, 10% glacial acetic acid, 2.5g/l Coomassie Blue-R250 and de-stained 
overnight in 20% methanol, 10% glacial acetic acid. 
8.5.3 	Western Blot 
Wet transfer of proteins to PVDF was carried out in a BioRad Mini Trans-Blot cell, 
according to the manufacturer's instructions. Briefly, SDS-PAGE gels were placed in 
a sandwich of blotting paper sheets and fibre pads saturated in NuPage Transfer 
Buffer (Invitrogen T1) and run at 30V for 1 hour. After transfer, blots were blocked 
with PBSTM (PBS, 0.5% powdered non-fat milk, 0.1% Tween-20) for one hour at 
room temperature or overnight at 4°C with gentle agitation. Antibodies were made 
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up in PBSTM at appropriate dilutions. Membranes were incubated with antibodies 
for one hour at room temperature, with agitation, followed by three washes of 15 
minutes each in PBST. For blots incubated with HRP-conjugated secondary 
antibodies, blots were developed using an enhanced chemi luminescence system 
(Amersharn Pharmacia) according to the manufacturer's instructions and placed 
between clear acetate sheets for exposure to photographic film. For nitrocellulose 
blots incubated with AP-conjugated secondary antibodies (Section 5.2.3), proteins 
were visualised by incubating for up to 1 hour in 100mM Tris-HCI (pH 9.5), 100mM 
NaCl, 5mM MgC12 , in which 3.3tl/ml BCIP (5-bromo-4-chloro-3-indolyl phosphate; 
SOmg/ml in 100% dimethyl formamide) and 6.6pi/ml NBT (nitro-blue tetrazolium; 
50mg/ml in 70% (vlv) dimethyl formamide) were added. Once protein bands were 
apparent. the development reaction was stopped using H 2 0. 
	
8.5.4 	Quantitation of Protein Samples 
The Bio-Rad DC Protein Assay was used for an accurate determination. A series of 
BSA standard solutions between 0.2mg/mi and 2mg/mi were prepared. 5p1 of each 
standard and of each sample at an appropriate dilution were transferred to a 96-well 
plate. 25t1 of Reagent A was added to each well and mixed with 200111 of reagent B. 
The mixture was allowed to stand for 15 minutes and the absorbance at 750nm was 
read using a Multiskan Ascent Labsystems plate reader. Sample concentrations were 
calculated from standard curves. 
8.5.5 	Ammonium Sulphate Precipitation 
300111 supernatant was mixed with 1200111 of saturated ammonium sulphate and left 
on ice for 20 minutes, followed by centrifugation for 15 minutes at maximum speed 
in a microfuge. Supernatant was discarded and the pellet was re-suspended in PBS. 
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8.5.6 	Mass Spectrometry 
Matrix assisted laser desorption!ionization-time of flight (MALDI-TOF) analysis 
was performed by Dr Alexander Henzing and Dr Jim Creanor at SIRCAMS (the 
Scottish Instrumentation and Resource Centre for Advanced Mass Spectrometry), 
University of Edinburgh, using a Bruker Daltonics 9.4 T Apex III Fourier Transform 
Ion Cyclotron Resonance Mass Spectrometer (FT-ICR MS). Briefly, the sample was 
digested with trypsin and cysteines were treated with iodoacetamide to form 
carbamidomethyl-cysteines, thus making cysteine modification uniform in the 
sample. Simply, the N4ALDI-TOF technique involves protein fragments being 
charged with protons in a matrix before being flown through a tunnel using a laser 
beam. The movement of charged particles is detected as a charge-dependent mass 
output, dependent on the 13C isotope content of the peptide. For each peptide, the 
result is a range of masses that are all 1 value apart. These can then be collapsed to 
Z-1 
one mass for each peptide. The mass list for the protein can then blasted against 
the protein database (NCBI). For proteins whose amino acid sequences are not 
available on the database (as with the varO protein), the mass list was compared to 
that derived from a virtual digest of the predicted protein sequence, using the 
program available at http://us.expasy.org/tools.  
8.6 	DNA Immunisation 
8.6.1 	Preparation of DNA-Coated Gold Microcarriers 
Plasmid DNA was isolated using a QiAprep Midiprep kit (QIAGEN) and diluted to 
lg/ml. 45mg of 1.0tm gold microcarriers (BioRad) were weighed into a sterile 
microfuge tube. 100tl of 0.05M spermidine, 90tI of DNA and 100tl calcium 
chloride were added. The mixture was vortexed well and sonicated for 15 seconds 
between each addition and then left to stand for 5 minutes at room temperature. After 
a brief spin to form a pellet, the supernatant was removed and saved for analysis. The 
pellet was washed three times by vortexing in 500d of 100tl of anhydrous 100% 
ethanol and finally re-suspended in 5.3ml of ethanol. Bullets were prepared using the 
BioRad tubing prep station, according to the manufacturer's instructions. Briefly. 
Tefzel® (DuPont) tubing was cut to size and allowed to purge with 0.51/min nitrogen 
for 15 minutes. Using a syringe attached to the end of the tubing, the freshly vortexed 
and sonicated gold/DNA slurry was drawn into the tube, leaving 2-3cm of air at 
either end and keeping as close to horizontal as possible. This was left to stand in the 
prep station for 5 minutes, allowing the tubing to become coated with the gold 
particles. After 5 minutes, the ethanol was drawn off in a single smooth movement. 
The tubing was rotated in air for 1 minute and then for 4 minutes in 0.51/mm 
nitrogen, before removal from the prep station. Where the tubing had been evenly 
coated, it was cut into bullets of standard length using a tubing cutter. Bullets were 
stored at 4C with silica desiccant tablets. The coating quality was examined by 
analysing equivalent amounts of plasmid and supernatant from the binding step on a 
1% agarose DNA gel. The DNA from one bullet (approximately 1tg) was eluted by 
sonication in 200tl of water and the absorbance of this solution at 260nm was 
determined to ensure the loading was within acceptable boundaries (2-10tg/ml). 
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8.6.2 	Immunising Mice 
To collect serum samples from mice prior to and post immunisation, tail bleeds were 
carried out whilst mice were held in a restraining chamber. Tails were warmed in 
water for about 1 minute to dilate the blood vessels and aid bleeding. The very end of 
the tail was cut and 'milked' until about 200.tl blood was collected. Bled mice were 
identified by marking each with a pen after bleeding. Blood was left at room 
temperature for 2 hours to coagulate, after which the samples were spun at top speed 
in a microfuge for 2 minutes. Serum was removed and collected in clean microfuge 
tubes for storage at —70C. The cell pellet was discarded. Mice were numbered by 
ear-tagging and prepared for DNA delivery by shaving a —2cm 2 area of the abdomen. 
The helium-powered BioRad Helios Gene Gun was used to deliver DNA by means 
of' gold 'bullets' (DNA coated gold microcarriers), using 400psi helium for each 
Shot. 
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8.7 	Screening Anti-Sera 
8.7. 1 	Live iRBC Im munofluorescerice Assay 
Infected red blood cells at 5-8% parasitaemia (4% trophozoites) were washed and 
10tl cell pellet per sample was re-suspended in 100tl PBS/1% BSA containing 
primary antibody at the appropriate dilution. Samples were incubated on ice for 30 
minutes with flicking every 10 minutes to re-suspend cells. Between incubations, 
cells were washed three times in imI PBS/1% BSA and re-suspended in 100tI FITC-
conjugated secondary antibody, at the appropriate dilution in PBS/1% BSA. 
Incubation with secondary antibody was as previously but in the dark to prevent 
bleaching of fluorescence. Cells were washed three times as previously and re-
suspended at 20-40% haematocrit with 50:50 glycerol:PBS containing 0.1% Evans 
Blue, 0.001% DAPI and 1.25 mg/mI DABCO. A drop of each sample was spotted 
onto a clean glass slide, mounted for observation and sealed with nail varnish to 
prevent drying out. Parasites were visualised by DAPI -fluorescence (DNA specific) 
and antibody-reactive parasites by FITC -fluorescence (antibody specific) with 
incident light of 450-490nm and 390-440nm respectively, using x 400 or x 1000 
ma.tni fication. 
8.7.2 	Fixed 1RBC Immunofluorescence Assay 
Microspot slides were transferred from storage at —20°C and allowed to equilibrate to 
room temperature, for 15 minutes. For dry IFA they were used thus. For fixed IFA, 
one of two methods of fixing cells was employed - paraformaldehyde fixing or 
acetone fixing. To fix using paraformaldehyde, slides were covered in 2% 
paraformaldehyde/PBS for 5 minutes, followed by 90% methanol/ 10% acetone for 1-
2 minutes. Slides were then air-dried and re-equilibrated in PBST/0.l% Tween-20 
for 20 minutes. To acetone-fix, slides were immersed in room temperature acetone 
for 10 minutes and air-dried. Antibodies were made up in 1% BSA/PBS at 
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appropriate dilutions and 30-50t1 per spot was used for each incubation. To stain 
parasite nuclei, Hoerscht or DAPI was added to secondary antibody solutions at a 
dilution of 1:1000. Incubations were for 30 minutes at 37°C followed by 3 washes in 
PBS, 10 minutes each, with gentle agitation. After the final wash, slides were 
mounted using 2-3 drops of Vectashield®, sealed with nail varnish and observed as 
in Section 8.7.1. 
	
8.7.3 	Enzyme-Linked 1mm unosorbent Assay (ELISA) 
96-well Plates (Immulon 4. Dynatech Laboratories) were coated with 50- 1 OOng of 
protein in 100tl of coating buffer (15mM Na 2CO3 , 35mM NaHCO3 , pH 9.3) and left 
at 4°C overnight. Wells were washed three times with 200tl washing buffer (PBS, 
0.05% Tween 20). Unoccupied protein binding sites were blocked with 200tl per 
well of blocking buffer (1% [wlv] Marvel skimmed milk powder (Premier Brands, 
Spalding, UK) in washing buffer) for 5 hours at room temperature and washed again 
three times. Primary antibodies diluted in blocking buffer (100tl per well) were 
added to duplicate antigen-coated wells and incubated overnight at 4°C. After three 
washes, wells were incubated for 3 hours at room temperature with I00tl per well of 
appropriate HRP conjugated secondary antibody (detailed in appropriate results 
chapters). Plates were washed three times before incubating for 15 minutes at room 
temperature with I00tl of substrate (0.1 mg ml' o-pheny!enediamine, 0.012% H,0 2 ) 
in development buffer (24.5mM citric acid monohydrate and 52mM Na 2 HPO4 , 
p1-15.0). The reaction was stopped by addition of 25tl of 2M H.-SO4  and OD was 
measured at 492nm. 
8.7.4 	Peptide ELISA 
To test the reactivity of DNA immunisation sera to peptides specific to the 
immunogen, biotinylated peptides were synthesised by Eurogentec. NUNC TM  
streptavidin plates were blocked with 200il blocking buffer (PBS. 1% w/v BSA, 
0.1% Tween-20) for 1 hour at 37°C. After washing three times with washing buffer, 
193 
(PBS, 0.1% Tweeii-20), !00il of peptide, at approximately l0ng/tI in washing 
buffer was added to each well and allowed to stick to the plate overnight at room 
temperature, with gentle agitation. Plates were washed three times before adding 
primary antibodies (100tl per well), at appropriate dilutions and incubating at 37°C 
for one hour. Plates were again washed three times before the addition of 100tl per 
well of appropriate HRP conjugated secondary antibody (detailed in appropriate 
results chapters), incubated at 37°C for one hour. After three washes, as previously, 
plates were developed by incubating for 10 minutes at room temperature with 100d 
per well of OPD substrate (0.1M Citric Acid, 2.OM Na 2 HPO4 0.04% H 202 , 10m9 
OPD. The enzymatic reaction was stopped by the addition of 25tl 2.OM H2SO4 and 
the reactivity assessed by reading the absorbance at 492nm using a Multiskan Ascent 
Labsystems plate reader. 
8.8 	Purification of Recombinant Proteins and 
Antibodies 
	
8.8.1 	Immobilising Peptide DBLpepl 
Peptide DBLpepl was immobilised using the SulfoLink ® Kit (Pierce Biotechnology), 
according to the manufacturer's recommendations. Briefly, the peptide was first 
analysed for the presence of free sulfhydryls using Eliman's Reagent (Pierce 
Biotechnology, product 22582T). Oxidised sulfhydryls were reduced using 
3—mercaptoethanol, to enable coupling to sepharose. Reduced peptide was passed 
over a PD-10 desalting column (Amersham Biosciences) and equilibrated in 
coupling buffer before coupling to the SulfoLink ® coupling gel (a 6% cross-linked 
beaded agarose matrix). Non-specific binding sites in the gel were blocked using 
0.05M L-cysteine.HCI. The immobilised peptide column was then used to affinity 
purify anti-DBLpepl antibodies; sera were applied to the column and incubated at 
room temperature for 1 hour. After washing, bound IgG was eluted with 
ImmunoPure® Elution Buffer in Iml fractions, neutralized with 50tl of 1M Tris, 
p1-19. Protein containing fractions were pooled and buffer exchanged into PBS by 
centrifugation 4 times at 3,000g for 30 minutes using a Vivaspin 6 column, 30,000 
MWCO (Vivascience). 
8.8.2 	Production and Purification of (CR2) 2-IgG 
J558L 11Db cells (a gift from Dr Andy Knight) were used for the production of 
(CR2) 2-1gG fusion protein (Hebell et al. 1991). Cells were cultured as described in 
Ilitre volumes of cRPMI (1mg/mi G418) in roller bottles. Cultures were incubated 
for 4-7 days and harvested when the medium had turned orange-yellow. Supernatants 
were filtered through 2 Whatman filter papers and protein was precipitated by slowly 
stirring with 291g per litre of ammonium sulphate, overnight at 4°C. Protein was 
precipitated by centrifugation at 4225g for 20 minutes and re-suspended in a minimal 
volume of PBS. Re-suspended protein was dialysed against a large volume of PBS, 
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overnight at 4°C and centrifuged again at l,lOOg for 10 minutes to remove any 
debris. It was then filtered through a 0.2tm syringe filter and purified on Protein G 
by affinity chromatography using the AKTAprime automated chromatography 
system (Amersham Pharmacia Biotech). Protein was passed over imI Protein G, at a 
flow rate of imI/min. 
8.8.3 	Coupling to CN-Br Activated Sepharose 4B 
Affinity columns for the purification of proteins/antibodies were made by coupling 
proteins to CN-Br activated sepharose 413. The protein to be coupled was dialysed 
for 24-48 hours at 4°C with constant stirring, against coupling buffer (0.5M NaCl, 
0.25M NaHCO3 , pH 8.5). 1.2g CN-Br activated sepharose 413 (Sigma) was added to 
50m] of 1mM HCI and re-hydrated with constant agitation for 2-3 hours. The 
sepharose was washed twice with 1mM HCI, followed by one wash with coupling 
buffer. 3-4mg of protein in approximately 3m1 of coupling buffer was then added and 
the mixture spun immediately at 500g for 10 seconds. The 0D 280 of the supernatant 
was measured and the protein left to couple with constant agitation, for 1-2 hours, 
until the 0D 280 of the supernatant was approximately 20% of the initial reading. 
30m1 1M Tris, pH 8.0 was then added to quench and the mixture agitated at room 
temperature for a further 2 hours. The sepharose was then washed six times - 
alternately in 0.1M Na Acetate, 0. 5M NaCl, pH4, and 0.25M NaHCO 3 , 0.5M NaCl, 
pH 8.5. A final wash in PBS was carried out before the sepharose was re-suspended 
as a 50% slurry in PBS and packed into a glass column. Affinity columns were 
stored in 0.1% azide, at 4°C. 
8.8.4 	Preparation of COS7-Cell Supernatant 
C3d3 sticks to plastic and is best kept on ice and contact with plastic avoided where 
possible. Pooled supernatants were spun at maximum speed in a bench top centrifuge 
at 4°C and the resultant supernatant was run through a Steritop TM filtration system 
(Millipore) fitted with a PVDF 0.22tm filter and a fibreglass pre-filter. The pH of 
the filtered supernatant was checked and adjusted to pH 7. Filtered supernatants were 
stored in glass bottles at —80°C. 
8.8.5 	Affinity Chromatography 
Columns for affinity purification (lml diameter, 5ml bed volume) were equilibrated 
with 5 bed volumes of PBS. A small end sample was removed and collected in a 
cuvette for use as a baseline standard. Samples for purification were pooled and spun 
at 1000g for 30 minutes to remove debris and clear supernatants were loaded on the 
column at a flow rate of 1.2-1.5mllmin. Flow-through was collected in a clean glass 
beaker and the column was washed with 5 bed volumes of PBS. Bound proteins were 
eluted with 0.lM glycine (pH 3.0) and ImI fractions collected in eppendorfs 
containing 25tl 1M Tris-base (pH 10.5) to neutralise. Samples were analysed by 
SDS-PAGE/Coomassie staining and quantified by reading the Anm of the 
fractions after BioRad DC protein assay. Samples with the greatest concentration of 
protein were pooled and buffer exchanged into PBS using a Vivaspin column 
(Vivascience) with MWCO appropriate to the protein of interest. After protein 
elution the matrix was washed with a further 3 bed volumes of elution buffer to 
remove all traces of bound protein and then with 5 bed volumes of PBS to restore p1-I 
to neutral. 
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8.8.6 	Determination of Starting Conditions for Ion Exchange 
Proteins can be purified by ion exchange chromatography on the basis of their 
differing isolelectric points at a known pH (p1). To determine the p1 for a particular 
protein, a series of 1.5ml microfuge tubes was set up and imI 50% (wlv) 
diethylaminoethyl (DEAE)-sephadex resin in PBS/0. 1% azide added to each. After a 
spin at maximum speed in a microfuge for 5 minutes, the supernatant was removed 
and the gel in each tube equilibrated by washing 3 times with imI of 0.5M Tris 
(I OX). Samples were set up at a pHs of 5.5,6,7,8 and 9. Gels were equilibrated at a 
lower ionic strength by washing each 3 times with ImI of 0.05M Tris at the same 
pHs. Iml of sample supernatant was added to each tube (previously equilibrated by 
adding 900tl of supernatant to 1001.11 of 0.5M Tris at the appropriate pH). Samples 
were mixed on a rotating wheel at 4°C for 20 minutes and the gel allowed to settle by 
spinning, as previously, for 5 minutes. 42tl of supernatant and 42p.l of resin were 
removed and assayed for presence of protein by SDS-PAGE and Coomassie staining. 
8.8.7 	Ion Exchange Chromatography 
Ion exchange chromatography was used to purify crude supernatant from P. pastoris 
fermentation. 1M Tris, pH 8.0, was added to the crude supernatant, to a final 
molarity of 0.07M. This solution was filtered twice, using a 0.22tm filter and 
purified by passing over I ml DEAE-sephadex at the pre-determined p1 of the protein 
of interest (Section 8.8.6), at a flow rate of ImI/min, using the AKTAprime 
automated chromatography system (Amersham Pharmacia Biotech). Bound proteins 
were eluted with 50mM Tris, 1M NaCl, pH 8.0. 
8.9 	FACS Analysis 
Characterisation of the surface of B-lymphocytes was carried out by indirect 
immunofluorescence using a Becton Dickinson FACSCAN benchtop flow 
cytometer. B cells were removed from culture and centrifuged at 300g for 5 minutes. 
Supernatant was removed and cells re-suspended in cRPMI. A cell count was made 
to ensure cells were at least 70-80% viable and 0.25-0.5 x 106  cells per sample were 
re-suspended in PBS/2% FCS and transferred to a round-bottomed 96 well plate. 
Cells were washed once in PBS/2% FCS and re-suspended in lOOp] PBS/2% FCS 
containing appropriate amounts of primary antibody. After incubation on ice for 30 
minutes, cells were washed three times in PBS/2% FCS and re-suspended in lOOp] 
PBS/2% FCS containing appropriate amounts of FITC-conjugated secondary 
antibody. For the second incubation, plates were wrapped carefully in tin foil to 
prevent photobleaching and left in the dark and on ice for 30 minutes. Cells were 
washed three times in PBS/2% FCS and fixed by re-suspending in 200tl PBS/1% 
formaldehyde before being transferred to labelled FACS tubes containing 200p] 
PBS/2% FCS and kept on ice, in the dark. Data was analysed using Howio software 
(Tree Star). 
199 
Appendix 1: Suppliers 
Amersham Biosciences UK Limited, Amersham Place, Little Chalfont, Buckinghamshire, 
UK, HP79NA 
Applied Biosystems Inc., 850 Lincoln Centre Drive, Foster City, CA 94404, USA 
BioRad Laboratories, 1000 Alfred Nobel Drive, Hercules, CA 94547 
C.A. Hendley (Essex) Ltd, Oakwood Hill Industrial Estate, Loughton, Essex IGIO 3TZ 
DakoCytomation Ltd, Denmark House, Angel Drove, Ely, Cambridgeshire, C137 4ET 
DuPont Ltd., Maylands Avenue, Hemel Hempstead, Herts, UK, HP2 7DP 
Dynatech Laboratories, 14340 Sullyfield Cir, Chantilly, VA 20151-1621 
Electron Microscopy Sciences, P.O. Box 550, 1560 Industry Road, Hatfield, PA 19440 
Immuno Diagnostic Oy, Kaivokatu 16, 13100 HAMEENLINNA, FINLAND 
Invitrogen and Gibco, 3 Fountain Drive, Inchinnan Business Park, Paisley, UK 
MWG Biotech, Mill Court, Featherstone Road, Wolverton Mill South, Milton Keynes, UK, 
MKI2 5RD 
New England Biolabs, 32 Tozer Road, Beverly, MA 01915-5599 
NuncTM , Kamstrupvej 90, Postbox 280, DK-4000, Roskilde 
Pierce Biotechnology, Perbio Science UK Ltd., Unit 9, Atley Way, North Nelson Industrial 
Estate, Cramlington, Northumberland NE23 1 WA 
Promega, Delta House, Chilworth Science Park, Southampton, UK, S016 7NS 
QiAgen, QIAGEN House, Fleming Way, Crawley, West Sussex, UK, RH1O 9NQ 
Sartorius AG, Weender Landstrasse 94-108, D-37075 Gocttingcn, Germany 
Sigma-Aldrich Company Ltd, The Old Brickyard, New Road, Gillingham, Dorset, UK, 
SP8 4XT 
Stratagene, 11011 N. Torrey Pines Road, La Jolla, CA 92037 
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Appendix 2: Media 
Basal Salts Medium 
For 1 litre: 
12.5ml 8.5% phosphoric acid 
93g calcium sulphate 
18.2g potassium sulphate 
14.9g magnesium sulphate (7.1-1 20) 
4.13c, potassium hydroxide 
40g glycerol 
BMMY 
1 % yeast extract 
2% peptone 
100mM potassium phosphate, pH 6.0 
1.34% YNB 
4 x 10-5 % biotin 
1% methanol 
MD 
For 1 litre: 
1.34% YNB 
4 x 10-5 % biotin 
2% dextrose 
BMGY 
1% yeast extract 
2% peptone 
100mM potassium phosphate, p1-I 6.0 
1.34% YNB 








For 1 litre: 
1.34% YNB 
4 x 10 -5 % biotin 
0.5% methanol 
PTM 
For I litre: 
6g cupric sulphate 51-1 20 6g 
0.08g sodium iodide 0.08g 
3g manganese sulphate.1-1 20 
0.2g sodium molybdate.21-1 20 
0.02g boric acid 
0,5g cobalt chloride 
20g zinc chloride 
65g ferrous sulfate.71-1 20 
0.2g biotin 
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